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Abstract 
 
The human central nervous system, one of the most complex organ systems anatomically 
and physiologically in the human body, is the body control center which manages and 
coordinates functions of all different organ systems. The lack of effective treatments and 
therapeutic intervention make injuries and disorders associated with the central nervous 
system one of the most dangerous and fatal health conditions worldwide.  
The adult nervous system has a limited capability of self-repair and regeneration following 
either a neurological disorder or injury. Despite being limited and ineffective in initiating 
recovery from injuries and disorders,   this property opened the doors for a new direction of 
research aimed at investigating the possibility of developing therapies and treatments for 
central nervous system injuries and disorders based on the concept of regeneration and cell 
transplantations. 
Stem cells have gained significant public attention over the past decade due to their 
differentiation capabilities and potential utilization in clinical applications. The ability to 
differentiate stem cells into neural lineages including neurons and glial cells, highlighted 
their potential role as a therapeutic tool for central nervous system injuries and disorders.  
The main aim of this thesis is to show that umbilical cord blood stem cells are a potential 
source of cells that could be used therapeutically in central nervous system injuries and 
disorders. A distinct population of cells has been purified from human umbilical cord 
blood. These cells have been characterized and differentiated in-vitro into neuron-like cells 
using fully defined sequential neuronal induction protocol. The differentiated cells were 
shown to have similar morphological and functional properties to developing central 
nervous system endogenous neurons using several different techniques, including 
immunocytochemistry, real-time PCR, cDNA arrays and calcium imaging. The results 
highlight the potential role of umbilical cord blood stem cells as a therapeutic tool for 
central nervous system injuries and disorders for which current mode of therapy is 
  xix 
inadequate. In addition, they might provide an in-vitro model of neural cells for toxicology 
and drugs testing research. 
 
Introduction 
 1 
 
 
Chapter 1. Introduction 
 
1.1 A historic perspective of stem cells 
Although stem cell biology has gained significant public attention over the past decade, its 
history dates back to the 1950s. It was in 1954 when the differentiation characteristics of 
stem cells were reported for the first time through work on mice testicular teratoma. Upon 
analyzing the tumors, the presence of many different adult tissues and cell types were noted 
within the tumor (Stevens and Little, 1954). Continuing on from this, it was later shown 
that a single cell isolated from the tumor could generate many cell types once injected into 
a mouse (Kleinsmith and Pierce, 1964). It was clear by that time that some of the tumor 
cells could actually transform into many different cell types, however the identity and cell 
biology of those interesting cells was yet to be determined. Later in-vitro cell lines derived 
from mouse embryonic tumors were generated and their cell biology including morphology 
and differentiation properties were investigated (Rosenthal et al., 1970). Conclusions from 
these studies suggested the presence of stem cells that are able to differentiate into multiple 
cell types. However knowledge of the mechanisms governing these differentiation 
processes was still naïve.  In 1981 two independent groups derived for the first time mouse 
embryonic stem cells from the blastocyst (Evans and Kaufman, 1981, Martin, 1981). Later 
those isolated cells were tested successfully for their ability to generate germline chimaeras 
and proved their pluripotent properties (Bradley et al., 1984). In 1998, James Thompson 
from the University of Wisconsin at Madison established the first human embryonic stem 
cell line isolated from human blastocyst. Embryos used for this study were created using in-
vitro fertilization (IVF) (Thomson et al., 1998). The establishment of such cell lines 
allowed the scientists to study in greater detail the mechanisms and factors governing the 
differentiation of these stem cells into various cell types. In addition to embryonic stem 
cells, many other types of stem cells have been discovered including those from cord blood 
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tissues and adults stem cells.  The field of stem cell biology has been advancing with a 
great pace in the past decade and attracted tremendous interest due to the potential it is 
offering that would revolutionize current medicinal practice by providing therapies for 
diseases and injuries for which current modes of therapy are inadequate. 
1.2 What is a stem cell? 
By definition, a “stem cell” is an unspecialized cell that is capable of: 
 Self-renewal: This is the process by which a stem cell divides to produce one or 
two stem cells with similar characteristics to the original stem cell. This is achieved 
by either symmetrical or asymmetrical cell divisions. In symmetrical cell divisions, 
a cell divides to produce two identical cells, for example a stem cell can give rise to 
either two stem cells or two more differentiated cells; this kind of division is 
common in early stages of development (figure 1). On the other hand, in 
asymmetrical cell divisions, a cell divides into two cells, one of them being identical 
to the original cell and the other being a different type of cell, for example a stem 
cell can divide into two cells, one of them being a stem cell and the other being a 
more differentiated cell (figure 1). This kind of division maintains the pool of stem 
cells whilst producing more differentiated tissue specific cells, and is dominant in 
adult tissues (Verfaillie, 2009, Fortier, 2005, He et al., 2009, Stewart et al., 2006). 
 Differentiation: This is the process by which a stem cell develops into a specialized 
cell with specialized functions.    
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Figure 1. Symmetrical and asymmetrical cell divisions. In symmetrical cell division, one mother cell 
divides to give two daughter cells either both identical to the mother cell or both identical but more 
differentiated to the mother cell. In asymmetrical cell division, one mother cell divide to give one daughter 
cell identical to mother cell and one differentiated cell, and so the mother cell pool stays the same.  
 
1.3 Classification of stem cells  
1.3.1 Stem cells potency 
There are many different types of stem cells that exist in human tissues and organs at 
different stages of development, starting from embryonic stages and into adulthood. Each 
type of stem cell has its own distinguishable differentiation properties. Stem cells can be 
classified based on their differentiation potential or what is known in cell biology as “cell 
potency” into: 
 Totipotent: These are stem cells capable of forming all cell lineages of the three 
germ layers (endoderm, ectoderm, and mesoderm) that exist in a human body  as 
well as extraembryonic tissue such as the trophoectoderm.  Totipotency is a 
property maintained by the fertilized egg (zygote) to at least the 4-cell stage of the 
morula (figure 2) (Mitalipov and Wolf, 2009, Sills et al., 2005).  
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 Pluripotent: These are stem cells that are capable of differentiating into all cell 
lineages of the three germ layers (endoderm, ectoderm, and mesoderm) that exist in 
the human body but cannot give rise to a complete human being because they lack 
the potential to form trophoectoderm that is needed for the development of 
extraembryonic tissues such as the placenta and umbilical cord. The best example of 
pluripotenct stem cells is embryonic stem cells (figure 2) (Mitalipov and Wolf, 
2009, Smith et al., 2009).   
 Multipotent: These are stem cells that can develop into a restricted subset of cell 
lineages. Hematopoietic stem cells are a good example of multipotent stem cells. 
They can develop into any cell type certainly within the limits of the hematopoietic 
system and possibly also a few other lineages (Muller-Sieburg et al., 2002, Fortier, 
2005).  
 Unipotent: These are stem cells that can only differentiate into a single type of 
specialized cells or cell lineage, for example adult muscle stem cells (Leeb et al., 
2010).  
 
Figure 2. Human early embryonic development. After the sperm fertilize the egg, the zygote is formed 
which then divides rapidly (embryonic cleavage) with no significant growth in size producing the morula. The 
zygote and at least the 4-cell stage of morula demonstrate totipotent differentiation potential. When the 
morula reaches the 16-cells stage, the inner morula cells differentiate to become the inner cell mass from 
which embryonic stem cells with pluripotent differentiation potential are derived. The surface cells of morula 
differentiate to form the outer layer of the blastocyst known as trophoblast.  
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1.3.2 Sources of stem cells at different stages of development 
Stem cells are also classified based on the developmental stage from which they are 
isolated, although this has been a source of debate amongst stem cell biologists: for 
example, whether umbilical cord blood is a source of adult stem cells (Tuch, 2006, Denner 
et al., 2007) or a source of stem cells different from both embryonic and adult stem cells 
(McGuckin et al., 2006, van de Ven et al., 2007).  Umbilical cord blood stem cells 
demonstrated a number of differences to adult stem cells. They show longer telomeres and 
higher proliferation potential in comparison to adult stem cells (McGuckin and Forraz, 
2008, Mayani, 2010). In addition, umbilical cord blood stem cells are isolated 9 months 
after the point of fertilization (postnatal, right after birth) in contrast to adult stem cells 
which are isolated from older individuals, highlighting different developmental stages at 
which adult and cord blood stem cells are obtained. Therefore, it can be reasonably argued 
that umbilical cord blood stem cells should be listed as a separate class of stem cells in 
addition to embryonic and adult stem cells: 
 Embryonic stem cells: These are pluripotent stem cells derived from the inner cell 
mass (ICM) of 5-8 days old human blastocyst (figure 2) (Sills et al., 2005, Stewart 
et al., 2006). Their pluripotent properties make them capable of differentiating into 
any cell type in the human body.  
 Umbilical cord blood stem cells: These stem cells are isolated from blood in the 
umbilical cord blood vessels and placenta right after birth (postnatally). Umbilical 
cord blood contains different types of stem cells including hematopoietic stem cells, 
non-hematopoietic stem cells (McGuckin et al., 2005) and mesenchymal stem cells 
(Lee et al., 2004). Each type of these stem cells has its own properties and 
differentiation potential (this will be discussed further in later sections).  
 Adult stem cells: These stem cells are found in various tissues throughout the adult 
human body. Adult stem cells have different properties and differentiation 
potentials; in general, they vary from being multipotent to unipotent. Adult stem 
cells are crucial in maintaining tissue and organ mass during normal cellular 
turnover and tissue repair (Fortier, 2005). Examples of adult stem cells include 
neural stem cells which are multipotent stem cells that reside in neural tissue and 
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hepatic stem cells which are generally considered unipotent and reside in adult liver 
tissues. 
 
1.4 Molecular control of pluripotency 
Pluripotency and indefinite self-renewal potential are two characteristics associated with 
embryonic stem cells (He et al., 2009, Pardo et al., 2010, Stewart et al., 2006). These two 
distinct features of embryonic stem cells are established and regulated by a unique set of 
key transcription factors including OCT4, SOX2, and NANOG.  
The POU domain transcription factor OCT4 (also known as POU class 5 homeobox 1, 
POU5F1) has been identified as an essential regulator highly involved in the establishment 
and maintenance of the pluripotent state of embryonic stem cells (Pardo et al., 2010). 
Studies on embryonic stem cells showed that over-expression of OCT4 causes 
differentiation into primitive endoderm and mesoderm lineages while downregulation or 
loss of OCT4 induces differentiation to trophectoderm lineage. This emphasizes the strict 
control required on levels of OCT4 expression in maintaining the pluripotency of 
embryonic stem cells (Nichols et al., 1998, Niwa et al., 2000). OCT4 has been shown to 
occupy a central role in the core transcriptional regulatory circuitry that regulates the 
expression levels of other genes in order to establish and control pluripotency and self-
renewal in embryonic stem cells (Boyer et al., 2006).  
OCT4 interacts with other transcription factors in order to establish and maintain 
embryonic stem cell identity. Among these factors is SOX2, which is a transcription factor 
member of SOX (SRY-related HMG-box) family. It has been shown that OCT4 and SOX2 
form a hetero-dimer transcription factor complex that regulates gene expression in 
embryonic stem cells (Rodda et al., 2005, Chew et al., 2005, Masui et al., 2007, Okumura-
Nakanishi et al., 2005). Unlike OCT4 which functions predominantly in pluripotent stem 
cells, SOX2 is also involved in the maintenance of neural progenitor identity in neural 
tissues (Graham et al., 2003), in addition to its role in the maintenance of pluripotency and 
lineage specification (Boyer et al., 2006). SOX2 involvement in pluripotency regulation has 
been illustrated in studies where the loss of SOX2 gene expression resulted in inappropriate 
differentiation and loss of the stem cell undifferentiated state (Fong et al., 2008). 
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 In addition to OCT4 and SOX2, it has been shown that NANOG, a homeobox transcription 
factor, is also critically involved in maintenance of the pluripotent state and the self-
renewal properties of embryonic stem cells (Hyslop et al., 2005). NANOG, which is 
normally expressed in pluripotent embryonic stem cells and in the developing germline, is 
also crucially required for early embryonic development. Deletion of NANOG in founder 
cells of the inner cell mass results in the failure of epiblast generation (Mitsui et al., 2003, 
Silva et al., 2009). Moreover, down-regulation of NANOG in embryonic stem cells results 
in loss of pluripotency and differentiation of these cells to extraembryonic endoderm 
lineages (Mitsui et al., 2003, Boyer et al., 2006).  
OCT4, SOX2 and NANOG transcription factors are the key players involved in specifying 
the pluripotent status of embryonic stem cells as well as coordinating early fate decisions. 
Their collaborative interactions with each other and other transcription factors form the 
transcriptional regulatory network that controls the expression patterns and levels of many 
genes involved in pluripotency and fate specifications (figure 3) (Boyer et al., 2005, Liang 
et al., 2008). The cooperative interactions between OCT4, SOX2 and NANOG were 
revealed using genomic scale location analysis which showed that the three transcription 
factors co-occupied the promoters of a large numbers of genes involved in fate 
specification and development (Boyer et al., 2005, Loh et al., 2006). A large proportion of 
the co-targeted genes code developmentally important homeodomain transcription factors 
which in turn regulate other target genes. This forms a transcriptional regulatory hierarchy 
with OCT4, SOX2 and NANOG occupying the top position (Boyer et al., 2005, Boyer et 
al., 2006). Studies also reveal that OCT4, SOX2 and NANOG regulate the expression 
levels of their own genes forming auto-regulatory loops which stabilize genes expression 
and provide a fast response regulatory pathway (figure 3) (Chew et al., 2005, Okumura-
Nakanishi et al., 2005, Rosenfeld et al., 2002). OCT4, SOX2 and NANOG expression and 
functions are highly linked to each other and their cooperative interaction is fundamental in 
the regulation of the pluripotent state of embryonic stem cells as well as fate specification 
during development.  
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Figure 3. Core transcriptional regulatory networks in pluripotent stem cells. OCT4, SOX2 and NANOG 
transcription factors (blue spheres) form the core of the network. They regulate their own genes (red boxes) 
forming auto-regulatory circuits in addition to the expression of other genes to either establish and maintain 
the pluripotent status or regulating differentiation and fate specification. Adapted from (Boyer et al., 2005, 
Boyer et al., 2006).  
 
1.4.1 Induced pluripotent stem cells (iPS cells) 
Induced pluripotent stem cells (iPS cells) are pluripotent stem cells derived artificially from 
non-pluripotent cells, usually fully differentiated somatic cells, by introducing certain genes 
which reprogram the cell and de-differentiate it back to the pluripotent state (Yamanaka, 
2008). iPS cells were first generated by Takashi and Yamanaka in 2006. They 
reprogrammed mouse fibroblasts to generate iPS cells by transfecting them with four genes 
(Oct4, Sox2, c-Myc and Klf4) using a retroviral delivery system. The iPS cells had similar 
morphology to embryonic stem cells and formed teratomas when transplanted into SCID 
mice (mice with severe combined immune deficiency) confirming their pluripotent 
properties (Takahashi and Yamanaka, 2006, Yamanaka and Takahashi, 2006). Although the 
generated cells showed pluripotent properties, they failed to produced chimeras when 
injected into developing embryos suggesting partial reprogramming (Yamanaka, 2008). 
This experiment was followed by three independent experiments that reported the 
successful production of iPS cells which this time also produced chimeras when injected 
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into developing mice embryos. The three groups used the same four genes for 
reprogramming (Oct4, Sox2, c-Myc and Klf4) but unlike Yamanaka who used Fbx15, a 
protein expressed by embryonic stem cells, as a selection marker for iPS cells, they used 
Nanog and produced germline-competent iPS cells with more similar ES-cell-like gene 
expression and DNA methylation patterns compared with iPS cells selected with Fbx15 
(Maherali et al., 2007, Okita et al., 2007, Wernig et al., 2007).   
In 2007, the first human iPS cells were generated by two independent groups. Yamanaka‟s 
group used the same set of markers they previously used on mice fibroblasts, to reprogram 
human fibroblast into iPS cells (Takahashi et al., 2007). The second group used OCT4, 
SOX2, NANOG and LIN28 to reprogram human fibroblasts into iPS cells (Yu et al., 2007). 
Both groups reported similarities between their generated iPS cells and human embryonic 
stem cells using a set of assays including morphological studies, epigenetic analysis, 
embryoid body formation, differentiation potential analysis and teratoma formation in vivo 
(Yu et al., 2007, Takahashi et al., 2007).  
In following studies, different sets of factors were used to generate iPS cells. A group at 
Kyoto University in Japan used fibroblasts expressing endogenous c-Myc which were 
reprogrammed using Oct4, Sox2 and Klf4 only, without c-myc. Although they reported 
successful generation of iPS cells, the efficiency was low compared to induction with a full 
set of genes including c-Myc (Wernig et al., 2008, Nakagawa et al., 2008). Another 
experiment showed that mice neuronal progenitor cells expressing endogenous Sox2 and c-
Myc were reprogrammed using only Oct4 and Klf4, Oct4 and c-Myc and finally Oct4 on its 
own. Successful generations of iPS cells were recorded for all three trials but again with 
lower efficiency rates compared to induction with all the four genes (Kim et al., 2008, Kim 
et al., 2009).  
The iPS cell experiments provide further supporting evidence for the crucial role of OCT4 
as a key central element in the pluripotency transcriptional network, based on the findings 
that OCT4 was the only factor that could not be substituted in the generation of iPS cells. 
The ability to induce and reprogram differentiated cells back to the undifferentiated 
pluripotent state by over-expression of certain markers including OCT4, SOX2 and 
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NANOG emphasizes the crucial role that all these factors have in the pluripotent properties 
of embryonic stem cells.  
1.4.2 Assessing pluripotency: the gold standards 
Scientific organizations around the world are trying to establish specific criteria for 
assessing and determining pluripotency of human cell lines in an attempt to standardize 
definitions within the field of stem cells. Nevertheless this issue continues to be a debatable 
focal point at both the scientific and political levels worldwide.  
As mentioned earlier, the term “pluripotent” is defined as the potential of a stem cell to 
differentiate into any cell type from the three germ layers but not extraembryonic tissues. 
Therefore, the „gold standard‟ way to test for pluripotency is by demonstrating that the 
tested cells can functionally produce all the cell types from all the germ layers. 
In mice, this has been demonstrated by introducing the candidate cells into the blastocyst 
with the production of chimaeras that are germ line competent (Okita et al., 2007). In other 
studies, pluripotency has been demonstrated using “tetraploid complementation”. In this 
protocol, a 4n blastocyst is generated by fusing the two cells of the two-cell stage blastocyst 
by applying an electrical charge. Then the candidate cells are introduced into the tetraploid 
blastocyst which will continue to divide and develop into mid to late stage embryos. Since 
the 4n cells cannot produce somatic cells, the generated embryo is composed entirely from 
the introduced candidate cells (Nagy et al., 1993, Hanna et al., 2008, Smith et al., 2009).  
For human cells, generating chimaeras or using “tetraploid complementation” is 
undoubtedly unethical. Hence, scientists use the in vivo teratoma formation test in animal 
models as an alternative to assess the pluripotency of human candidate cells (Smith et al., 
2009, Thomson et al., 1998, Odorico et al., 2001).  
A teratoma is a tumor that is composed of cells derived from all three germ layers. In 
laboratories, they are produced by introducing the candidate cells into a (SCID) mouse by 
injection into specified sites, for example, subdermal, intratesticular, intramuscular or 
kidney-capsule. If the introduced cells are pluripotent, they will develop teratomas 
composed of cells from the three germ layers (Smith et al., 2009, Thomson et al., 1998).  
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Nevertheless, using teratoma formation as a test to assess pluripotency of human cells has 
its limitations:  
 Significant histological expertise is required to determine the tumor compositions 
and cells lineages. 
 Assessment of cells lineages is based on morphology and histology rather than 
function.  
  Different injection sites and different mouse strains affect the frequency of 
teratoma formation and its composition (Prokhorova et al., 2009, Cooke et al., 
2006). 
 The formation of teratomas can take up to several weeks (Cooke et al., 2006).  
 
Despite these limitations, teratoma formation is the current gold standard for determining 
the pluripotency of human cell lines. Many scientific organizations such as the National 
Institute of Health (NIH) in the USA have selected the teratoma formation assay as the 
main determinant of pluripotecy in combination with the expression profile of certain 
transcription factors and cell surface markers expressed by human embryonic pluripotent 
stem cells (Smith et al., 2009).  
 
1.5 Umbilical cord blood 
1.5.1 Introduction 
Human umbilical cord blood is the blood found in the blood vessels of umbilical cord and 
placenta. The cord blood is regarded as the “life line” that supplies the developing fetus 
with the important nutrition elements and oxygen required for proper fetal development.  
Beside its role in development, umbilical cord blood has been also involved in therapeutic 
applications which reported for the first time in 1972 by the pioneer doctors in the United 
States, Ende and Ende, to treat a lymphoblastic leukemia (Ende and Ende, 1972). It was 
later used regularly for transplantation in hematology setting for bone marrow replacement, 
following either hematological malignancy or bone marrow failure after any chemotherapy 
side effect. Umbilical cord blood was, for many years, considered to be restricted to blood 
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disease therapy (Gluckman et al., 1989, Slatter et al., 2006). However, advances in the 
production of tissue groups, from the three germ layers, has highlighted the additional 
potential of umbilical cord blood in treatment of other pathological disorders and medical 
applications including regenerative medicine and tissue engineering (McGuckin and Forraz, 
2008, McGuckin et al., 2006, Watt and Contreras, 2005, Denner et al., 2007).  
 
1.5.2 Umbilical cord and placenta: structure, development and function 
 Umbilical cord 
The umbilical cord is the cord that connects the developing fetus to the placenta. The 
umbilical cord originates from the same zygote as the fetus. It develops from the yolk sac 
and allantois by the 5
th
 week of fetal development and replaces the yolk sac as the nutrient 
supplier for fetus (Exalto, 1995). The umbilical cord averages 50-60 cm in length and about 
2 cm in diameter at the end of gestation (figure 4) (Di Naro et al., 2001). The umbilical 
cord contains three blood vessels, one vein and two arteries which coil around the vein in a 
helical configuration (figure 4) (Chaurasia and Agarwal, 1979). The vein supplies the fetus 
with nutrient-rich oxygenated blood from the placenta and the arteries takes the nutrient-
depleted deoxygenated blood back to the placenta. The three blood vessels are insulated 
with a gelatinous substance called Wharton‟s jelly that protects these vessels and prevents 
their compression (figure 4A) (Ferguson and Dodson, 2009). The umbilical cord is 
connected to the fetus at the abdominal area at the point which after birth becomes the 
umbilicus. Once inside the fetus, the vein of the umbilical cord splits into two branches, one 
joins the hepatic portal vein which directs blood to the liver and the second allows the 
majority of blood to bypass the liver and directs it to the fetal heart via the left hepatic vein 
and inferior vena cava. The umbilical cord arteries branch from the fetal internal iliac artery 
which is the main artery in the pelvic area (Currarino et al., 1991).  
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Figure 4. Anatomy of umbilical cord. (A) Umbilical cord has three blood vessels, two arteries and one vein 
that course through Wharton‟s jelly in a helical configuration. (B) Cross section of umbilical cord showing the 
vein and two arteries.  
 
 Placenta  
The placenta is the organ that connects the developing fetus via the umbilical cord to the 
maternal uterine wall carrying out nutritive, respiratory, and excretory functions (Desforges 
and Sibley, 2010). Similar to the umbilical cord, the placenta originate from the same 
zygote as the fetus. It begins to develop during implantation of the blastocyst into the 
maternal endometrium and grows throughout pregnancy (Cross et al., 2006). The placenta 
has a dark maroon color and round flat appearance. It averages around 20 cm in diameter 
and 2.5 cm in thickness at the end of gestation (figure 5). 
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Figure 5. Human placenta and umbilical cord before cord blood collection. Photograph taken minutes 
after delivery.  
 
The placenta is divided into two portions, the fetal portion and the maternal portion. The 
fetal portion consists of the chorionic villi which are villi that merge from the chorion to 
maximize the contact area with maternal blood. The maternal portion contains the 
intervillous space which is the space between the fetal chorionic villi and maternal blood 
vessels.  The delicate walls of the chorionic villi allow the fetal blood to absorb nutrients 
and oxygen from the maternal blood and discard waste products into it without 
intermigration of the two blood currents (Cross et al., 2006, Desforges and Sibley, 2010). 
 
 
 
 
Introduction 
 15 
1.5.3 Umbilical cord blood contains different types of stem cells 
The increasing interest in umbilical cord blood after its involvements in hematological 
clinical applications in the past couple of decades focused efforts on analyzing and 
characterizing the constituents of umbilical cord blood. Beside the blood cells including 
erythrocytes, leukocytes and thrombocytes, the umbilical cord blood was found to contain 
different populations of stem cells, a unique feature not shared with peripheral blood. 
Scientists and researchers have characterized the following stem cell populations from 
umbilical cord blood; hematopoietic stem cells (HSCs), multipotent non-hematopoietic 
stem cells and mesenchymal stem cells (MSCs).  
 Hematopoietic stem cells (HSCs) 
Haematopoiesis is the process by which blood cells are formed. All blood cellular 
components are derived from a multipotent stem cell population called hematopoietic stem 
cells through a series of complex proliferation and differentiation events (figure 6) (Muller-
Sieburg et al., 2002). Specialized hematopoietic cells can be categorized into erythrocytes 
(red blood cells), leukocytes (white blood cells) and thrombocytes (platelets) (table 1). The 
blood cellular components have been analyzed using special cell surface markers termed 
“the cluster of differentiation” or “CD” (table 2). These markers have been used to identify 
and define certain blood cell types and indicate the stage of differentiation (Zola et al., 
2005, Weissman and Shizuru, 2008). For example CD133 has been associated with 
immature “naive” stem cells (Suzuki et al., 2010), CD34 has been used as a hematopoietic 
stem cell marker (Weissman and Shizuru, 2008, Kim et al., 1999) whilst other CD 
molecules have been associated with certain specialized hematopoietic cells (table 2).  
Haematopoiesis takes place in different sites throughout development. At early embryonic 
stages, it occurs in the blood islands of the yolk sac, and later it moves to the fetal liver. 
Around the time of birth, the hematopoietic stem cells from the fetal liver colonize the bone 
marrow which will eventually becomes the main site of Haematopoiesis throughout adult 
life (Palis and Yoder, 2001, Zon, 1995).  
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Figure 6. Human Haematopoiesis. Multipotent hematopoietic stem cells give rise to all lineages of blood 
cells. All hematopoietic specialized cells are derived from either myeloid or lymphoid progenitors which in 
turn are derived from the multipotent hematopoietic stem cells. Image adapted from 
http://commons.wikimedia.org/wiki/File:Hematopoiesis_simple.png. 
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Table 1. Hematopoietic cell types and their functions  
Cell type Function 
Lymphocytes 
Natural killer cells Fighting tumor and viral infected cells 
T cells Involved in adaptive immune response and cell-mediated immunity 
B cells Involved in humoral immune response 
Erythrocytes (red blood cells) Carry oxygen to the body organs and tissues 
Monocytes 
Involved in initiation of immune reaction in response to 
inflammation signals. Production of macrophages and dendritic cells. 
Macrophages Involved in innate and adaptive immunity. 
Dendritic cells 
Antigen-presenting cells. Involved in both innate and adaptive 
immunity 
Neutrophil Fast immune response to microbial inflammations 
Basophil Immune response to inflammations related to allergies and asthma 
Eosinophils 
Combating multicellular parasites and also involved in fighting 
against viral infections 
Thrombocytes (platelets) Maintenance of hemostasis 
Sources: (Schroeder, 2009, Hayashi et al., 2003, Hogan et al., 2008, Chaplin, 2010, Beaulieu and 
Freedman, 2010). 
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Table 2. List of human CD antigens, cells on which they are expressed and brief description of their 
hematopoietic associated functions 
Human CD 
antigen 
Cell types expressed on Function 
CD2 
T cells, thymocytes, Natural killer 
cells 
Adhesion molecule and T cells activation 
CD3 T cells, thymocyte subset 
Associated with the T cell antigen receptor. Involved in T cell receptor 
(TCR) surface expression and signal transduction 
CD4 
Thymocyte subsets, monocytes, 
macrophages 
MHC class II co-receptor, HIV receptor, T cell differentiation and 
activation 
CD7 T cells, Natural killer cells T cells interaction and activation 
CD14 Monocytes, Macrophages 
Act as a co-receptor for detection of bacterial lipopolysaccharide (LPS). 
Involved functionally in the innate immune system. 
CD16 
Neutrophils, Natural killer cells, 
Macrophages 
Component of low affinity Fc receptor and mediate phagocytosis 
CD19 B cells B cells activation and differentiation 
CD24 B cells, Granulocytes Binds P-selectin 
CD33 
Myeloid progenitor cells, 
Monocytes 
Regulation of human lymphoid and myeloid cells. 
CD34 
Hematopoietic stem/progenitor 
cells 
Stem cell marker and adhesion 
CD36 Platelets, Monocytes Adhesion, phagocytosis 
CD38 
Variable levels on majority of 
leukocytes 
Cell adhesion, signal transduction and calcium signaling. 
CD45 Hematopoietic cells 
Tyrosine phosphatase, enhance signals through T cells and B cells 
receptors 
CD56 Natural killer cells and T subset Adhesion 
CD66b Granulocytes Activation and adhesion 
CD133 Hematopoietic stem cell subset Adhesion 
CD235a 
(Glycophorin A) 
Erythrocytes Unknown 
Sources : (Sempowski et al., 1999, McGuckin et al., 2007, Kitchens, 2000, Wilkins et al., 2003, Chen et al., 
2004, Malavasi et al., 2008, Hernandez-Caselles et al., 2006, Yoon et al., 2007) 
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Umbilical cord blood has been shown to contain a population of hematopoietic stem cells 
(HSCs) at different stages of hematopoietic commitment characterized by their differential 
expression of hematopoietic antigens CD133, CD34 and CD45 according to a model 
previously described (figure 7) (McGuckin et al., 2003, McGuckin et al., 2007). It has been 
shown that cord blood hematopoietic stem cells can be selectively induced into specific 
hematopoietic lineages in-vitro including erythroid, megakaryocytic and monocytic 
lineages (Felli et al., 2010).  
 
 
Figure 7. Subtypes of hematopoietic stem cells and their surface CD antigens. Differentiation of HSCs 
occurs in three sequential stages, each defined with specific surface antigen expression. At the early stage, the 
HSCs express CD133 while CD45 expression is weak and CD34 is absent. At the Mid stage, the HSCs 
express all the three antigens, CD133, CD34 and CD45. At the late stages of differentiation, HSCs express 
CD34, CD45 but not CD133. Image adapted from (McGuckin et al., 2007).  
 
 Multipotent non-hematopoietic stem cells 
A unique population of multipotent non-hematopoietic stem cells has been identified in 
umbilical cord blood. These stem cells are small in size and exist at low density in cord 
blood and are negative for the major hematopoietic marker CD45 (Kucia et al., 2007, 
McGuckin et al., 2005, Zhao et al., 2006). This population of cells has been shown to 
express transcription factors normally expressed by embryonic stem cells including 
pluripotency key players OCT4, SOX2 and NANOG. In addition they expressed specific 
surface markers which have been used previously to characterize human embryonic stem 
cell lines. These markers include state-specific embryonic antigens, SSEA-3 and SSEA-4 in 
addition to tumor rejection antigens TRA1-60 and TRA1-80 (McGuckin et al., 2005, Kucia 
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et al., 2007, Zhao et al., 2006, Adewumi et al., 2007, Inamdar et al., 2009). These stem cells 
have been shown to differentiate into various cell types representing the three germ layers. 
Many groups have reported successful neural induction of cord blood stem cells 
representing ectodermal commitment (Ali et al., 2009, Zangiacomi et al., 2008, Habich et 
al., 2006), whilst other groups have successfully differentiated cord blood naïve stem cells 
into endodermic lineages including hepatic and pancreatic cells (McGuckin et al., 2005, 
Denner et al., 2007), and other groups have reported the successful generation of 
endothelial cells from cord blood naïve stem cells representing the mesodermal lineage 
(Senegaglia et al., 2010, Ma et al., 2006).  
Due to their marker expression profile, McGuckin et al. (2005) named these cells cord 
blood derived embryonic-like stem cells (CBEs) while Kucia et al. (2007) named them very 
small embryonic-like stem cells (VSELs). Other groups have also named them cord blood 
pluripotent stem cells (Leeb et al., 2010, Kogler et al., 2004, Harris and Rogers, 2007). 
Besides the confusion caused by the introduction of different names and acronyms for these 
cells (due to the absence of standardized criteria for naming them,) the use of terms such as 
“embryonic-like” and “pluripotent” to describe these cells might be inaccurate  and 
misleading. The term “embryonic-like” was given to the cells based on their expression of 
so-called embryonic stem cell markers such as OCT4, the main pluripotency key player in 
embryonic stem cells (Buitrago and Roop, 2007). It has been shown that OCT4 has two 
splice variants OCT4A and OCT4B that differ only in their N terminals whilst having 
identical C terminals. The splice variants have been shown to have different temporal and 
spatial expression patterns. Whilst OCT4A was expressed mainly in the nuclei of human 
embryonic stem cells, OCT4B was detected in many different types of differentiated cells 
(Cauffman et al., 2006, Lee et al., 2006).  McGuckin et al. (2005), Kucia et al. (2007) and 
Zhao et al. (2006) have all used OCT4 antibodies that were not specific for the OCT4A 
variant in their studies, and such antibodies have been shown to give positive results on 
mature hematopoietic cells isolated from adult human peripheral blood (Zangrossi et al., 
2007). Therefore, drawing conclusions based on such results could be inaccurate and 
misleading.  
Using the term “pluripotent” to describe the differentiation potential of such cells based on 
the expression profiles of certain markers might not be appropriate even if the cells have 
been shown to differentiate into some but not all cell types representing the three germ 
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layers. The reason for this is that cord blood stem cells do not form teratomas after 
transplantation in SCID mice, which as mentioned before is a unique characteristic of 
pluripotent stem cells. These stem cells, therefore do not satisfy the current criteria for 
defining pluripotent stem cell (Sangeetha et al., 2010).   
Hence to avoid confusion, in this thesis these cells are termed “non-hematopoietic 
multipotent stem cells” which defines their differentiation potential and distinguishes them 
from cord blood hematopoietic stem cells.  Such terminology would avoid the inappropriate 
linking between these cells and embryonic stem cells and better describe their cell biology.  
 Mesenchymal stem cells (MSCs)  
Mesenchymal stem cells (MSCs) are a multipotent stem cell population found originally in 
the bone marrow (Short et al., 2003, Pittenger et al., 1999). These cells have demonstrated 
the ability of differentiation into osteogenic, adipogenic and chondrogenic lineages as well 
as non-mesodermal lineages including neural and hepatic lineages (Pittenger et al., 1999, da 
Silva Meirelles et al., 2006, Black and Woodbury, 2001, Krause et al., 2001). MSCs have 
been also isolated from umbilical cord blood (Erices et al., 2000, Kern et al., 2006, Bieback 
et al., 2004). Umbilical cord blood derived MSCs show high morphological and molecular 
similarities to bone marrow derived MSCs including the lacking of hematopoietic surface 
antigens CD133, CD34 and CD45 (Erices et al., 2000, Lee et al., 2004, Bieback et al., 
2004, Lindner et al., 2010). Although  the frequency of isolating MSCs from umbilical cord 
blood has been shown to be very low compared to the bone marrow, cord blood derived 
MSCs demonstrate higher proliferation capabilities than bone marrow MSCs (Bieback et 
al., 2004). 
 
1.5.4 Stem cells of choice: Why umbilical cord blood stem cells? 
There has been great debate on the stem cell source of choice for research and clinical 
applications. Embryonic stem cells, the least committed stem cells, have been shown to 
have high proliferation and extensive differentiation capacities which make them a 
powerful research platform for studying differentiation pathways and lineage commitment 
of stem cells (Thomson et al., 1998, Kogler et al., 2004). Nevertheless, when considering 
potential clinical applications, embryonic stem cells have shown some major limitations. 
Embryonic stem cells have high tumorigenic characteristics which might limit and delay 
any potential clinical use (Ben-David and Benvenisty, 2011). Further to this, embryonic 
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stem cells often lack the proper imprinting patterns and regulation of certain genes which 
might lead to spontaneous uncontrolled differentiation and developmental abnormalities 
(Sapienza, 2002). It has also been found that embryonic stem cells increase their 
immunogenicity by gaining human leukocyte antigens (HLA) during and after 
differentiation, which might increase the risk of rejection (Swijnenburg et al., 2008, 
Swijnenburg et al., 2005, Kofidis et al., 2005). Nevertheless, the ability to generate 
pluripotent stem cells from the patient‟s own cells (iPS cells) should offer an alternative to 
bypass this limitation.  Moreover, the isolation of embryonic stem cells from the inner cell 
mass of the blastocyst involves the destruction of an embryo which itself creates ethical, 
religious and political problems.  
Umbilical cord blood offers an alternative source of stem cells with both research and 
clinical advantages over other sources of stem cells. Moving toward effective clinical 
applications requires a readily abundant supply of stem cells to provide the needed amounts 
of stem cells. With the global birth rate reaching 200 millions/year, umbilical cord blood 
can be considered as one of the most abundant sources of stem cells (McGuckin et al., 
2006, McGuckin et al., 2008). In addition, unlike embryonic stem cells, umbilical cord 
blood stem cells collection does not raise any ethical or religious concerns which makes it 
more appealing to both the research and clinical fields (Ballen et al., 2008, McGuckin et al., 
2006, Watt and Contreras, 2005).  
Umbilical cord blood stem cells also show a number of advantages over adult stem cells 
sources like bone marrow. The collection of umbilical cord blood stem cells is a safe and 
non-invasive procedure, unlike the collection of adult stem cells from bone marrow 
(McGuckin et al., 2006). Moreover, umbilical cord blood stem cells occupy an intermediate 
age stage between embryonic stem cells and adult stem cells, which leads to higher 
proliferating potential and longer telomeres than other adult stem cells (Pipes et al., 2006, 
Slatter and Gennery, 2006, Kim et al., 1999). 
Allogenic transplantation with adult HSCs is regarded as a life-saving procedure in the 
treatment of severe hematological diseases such as hematopoietic malignancies, bone 
marrow failure syndromes and hereditary immunodeficiency disorders (Brunstein and 
Wagner, 2006). Yet, this procedure is limited by the availability of suitable HLA-matched 
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donors (Tse and Laughlin, 2005). Due to the immature HLA status of umbilical cord blood 
cells, transplantation with cord blood shows better tolerance for HLA-mismatching in 
comparison with adults HSCs (Liu et al., 2004). This unique feature of cord blood allows 
the safe use of unrelated and HLA-mismatched donor samples when HLA-identical donors 
are not available, thus providing the clinicians with alternative effective therapeutic options 
(Ringden et al., 2008, Slatter et al., 2006). Furthermore, transplantation with HLA-
mismatched cord blood samples shows a lower risk of graft-versus-host diseases (GvHD) in 
comparison with bone marrow transplantation. This is also attributed to the fact that the 
cells transplanted from umbilical cord blood are more naïve and have lower (HLA) protein 
expression than adults stem cells including bone marrow stem cells (Fasouliotis and 
Schenker, 2000, Ringden et al., 2008, Slatter and Gennery, 2006, Mochizuki et al., 2008). 
In addition, umbilical cord blood transplantation was shown to be associated with a lower 
risk of infection transmission in comparison with bone marrow transplantation (Behzad-
Behbahani et al., 2005).  
On the other hand, the low number of stem cells per cord blood unit  represents a limitation 
that is associated with delayed engraftment of these cells into host targeted tissues (Tse and 
Laughlin, 2005, Stanevsky et al., 2009). However this obstacle has been tackled with the 
possibility of combining multiple cord blood units in order to increase the final transplanted 
cell dose resulting in improved engraftment and survival of the transplanted cells 
(Brunstein and Wagner, 2006, Stanevsky et al., 2009, Ringden et al., 2008, Slatter et al., 
2006).  
Another advantage of umbilical cord blood is the ability to store and cryo-preserve cord 
blood units in cord blood banks for future use.  This feature provides clinicians and patients 
with an immediate and abundant supply of cord blood units for transplantation. It also 
increases the chance of finding the right HLA-matched units for patients requiring 
allogeneic transplantation. Many cord blood banks have been established in the U.K, 
France and many other countries worldwide for such purposes (Solves et al., 2008, Lee et 
al., 2007, McGuckin et al., 2006, Watt and Contreras, 2005). 
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Umbilical cord blood has added advantages over other sources of stem cells (table 3), 
highlighting its potential as a promising therapeutic tool for many diseases and disorders 
for which the current form of treatment is inadequate.  
 
Table 3. Summary of advantages and disadvantages of different stem cell sources. 
 Advantages Disadvantages 
Embryonic 
stem cells 
 Pluripotency: can differentiate into 
any cell type in the body. 
 Serve as a strong platform for 
pluripotency, developmental and 
lineage commitment studies.  
 Ethical, religious and political 
concerns. 
 High chance of transformation 
into cancer cells (teratomas). 
 Cells instability in-vitro due to 
lack of proper imprinting 
patterns.   
Umbilical 
cord blood 
stem cells 
 No ethical, religious or political 
controversies. 
 Collection procedure is totally safe 
and non-invasive   
 Abundant supply. 
 Low viral contamination.  
 Ability to store cord blood units in 
cord blood banks. 
 No risk of teratoma formation.  
 Lower risk of graft-versus-host 
diseases (GvHD). 
 Tolerance of HLA-mismatching. 
 Higher proliferation capacity 
compared with adult stem cells.  
 Limited number of stem cells 
per single cord blood unit. 
Adult stem 
cells 
 No ethical, religious or political 
controversies. 
 Effective in generation their tissue 
of origin.   
 No risk of teratoma formation. 
 Established clinical history.  
 Often invasive collection 
procedure. 
 Limited cell numbers in 
human body tissues. 
 Limited differentiation 
capabilities.  
 Limited supply. 
 Limited availability of HLA-
match donors. 
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1.5.5 Neural potential of cord blood non-hematopoietic multipotent stem cells 
To evaluate the potential role of umbilical cord blood stem cells as a promising therapeutic 
tool for the treatment of neural diseases, extensive research has focused on the neural 
capability of these cells. Umbilical cord blood non-hematopoietic multipotent stem cells 
have shown high potential for neural differentiation in-vitro. The mononuclear fraction of 
umbilical cord blood which contains the non-hematopoietic multipotent stem cells has 
produced neuron-like cells  expressing neuronal specific markers such as Neurofilament 
200 (NF200), β-TUBULIN III and mature neuronal proteins including  Neural Nuclei 
(NEUN) and post synaptic density protein 95 (PSD95) after controlled neuronal induction 
in-vitro (Ali et al., 2009, Neuhoff et al., 2007, Habich et al., 2006).  
In order to further understand and analyze the neural differentiation potential and molecular 
pathways governing neural commitment in umbilical cord blood non-hematopoietic 
multipotent stem cells, scientists have utilized various techniques to purify this population 
of cells from cord blood hematopoietic cells and subject them to neural induction protocols 
in-vitro, followed by various neural characterization assays to evaluate the cellular neural 
potential. Several groups have purified cells that are negative for hematopoietic markers 
CD34 and CD45 and showed this purified cell population to be capable of producing 
neuron-like, astrocyte-like and oligodendrocyte-like cells characterized by their 
morphological features and specific proteins expression patterns including β-TUBULIN III 
as a neuronal marker, S100β as a marker of astrocytes and galactosylceramidase protein 
(GALC) as a marker of oligodendrocytes (Buzanska et al., 2006b, Jurga et al., 2006, 
Buzanska et al., 2002, Domanska-Janik et al., 2006). Other groups utilized negative 
depletion strategies (which will be further discussed in chapter 3) to enrich umbilical cord 
blood multipotent non-hematopoietic stem cells and show that these cells exhibit several 
neural morphologies including neuron-like, astrocyte-like and oligodendrocyte-like 
morphologies and express specific proteins for each neural subtype after in-vitro neural 
induction protocols (McGuckin et al., 2008, Chua et al., 2009).   
Other research groups have investigated the functional properties of cord blood-derived 
neuron-like cells. They have shown that cord blood derived neuron-like cells expressed 
many functional neurotransmitter receptors and ion channels that are involved in neuronal 
signal transmission and the generation of an action potential (Zangiacomi et al., 2009, Sun 
et al., 2005, Buzanska et al., 2006a). Several other groups have demonstrated that cord 
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blood derived neurons can generate and transmit action potential in a similar pattern to that 
of primary cultures of neurons (Sun et al., 2005, Jurga et al., 2009). Other functional 
neuronal properties such as calcium-influx have also been confirmed in cord blood derived 
neuron-like cells (Zangiacomi et al., 2008).  
Umbilical cord blood multipotent non-hematopoietic stem cells have demonstrated neural 
differentiation capabilities in-vitro including the generation of functional neurons capable 
of firing and transmitting action-potential signals in a similar manner to those of primary 
cultures of neurons. The neural differentiation capability of umbilical cord blood stem cells 
highlights its potential as a promising therapeutic tool for neural injuries and disorders for 
which current modes of therapies is inadequate.  
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1.6 The human nervous system 
From a general perspective, the nervous system can be viewed as the control center of the 
human body which manages and coordinates functions of all different organ systems. The 
nervous system is also responsible for sensing and responding to different environmental 
stimuli, it receives information from sensory receptors, processes these information signals, 
determines a proper response and then sends commands to the appropriate destination to 
initiate the response. The nervous system is also responsible for sophisticated functions 
such as memory, learning, thinking and social communication.  
The nervous system is the system that defines us as human beings by providing us with the 
ability to think, learn and communicate in a way that distinguishes us from all other 
species. It is one of the most complex organ systems anatomically and physiologically in 
the human body.   The human central nervous system (CNS) forms the core of the entire 
nervous system. It is composed of two main structures, the brain and the spinal cord. The 
CNS is regarded as one of the most complex systems in the human body, from both 
anatomical and functional levels.  
 
1.6.1 The human adult brain  
The brain forms the core of the CNS. It resides in the head enclosed in the thick bone of the 
skull called the “cranium”. The brain is suspended in cerebrospinal fluid (CSF) which is a 
clear bodily fluid that cushions the brain providing it with extra protection in addition to 
providing the brain with nutrients (Di Terlizzi and Platt, 2006, Johanson et al., 2008, Bear 
et al., 2007). 
The human adult brain weighs an average of 1.5 kilograms and hosts about 100 billion 
neurons organized in distinct and complex functional and anatomical structures (Herculano-
Houzel, 2009, Noctor et al., 2007, Doetsch, 2003a, Azevedo et al., 2009).  
A medial cross section of the human adult brain reveales many of its deep parts and 
structures (figure 8). It shows the “brainstem” which consists of the “thalamus”, 
“hypothalamus”, “tectum”,”tegmentum”, “pons” and “medulla” (Bear et al., 2007). These 
structures  carry out several crucial functions. The “thalamus” is the largest structure of the 
“diencephalon” and is located on the top of the brainstem close to the center of the brain. It 
is involved in relaying sensory and motor inputs to the “cerebral cortex” (Guillery and 
Sherman, 2002). Beneath the “thalamus” lies the “hypothalamus” which is involved in the 
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control of the autonomic nervous system (ANS), the pituitary gland and other processes 
including body temprature, hunger and thirst (Chiamolera and Wondisford, 2009, 
Lopaschuk et al., 2010, Suzuki et al., 2010a, Nillni, 2010, Mebis and van den Berghe, 
2009). Beneath the “thalamus” lies the midbrain which consists of the “tectum” and 
“tegmentum”. The „tectum” which is located in the dorsal region of the midbrain controls 
auditory and visual responses (Cappe et al., 2009, Bear et al., 2007). The “tegmentum” 
which forms the floor of the midbrain controls motor functions and is also involved in 
regulation of consciousness, mood, pleasure and pain (Taube, 2007, Iniguez et al., 2010, 
Sukhotinsky et al., 2006). The lower part of the brainstem consists of the “pons” and 
“medulla” which are parts of the hindbrain. The “pons” which is ventral to the 
“cerebellum” and above the “medulla” forms a bridge between the “cerebrum” and the 
“cerebellum” by relaying information signals between these two structures (Bear et al., 
2007, Nieuwenhuys et al., 2008). Beneath the “pons” lies the “medulla” which forms the 
bottom part of the brainstem. The “medulla” hosts the cardiac, respiratory and vasomotor 
centers (Goodchild and Moon, 2009, Allen et al., 2009, Horiuchi et al., 2004). The posterior 
part of the bottom of the brain is formed by the “cerebellum” which is derived from the 
hindbrain. It is attached to the brainstem via the “pons”. The “cerebellum” plays a key role 
in coordinating the body movements, balance and equilibrium (Bastian, 2006, Bear et al., 
2007, Schmahmann, 2004). 
The largest component of the brain is the “cerebrum” which is divided into two 
symmetrical left and right “cerebral hemispheres” residing in the lateral regions of the brain 
above the brainstem. The outside of each cerebral hemisphere is covered by a layer of 
folded “grey matter” called the “cerebral cortex”. Deep inside the “cerebrum” lies a 
compact cluster of neurons forming the “basal ganglia” which is involved in learning and 
memory (Da Cunha and Packard, 2009, Packard and Knowlton, 2002). Medial to the lateral 
ventricle of the forebrain rests a specialized piece of cortex known as the “hippocampus” 
that is involved in long term memory functions (Bear et al., 2007, Axmacher et al., 2010). 
Collectively, the “cerebrum” is involved in controlling voluntary movement, sensory 
perception, learning, communication and memory (Bear et al., 2007, Zilles and Amunts, 
2010, Nieuwenhuys et al., 2008).  
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Figure 8. Cross section of human adult brain and associated structures. Image adapted from (Bear et al., 
2007). 
 
1.6.2 The human nervous system: cellular units  
Each organ in the human body is made up of specific cells that share specified features and 
performing certain tasks and functions. The human nervous system is built up of unique 
types of cells. These cells are classified into two main categories: neurons, which are 
specialized neural cells defined by their capability to generate and transmit electric signals 
in the form of action potentials, and glial cells that do not directly transmit signals but have 
a supportive role for neural cells (figure 9). The human adult brain consists of around 100 
billion neurons and 10 times more glial cells (Noctor et al., 2007, Nishiyama et al., 2005, 
Doetsch, 2003).  
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Figure 9. Cellular components of the nervous system. Neurons and glial cells are the building blocks of the 
nervous system.  
 
Each cellular component of the nervous system has its unique roles, tasks and features. The 
collaborative regulated interaction between neurons and glial cells is essential for the 
nervous system to function properly (Fields and Stevens-Graham, 2002, Allen and Barres, 
2009, Salmina, 2009). Below is a description of the main cellular component of the nervous 
system, the neurons. For information about glial cell, refer to table 18 in Appendix.I.  
 
1.6.2.1 Neurons: the main cellular component of the nervous system  
Neurons are the main functional and cellular component of the nervous system. They are 
defined as electrically excitable cells capable of processing and transmitting information 
signals in the form of action potentials. Neurons also transmit signals chemically through 
synaptic transmission from one neuron to the other (figure 10) (Bear et al., 2007, Allen and 
Barres, 2009, Barnett and Larkman, 2007).  
Nervous system
Neurons Glial cells
Astrocytes 
Oligodendrocytes 
/ Schwann cells
Microglia
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Figure 10. Neuronal synapse. Neurons transfer information between each other using neurotransmitters at 
the synapse. The action potential in the axon of the pre-synaptic cell triggers the release of neurotransmitters 
into the synaptic cleft from the synaptic vesicles. The neurotransmitters bind and activate their specific 
receptors on the dendrites of the post-synaptic cell. Depending on the type of the neurotransmitter (for 
example excitatory/inhibitory), specific response from the post-synaptic cell will be initiated (fire action 
potential or inhibit action potential firing). 
 
There are many different types of neurons and understanding how each single neuron 
contributes functionally in the nervous system is quite difficult. However, dividing neurons 
into subgroups/categories based on either morphological features or functional properties 
can help ease the complexity of this issue by understanding the properties of each subgroup 
and its functional involvement in the nervous system (Bear et al., 2007, Bota and Swanson, 
2007). 
Neurons can be classified based on morphological features including the number of 
neurites, morphology of dendrites and axon length. From a functional perspective, neurons 
can be classified based on their functional connections into: “sensory neurons” that deliver 
signals from sensory parts of the body to the CNS (Duchamp-Viret et al., 2003, Bear et al., 
2007). Neurons that deliver signals from the CNS to muscles and cause muscle contraction 
are classified as “motor neurons” (Lin et al., 1998, Bear et al., 2007). Neurons that are not 
sensory or motor neurons are termed “interneurons” (Ascoli et al., 2008, Markram et al., 
2004, Bear et al., 2007).  
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Neurons can also be classified based on the neurotransmitter they produce and utilize (table 
4)  (note: only common neurotransmitters are listed here) 
 
Table 4. Classification of neurons based on neurotransmitter production.  
Neuron Description 
Glutamatergic 
neurons 
These neurons utilize glutamate in signal transduction. Glutamate, a non-essential 
amino acid, is the principal and most common excitatory neurotransmitter in the 
CNS (Kaltschmidt et al., 1995, Meldrum, 2000, Greenamyre, 1986, Foster and 
Kemp, 2006). Neurons have 3 types of glutamate receptors AMPAR, NMDAR 
and mGluRs. The AMPAR and NMDAR complexes have ion channels which 
when activated allow Ca
2+ 
and Na
+
 into the cell mediating fast excitatory synaptic 
transmission (Nowak et al., 1984, Foster and Kemp, 2006). The mGluRs are 
coupled to G-protein complexes which when activated release Ca
2+ 
from internal 
calcium storage involved in modulating synaptic transmission and mediating 
intracellular signal transduction (Elmslie, 2003, Mattson, 2008, Ryglewski et al., 
2007, Meldrum, 2000, Palmada and Centelles, 1998, Foster and Kemp, 2006). 
GABAergic 
neurons 
 
These are the neurons that manufacture and utilize GABA as their 
neurotransmitter. GABA is synthesized in these neurons from glutamate through a 
chemical reaction mediated by the enzyme glutamate decarboxylase 1 (GAD1) 
(Foster and Kemp, 2006).   GABA is the most abundant inhibitory 
neurotransmitter in the CNS (Zeilhofer et al., 2009, Foster and Kemp, 2006). 
GABA has two types of receptors, GABA A receptors and GABA B receptors. 
GABA A receptors are ligand-gated ion channels while GABA B receptors are G-
protein coupled receptors (Enna and Möhler, 2007, Foster and Kemp, 2006). 
Cholinergic 
neurons 
These neurons manufacture and utilize acetylcholine (Ach) as neurotransmitter 
which is the major neurotransmitter at neuromuscular junctions (Zholos, 2006), 
while in the CNS it is more associated with anti-excitatory and modulary actions 
(Gulledge et al., 2009, Alkondon and Albuquerque, 2004, Gulledge et al., 2007). 
Ach has two types of receptors nAChR and mAChR (Gahring and Rogers, 2005). 
The nAChR are fast response ligand-gated ion channels that are permeable to ions 
such as Na
+
, K
+
 and Ca
2+
 and stimulated by nicotine and Ach. The mAChR are 
metabotropic receptors (G protein-coupled) stimulated by muscarine and Ach 
(Gahring and Rogers, 2005, Ishii and Kurachi, 2006). 
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Dopaminergic 
neurons 
 
These neurons manufacture dopamine, a monoamine, and utilize it as their 
neurotransmitter. They biosynthesize dopamine from L-Tyrosine which is first 
converted to L-DOPA via the enzyme Tyrosine hydroxylase (TH), the rate 
limiting enzyme. Then the L-DOPA is converted to dopamine via the enzyme 
dopa-decarboxylase (DDC) (Borges et al., 2002, Lee et al., 2008). Dopamine 
receptors are metabotropic G protein-coupled receptors (Girault and Greengard, 
2004). 
 
Serotonergic 
neurons 
 
Serotonergic neurons are the neurons that manufacture serotonin, a monoamine, 
and utilize it as their neurotransmitter. These neurons biosynthesize serotonin 
from L-tryptophan through a sequence of two successive reactions catalyzed by 
tryptophan hydroxylase (TPH), the rate limiting enzyme, and amino acid 
decarboxylase (DDC). Serotonin has two types of receptors: metabotropic G 
protein-coupled receptors and ligand-gated ion channels (Hannon and Hoyer, 
2008, Bockaert et al., 2006). The receptors exert both excitatory and inhibitory 
neurotransmission effects on target neurons when activated (Saruhashi et al., 
1994, Best and Regehr, 2008).  
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 Neuronal action potential 
Action potentials are generated and utilized by neurons to transfer information signals from 
once place to the other in the nervous system. It is defined as a short fluctuation of 
membrane potential as a result of rapid opening and closing of voltage-gated ion channels. 
It propagates along the neuron‟s axon until reaching its terminals transferring information 
signals (Bear et al., 2007). In addition to neurons, action potentials are also generated by 
other types of cells such as muscle cells which utilize the action potential in muscle 
contractions (Williams and Ratel, 2009) and endocrine cells where it is involved in the 
release of hormones such as insulin (MacDonald and Rorsman, 2006). 
In neurons, the action potential has a distinct pattern composed of certain parts as shown on 
the oscilloscope graph (figure 11). The first part is called the “rising phase” where the 
membrane potential increases rapidly above the resting potential (-70 mV) in response to a 
rapid depolarization of the membrane until it reaches a peak value around (40 mV). The 
part where the membrane potential has a positive value above (0 mV) is called the 
“overshoot phase”. The “falling phase” of the action potential is a phase caused by a rapid 
repolarization of the membrane until the membrane potential reaches a value less than the 
resting potential in a phase called the “after-hyperpolarization”. The membrane potential 
will gradually increase until the resting potential is once again restored. The action potential 
is a very rapid process; the entire process lasts for about 2 milliseconds (Barnett and 
Larkman, 2007, Bear et al., 2007, Nieuwenhuys et al., 2008).  
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Figure 11. Neurons action potential. The depolarization phase is stimulated by the movement of Na
+ 
into 
the cell through the Na
+
 voltage-sensitive ion channels until the K
+
 voltage-sensitive gated channels open and 
initiate the repolarization phase mediated by the movement of K
+
 outside the cell. Image adapted from (Bear 
et al., 2007).  
  
 
 
The generation and propagation of an action potential is a highly systematic process. The 
membranes of neuronal axons host a high density of voltage-sensitive ion channels. The 
rapid movements of ions including Na
+
 and K
+
 across the membrane in response to changes 
in membrane potential forms the basis of the action potential mechanism.   
The first phase of the action potential, which is characterized by rapid depolarization of the 
membrane, is mediated by rapid movement of Na
+ 
into the cell through the Na
+
 voltage-
sensitive ion channels. This event can be triggered in various ways, for example, in sensory 
neurons, a stretch of nerve fiber in skin by a mechanical force is sufficient to open special 
Na
+
 channels allowing Na
+ 
into the cell (Bear et al., 2007). In the CNS, synaptic events 
which include the release of neurotransmitters are integrated into signals sufficient to 
initiate membrane depolarization (Barnett and Larkman, 2007).  The initial depolarization 
which is mediated by an increase in membrane permeability to Na
+
 results in an increase in 
the membrane potential which induces the opening of a small number of Na
+
 voltage-
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sensitive ion channels allowing more Na
+
 to enter the cell since the voltage inside the cell is 
more negative than the voltage outside the cell. This influx of Na
+
 results in what is called 
the “local depolarizing response” of the membrane. The influx of Na+ continues to add to 
the depolarization of the membrane until it reaches a threshold (around -45 mV) which 
triggers rapid opening of more Na
+
 voltage-sensitive ion channels adjacent to the 
previously opened channels and causing the rapid depolarization phase which overshoots 
the membrane potential above (0 mV) (Bear et al., 2007, Barnett and Larkman, 2007). The 
increased potential of the membrane triggers the opening of K
+
 voltage-sensitive gated 
resulting in rapid movement of K
+
 outside the neuron and causing the repolarization of 
membrane which would bring the membrane potential back to a negative value. The 
systematic termination of the depolarization and initiation of repolarization phases are 
explained by the properties of Na
+
 and K
+
 voltage-sensitive ion channels. Na
+
 voltage-
sensitive channels stay open for a short period of time after activation (about 1 millisecond) 
before they closed (inactivate). They will remain close (inactive) until the membrane 
potential returns back to a negative value near the threshold. As the K
+
 voltage-sensitive 
channels continue to open and the Na
+ 
voltage-sensitive channels become inactive/closed, 
the membrane potential is driven back toward the resting potential. The activated K
+ 
channels start to close as the membrane potential hyperpolarizes, at this phase the 
membrane potential becomes slightly more negative than the resting potential before it 
gradually restores the resting potential (Barnett and Larkman, 2007, Bear et al., 2007).  
Depolarization of a certain area on the axon‟s membrane by the action potential produces 
local currents that depolarize the adjacent membrane. If these currents are sufficient enough 
to depolarize these areas to the threshold, the action potential will propagate down the axon 
until it reaches the axon‟s terminal and initiates synaptic transmission.  
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1.7 Central nervous system: injuries and disorders  
Beside its complex anatomy and physiology, the central nervous system is one of the most 
delicate systems in the entire human body. CNS injuries and disorders are one of the most 
dangerous and fatal health conditions worldwide.  In a report published by the World 
Health Organization (WHO), CNS related injuries and disorders including Stroke and 
Alzheimer‟s disease (AD) were reported among the leading causes of death globally  
( http://www.who.int/mediacentre/factsheets/fs310_2008.pdf).  
Despite the extensive efforts focused on developing treatments for CNS injuries and 
disorders, the current modes of therapy are inadequate and ineffective against such 
conditions. This highlights the need for an alternative approach to tackle this problem and 
offer effective treatments for CNS injuries and disorders. 
1.7.1 Neurodegenerative diseases: Alzheimer’s and Parkinson’s diseases  
Among the most devastating CNS disorders is a group of diseases collectively termed 
“neurodegenerative diseases”. As the name implies, these diseases are caused and 
associated with progressive loss or death of neurons in the brain. Alzheimer‟s and 
Parkinson‟s diseases (AD and PD respectively) are among the most common examples of 
neurodegenerative diseases. Both diseases show late-onset (progress with age) and are 
caused by accumulation of toxic proteins leading to progressive loss of neuronal function 
and eventually neuronal death (Rubinsztein, 2006, Hashimoto et al., 2003).    
 Alzheimer’s disease (AD) 
Alzheimer‟s disease (AD), the most common type of dementia,  was described for the first 
time in 1906 by the German psychiatrist Alois Alzheimer and was named after him 
(Goedert and Spillantini, 2006). AD is a neurodegenerative disease that is associated with 
impaired cognitive skills including loss of memory (Goedert and Spillantini, 2006). 
According to Alzheimer's Disease International federation (ADI), in the United States 
alone, 5.3 million people have Alzheimer disease, 96% of these people are aged 65 and 
older (Maslow, 2010). In 2007, AD was reported as the sixth leading cause of death across 
all ages in the United States (Xu, 2009). These devastating figures demonstrate the 
seriousness of AD and reveal the current lack of effective therapies and treatments.  
AD pathology is characterized by the presence of senile plaques, on the blood vessels and 
outside the neurons of the brain, composed mostly of amyloid-β, a 40-42 amino acid 
protein generated by the proteolytic cleavage of amyloid precursor protein (APP)  (Neet 
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and Thinakaran, 2008, Goedert and Spillantini, 2006). These senile plaques have toxic 
effects on brain neurons which eventually lead to their death. The genetic basis of AD is 
very complex with many genes involved in the pathogenic pathway of the disease. Current 
understanding of the disease suggest that AD can be viewed as a consequence of the 
imbalance between amyloid-β production and clearance which leads to its accumulation 
outside the neurons and in the blood vessels of the brain triggering its neurodegenerative 
effect (Bettens et al., 2010, Goedert and Spillantini, 2006).  
There are currently two classes of drugs for the treatment of AD approved by the US Food 
and Drug Administration (FDA), the cholinesterase inhibitors and the D-aspartic acid 
(NMDA) receptor antagonist memantine (Doody, 2003, Melnikova, 2007). Unfortunately, 
both classes of drugs have failed to either prevent or reverse the progression of the AD 
(Melnikova, 2007, Aderinwale et al., 2010). 
While the number of deaths caused by other major causes of death including the number 
one cause of death, namely heart disease, has declined over the past few years in the United 
States, the number of deaths caused by AD continues to rise (Maslow, 2010, Xu, 2009). It 
has been estimated that by 2030 the number of people aged 65 and above with AD in the 
United States will reach 7.7 million individuals, that is more than a 50% rise (Maslow, 
2010, Xu, 2009). Unless a major medical breakthrough provides successful and effective 
therapies to treat AD are found, the numbers of AD patients will continue to rise claiming 
more lives worldwide.  
 Parkinson’s disease (PD) 
Parkinson‟s disease (PD) is named after the English apothecary James Parkinson who first 
described the disease in 1817. PD patients show various symptoms, most of them are 
associated with body motor functions, including resting tremor, bradykinesia, postural 
instability, gait difficulty and muscular rigidity (Thomas and Beal, 2007, Wood-Kaczmar et 
al., 2006). PD is the second most-common neurodegenerative disease in the Western world 
after AD, latest estimations revealed that in the United States alone, there are more than 1.5 
million individuals affected with PD (Wood-Kaczmar et al., 2006, Thomas and Beal, 2007, 
Lesage and Brice, 2009). This devastating disease, which currently has no cure, is listed 
among the leading causes of death in the United States (Xu, 2009). 
PD is a late-onset chronic neurodegenerative disorder characterized by selective 
degeneration and progressive death of brain‟s dopaminergic neurons and the presence of 
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Lewy bodies which are abnormal protein aggregates, in the surviving neurons in several 
brain regions (Thomas and Beal, 2007, Wood-Kaczmar et al., 2006).   
The genetic basis of PD is very complex showing both dominant and recessive modes of 
inheritance (Lesage and Brice, 2009). A number of mutations in several genes have been 
shown to trigger and stimulate the pathogenic pathway of the disease which leads to the 
abnormal accumulation of α-synuclein-ubiquitin protein inside the neurons forming the 
Lewy bodies, a hallmark feature of PD (Lesage and Brice, 2009). This abnormal protein 
accumulation has a neurotoxic effect which leads to a progressive death of the neurons in 
the brain (Wood-Kaczmar et al., 2006, Lesage and Brice, 2009). 
Current therapies for PD include administration of L-DOPA (which is transformed to 
dopamine in dopaminergic neurons), dopamine agonists and monoamine oxidase (MAO) B 
inhibitors. All these drugs are based on the concept of exogenous replacement of dopamine. 
Unfortunately, beside their significant side effects, none of these drugs are able to slow or 
treat the progression of the PD as their effect is limited to mild symptom relief (Schapira, 
2005, Wood-Kaczmar et al., 2006).  
 
1.7.2 CNS injuries 
 Neurovascular injuries: Stroke 
Stroke is defined as a sudden death of brain cells in a localized area due to disturbance in 
the blood supply to these brain areas. According to the World Health Organization (WHO), 
stroke is the second most common cause of death after heart disease and a major cause of 
disability worldwide (Donnan et al., 2008, Deb et al., 2010).  
Stroke can be caused by either blockage or leakage of the blood supply to the brain tissues. 
Strokes caused by blockage are termed “ischemic strokes” which are the most common 
type of stroke. In ischemic stroke, the blood supply to a part of the brain is reduced, causing 
dysfunction and death of the neural tissues at this specific part. This reduction of blood 
supply is mostly caused by the underlying disease process of atherosclerosis, in which 
hardening and narrowing of the vessels promotes blood clotting and obstruction of blood 
flow. Blockage and reduction of blood supply to the brain tissues reduce the supply of 
oxygen and glucose to these tissues. Without sufficient amounts of oxygen and glucose 
supplied to the brain cells, these cells will stop functioning and die after a while leading to 
irreversible brain damage (Hall et al., 2009, Deb et al., 2010).  
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Stroke caused by leakage of blood from the blood vessels is termed “hemorrhagic stroke”. 
This type of stroke occurs mostly in people with high blood pressures or in people with a 
congenital weakness in the blood vessels. This type of stroke occurs when the blood vessel 
is ruptured leading to bleeding within the brain tissue causing damage and death of the 
affected brain tissues. Hemorrhagic stroke is regarded as more dangerous than ischemic 
stroke because the pathogenic impact is not only caused by disrupted blood supply to the 
brain tissue but mostly because of irritant pressure symptoms and toxic effects of the 
released blood on surrounding brain tissue (Deb et al., 2010).  
The symptoms of stroke vary depending on the affected area of the brain. The more brain 
regions affected, the more functions are affected and are likely to be lost, leading to various 
forms of disability and death. The irreversible damage and death of brain tissues caused by 
stroke underline its devastating outcomes (Deb et al., 2010, Donnan et al., 2008).  
Currently, much of the efforts are focused on stroke prevention by altering life-style risk 
factors such as hypertension, smoking, physical inactivity and diet (Deb et al., 2010). Other 
serious stroke risk factors such as carotid stenosis and atrial fibrillation are managed and 
treated using anti-coagulants drugs such as aspirin and warfarin, or in some cases by 
surgical intervention, in order to minimize the likelihood of stroke occurrence (Deb et al., 
2010, Mohr et al., 2001, Schwartz and Albers, 2010). However, when stroke occurs, 
therapeutic options become very limited. For acute ischemic stroke, the FDA has approved 
the use of thrombolysis with intravenous recombinant tissue plasminogen activator (tPA) 
but the effectiveness of this therapy is limited by stroke severity and the time of 
intervention after stroke occurrence (Deb et al., 2010, Katzan et al., 2004, Kimura et al., 
2010). The damage and death of brain tissues caused by stroke is an irreversible process 
and responsible for the severe outcomes including death. Current treatments and therapies 
are ineffective when it comes to functional recovery of the damaged brain tissues.  
 
 Traumatic brain injuries (TBI) 
Traumatic brain injury (TBI) occurs as a result of external mechanical forces causing 
traumatic damage to the brain. TBI is regarded as one of leading cause of death and 
disability worldwide. In the United States alone, it is estimated that 1.6 million people 
sustain a form of TBI per year causing 52.000 deaths and around 80.000 patients with brain 
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damage and behavioral impairment (Maegele and Schaefer, 2008, Corrigan et al., 2010, 
Summers et al., 2009).  
The pathological impact of TBI is subdivided into two categories, primary and secondary 
injuries. Primary injuries are caused by the direct mechanical insult to the brain tissue 
leading to neural tissue destruction and death and occur at the moment of trauma. 
On the other hand, secondary injuries can develop over a period of hours or days following 
the TBI assault. The secondary cascade of events occurs as a result of altered gene 
expression and impairment of the regulation of certain cellular functions which contribute 
to the damaging impact of the injury. These events include excitotoxicity, dysregulation of 
calcium homeostasis and mitochondrial dysfunction (Maegele and Schaefer, 2008, 
Richardson et al., 2010, Povlishock and Katz, 2005).    
Currently there is no effective treatment for TBI besides supportive care. Several clinical 
trials for using neuro-protective drugs that target the secondary cascade of events following 
TBI have failed to show any improvements in the outcomes (Maegele and Schaefer, 2008, 
Tolias and Bullock, 2004).  
 
1.8 Stem cells: a potential therapeutic tool for CNS injuries and disorder 
1.8.1 Historic overview: the discovery of neural stem cells (NSC) and adult neurogenesis 
It has been long thought that the adult human CNS is incapable of self-renewal and 
generating new neurons. In 1928, Ramon Y. Cajal, a pioneer brain histologist, wrote "In 
adult centers the nerve paths are something fixed, ended, immutable. Everything may die, 
nothing may be regenerated” (Colucci-D'Amato et al., 2006). What also influenced the 
entire field to accept such conclusion was the relative lack of recovery noticed after a CNS 
injury or disorder. So it was widely accepted that neurogenesis was completely arrested 
after birth and doesn‟t occur in the adult brain.  
In 1965, Joseph Altman utilized tritiated thymidine as a mitotic label and showed that cell 
divisions and proliferation occur constitutively in the adult brain, and specifically in the 
hippocampus (Altman and Das, 1965) and olfactory bulb (Altman, 1969). In 1981, Michel 
Kaplan reproduced Altman‟s results using the tritiated thymidine labeling in addition to 
electron microscopy (Kaplan, 1981). However, these results were not convincing to the 
scientific community because the criteria used to identify the new born neurons was mainly 
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based on morphological features due to the lack of neuronal specific immunocytochemical 
markers at that time.  In the early 1990s, laboratories in Canada and Australia demonstrated 
for the first time that neural stem cells could be isolated from adult mammals‟ brains, 
expanded and differentiated in-vitro to neurons (Reynolds and Weiss, 1992, Richards et al., 
1992). The advancing molecular technical tools during that time allowed both groups to 
utilize specific neuronal immunocytochemical markers to precisely and accurately identify 
and characterize neural stem cells and new born neurons. These isolated neural stem cells 
were later shown to have the potential to differentiate into neurons, astrocytes, and 
oligodendrocytes in-vitro (Reynolds and Weiss, 1996). These breakthrough results ended 
the previous dogma of neurobiology which restricted neurogenesis to embryonic brain 
tissues. It provided clear evidences that neurogenesis occurs in mammalian adult CNS. 
These findings established the basis of the new era of modern neuroscience from which 
more extensive studies and research were initiated to deeply investigate and understand the 
complex biology of the CNS.    
1.8.2 Adult neurogenesis and the neurogenic niches 
Adult neurogenesis has been shown to take place in two regions of the adult mammalian 
brain under normal conditions, the subventricular zone (SVZ) of the lateral ventricles and 
the subgranular zone (SGZ) of the dentate gyrus in the hippocampus (Zhao et al., 2008, 
Abrous et al., 2005, Sohur et al., 2006). Whether or not neurogenesis occurs in other 
regions of the adult mammalian brain is still being debated. At the SVZ and SGZ, special 
stem cell niches have been identified, these structures are specialized microenvironments 
that host the neural stem cells which are capable of differentiating into new neurons and 
glia cells throughout adulthood (Riquelme et al., 2008, Taupin, 2006). The cell-cell 
interactions mediated by the niche‟s cytoarchitectural organization (Fuchs et al., 2004, 
Conover and Notti, 2008), the extracellular matrix proteins (ECM), including laminin and 
collagen , and the diffusible factors and signals in niche‟s microenvironment, including b-
FGF and EGF, tightly regulate the balance between stem cell proliferation and 
differentiation (Kazanis, 2009, Riquelme et al., 2008, Doetsch, 2003b).  
The SVZ niche is composed of four major cells types: ependymal cells, neural stem cells 
(Type B cells), transit amplifying progenitor cells (Type C cells) and neuroblasts (Type A 
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cells) (figure 12). The ependymal cells line the walls of the ventricles forming a physical 
barrier between the SVZ and the cerebrospinal fluid (CSF). They also serve as a filtration 
system for ions and factors involved in the process of neurogenesis from the CSF. The 
neural stem cells are located subjacent to the ependymal cells surrounding the neuroblasts 
that are organized into chains forming the roastral migratory stream (RMS) leading to the 
olfactory bulb (OB). Between the neuroblasts lie the highly proliferative transitory 
amplifying progenitor cells. The niche cells are surrounded with extracellular matrix 
(ECM) that provides them with structural organization and support. The differentiation 
sequence starts when the neural stem cells (Type B cells), expressing glial fibrillary acidic 
protein (GFAP), are activated to generate transit amplifying progenitor cells (Type C cells), 
which are negative for GFAP. These highly dividing progenitor cells then differentiate into 
migrating neuroblasts (Type A cells) destined to the olfactory blulb (OB) through the RMS 
(Conover and Notti, 2008, Doetsch, 2003b, Riquelme et al., 2008). Once reaching the OB, 
these newly born neurons start terminal differentiation and maturation to produce mainly 
mature inter-neurons which are then integrated into the existing complex neuronal circuitry 
(Alvarez-Buylla and Garcia-Verdugo, 2002, Zhao et al., 2008). In addition to neurons, 
oligodendrocytes can also be generated in the adult SVZ (Ahn and Joyner, 2005, Riquelme 
et al., 2008, Menn et al., 2006).  
 
Figure 12. The SVZ neurogenic niche . It is composed of four main cell types: the ependymal cells (E) 
which separate the SVZ from the lateral ventricles, the neural stem cells (B) which surround the neuroblasts 
(A) and the transit amplifying cells (C). The neural stem cells (B) ,with self-renewal properties, divide to 
produce rapidly dividing transit amplifying cells (C) which differentiate into the neuroblasts (A) that migrate 
to the OB where they maturate and integrate into the brain‟s neuronal circuitry.  Image adapted from 
(Riquelme et al., 2008).  
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At the SGZ of the dentate gyrus in the hippocampus, the stem cell niche is smaller 
compared with the SVZ. The niche is located in close proximate to blood vessels between 
the granule cell layer and the hilus (figure 13). It contains neural stem cells that extend 
processes into the granule cell layer, dividing precursor cells (Type D cells) and newly 
generated neurons. In the SGZ, newly born neurons migrate a shorter distance, compared 
with the neurons of the SVZ, and reside in the granule cell layer of the dentate gyrus where 
they are integrated into the brain‟s neuronal circuitry throughout adulthood. Similar to the 
SVZ, the newly generated neurons at the SGZ originate from neural stem cells expressing 
GFAP in addition to NESTIN, an intermediate filament associated with multi-lineage 
progenitor cells with high proliferation characteristics. The neural stem cells divide to 
produce precursor cells (Type D cells), expressing NESTIN but not GFAP, which in turn 
differentiate into neurons which migrate, maturate and integrate in the granule cell layer of 
the dentate gyrus (Riquelme et al., 2008, Zhao et al., 2008, Doetsch, 2003b, Conover and 
Notti, 2008).  
 
Figure 13. The SGZ neurogenic niche. The niche has the shape of a pocket adjacent to the blood vessels 
(shown in yellow). The neural stem cells (B) with, self-renewal properties, divide to give the precursor cells 
(D) which differentiate into neuronal cells (A) that migrate and integrate in the granule cell layer of the 
dentate gyrus. Image adapted from (Riquelme et al., 2008).  
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Given its restricted regional occurrence, adult neurogenesis is likely to have specific 
functional contributions. It is has been demonstrated that adult neurogenesis in SVZ and 
SGZ, under normal conditions, is involved in some forms of learning and memory 
functions throughout a person‟s life (Sohur et al., 2006, Zhao et al., 2008). Adult 
neurogenesis is stimulated and enhanced by physiological factors and pathological 
processes such as stroke (Jin et al., 2006) and Alzheimer‟s disease (Yu et al., 2009, Jin et 
al., 2004). Cell tracking studies showed that newly generated neurons in the SVZ migrate, 
and integrate at the lesions sites (Arvidsson et al., 2002, Jin et al., 2003). But despite these 
facts, adult neurogenesis is still insufficient to induce recovery from such diseases and 
conditions due to its limited levels (Hess and Borlongan, 2008, Kim and de Vellis, 2009).  
Understanding the dynamics of the neurogenic niche, its cytoarchitectural organization, 
cell-cell interactions and the factors involved in neurogenesis holds the key to our 
understanding of adult neurogenesis and neuronal development which is very important 
when wanting to develop potential cellular therapies for CNS injuries and disorders.  
 
1.8.3 Neuronal differentiation of stem cells: in-vitro strategies   
The discovery of neural stem cells and adult neurogenesis focused the efforts to investigate 
the neuronal potential of different types of stem cells to assess the effectiveness of potential 
stem cell based therapies aimed at treating CNS diseases and disorders. This lead to the 
development of different in-vitro methods and strategies to differentiate different types of 
stem cell into neural lineages (figure 14). Among the common strategies is the use of 
conditioned media to differentiate stem cells into neural lineages in-vitro. These media are 
designed to mimic the in-vivo neurogenic microenvironments by containing specific 
morphogens and mitogens known to be crucial for the development of CNS and 
neurogeneis in neurogenic niches. Commonly, b-FGF, EGF and Retinoic acid (RA) are 
used to differentiate different types of stem cells into neuronal cells. The stem cells include 
embryonic stem cells, (Abranches et al., 2009, Wichterle et al., 2002, Zhou et al., 2008, Li 
et al., 2008, Li et al., 2005), mesenchymal stem cells (Wang et al., 2007, Lee et al., 2007), 
neural stem cells (Takahashi et al., 1999, Zahir et al., 2009) and iPS cells (Hu et al., 2010).  
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Figure 14. In-vitro strategies for neuronal differentiation of stem cells.   
 
Another neural differentiation strategy is achieved by the co-culture of stem cells with 
neural tissues and cells. This differentiation strategy is based on the fact that differentiated 
glial cells such as astrocytes secrete a number of factors that mediate, direct and regulate 
neurogenesis of neural stem cells in neurogenic niches (Chang et al., 2003, Nern and 
Momma, 2006). Several groups have successfully differentiated different types of stem 
cells using the co-culturing system. Rat neural stem cells have been differentiated into 
neurons using a co-culture system with cortical astrocytes (Song et al., 2002, Oh et al., 
2009). In another study, the co-culture of umbilical cord blood stem cells with astrocytes 
and oligodendrocytes promoted neuronal differentiation of the stem cells, while co-
culturing with differentiated neurons induced oligodendrogliogenesis of the same 
population of stem cells (Markiewicz et al., 2011).  
A relatively new strategy utilized RNA interference (RNAi) to differentiate stem cells into 
neuronal lineages in-vitro. This strategy is based on the concept of specific suppression of 
targeted gene translation by targeting its mRNA transcript using microRNA (miRNA). 
miRNA are short non-coding RNA molecules that are naturally found in many eukaryotic 
cells and are involved in post-transcriptional regulation of genes by binding to their 
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complementary sequences on corresponding mRNA molecules leading to translation 
suppression and gene expression silencing (Fire et al., 1998, Hannon, 2002, Bartel, 2004). 
It has been found that miRNA are involved in many biological processes including 
neuronal differentiation and adult neurogenesis (Papagiannakopoulos and Kosik, 2009, 
Shen and Temple, 2009, Cheng et al., 2009). Utilizing miRNA as an in-vitro tool to 
differentiate stem cells into neural lineages has attracted attention in recent years. 
Successful specific neuronal differentiation was reported when specific miRNA molecule 
(miRNA-125b) was ectopically expressed in human neural progenitor cells and 
neuroblastoma cell line (Le et al., 2009). In another study, the neuronal differentiation of 
neural stem cells, isolated from adult mouse forebrains, was enhanced when cells were 
transfected with the specific miRNA molecule (miR-9) (Zhao et al., 2009a). The fact that 
miRNA molecules are involved in regulating endogenous proliferation and differentiation 
of neural stem cells in the CNS offers a new in-vitro tool to direct the differentiation of 
stem cells into neuronal lineages (Perruisseau-Carrier et al., 2011). Nevertheless, more 
extensive research is required to fully understand the mechanisms of activity and pathways 
of miRNA molecules in stem cells and neuronal cells, which is crucial when considering 
potential cellular therapeutic applications.  
Recently, nanotechnology has also been utilized to differentiate stem cells into neurons. 
This technology utilizes nanoparticles, which are small clusters of atoms that have at least 
one dimension measuring 100nm or less, as carriers to transport certain factors and 
morphogens into the cells (Jiang et al., 2008, Maia et al., 2011). Maia et al.(2011) showed 
that SVZ neural stem cells can be differentiated in-vitro into functional neurons using 
nanoparticles coated with RA. Such result demonstrates the effectiveness of nanoparticles 
in transporting and releasing the desired growth factors and morphogens into the cells 
which might aid the development of novel treatment strategies for certain neurological 
conditions.  
The technology used to generate iPS cells was also utilized to produce neuronal cells from 
fibroblasts. Three genes (Mash1, Bm2 and Myt1) were introduced in rodent fibroblast cells 
using lentiviral vectors. The fibroblast cells converted into neurons in-vitro, after 
transfection with viral vectors, and were reported to generate action potentials and form 
functional synapses (Vierbuchen et al., 2010).  
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1.8.4 Stem cells based therapies for CNS injuries and disorders 
The discovery of adult neurogenesis in addition to the development of in-vitro strategies to 
differentiate various types of stem cells into neural cells, including neurons and glial cells, 
established the basis of a new direction of potential therapies for CNS injuries and 
disorders, arguably the most difficult conditions to treat, based on stem cells. The aim of 
these potential therapies is to compensate the diseased or injured CNS with new neurons to 
replace the damaged or dead ones in order to stimulate and enhance the recovery and 
reduce the pathological impact of the targeted diseases and disorders. The development of 
such therapies for CNS injuries and disorders requires an extensive detailed knowledge of 
the pathological process of the disease and its molecular and physiological impact on the 
brain cells and tissues.  
Stem cells have already been involved in studies aimed toward the development of 
potential therapies for CNS injuries and disorders and have shown promising results. In a 
rodent model of PD, embryonic stem cells have been transplanted into the striatum of the 
animals and results indicated that these transplanted cells differentiated into dopaminergic 
neurons. The study indicated gradual and sustained behavioral restoration of motor deficit 
in the animals after transplantation (Bjorklund et al., 2002). In another study on a mouse 
model of PD, embryonic stem cell derived dopaminergic neurons were transplanted into the 
animals and results reported indicated improvements for the behavioral and motor deficits 
(Barberi et al., 2003). Adult stem cells such as mesenchymal stem cells have also been used 
on mouse models of PD. The transplanted cells were reported to express tyrosine 
hydroxylase (TH) and the recipient animals demonstrated functional improvements (Li et 
al., 2001). In another study using a rat model of PD, human neural stem cells (NSC) were 
reported to stimulate significant behavioral improvements after transplantation into the 
striatum of the animals compared with the negative control (Yasuhara et al., 2006). 
Development of therapies for Alzheimer‟s disease (AD) is relatively more challenging 
compared with other diseases, because the AD pathological impact affects multiple brain 
regions and cell types. In an attempt to tackle the disease, both gene and cell therapies have 
been integrated together to treat the neuronal degeneration and cell death in AD patients. In 
a phase 1 clinical trial, autologous fibroblast cells have been genetically modified to 
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express human nerve growth factor (NGF), which has previously been shown to have a 
neuronal protective role in animal models of ageing and amyloid toxicity (Tuszynski and 
Blesch, 2004), and these fibroblast were then implanted in the brains of eight patients with 
mild AD. After a mean follow-up period of 22 months in six of the eight patients, the 
cognitive decline rate was improved and brain autopsy from one patient demonstrated 
robust neuronal growth in response to NGF secreted by the transplanted fibroblasts 
(Tuszynski et al., 2005, Tuszynski, 2007). Stem cells, which can be genetically engineered 
to express the wanted genes (Kim, 2004), have been proposed as an alternative to 
fibroblasts due to their high migratory capacity after brain transplantation (Flexman et al., 
2007, Kim and de Vellis, 2009). In a recent study on a mouse model of AD, neural stem 
cells were transplanted into the animals and improvements in cognitive function were 
reported and attributed to the enhancement of synaptic density in the hippocampus 
mediated by the brain-derived neurotrophic factor (BDNF) secreted by the transplanted 
cells (Blurton-Jones et al., 2009).  
Stem cells have also been involved in research aimed towards development of effective 
treatments for stroke. Emerging evidences has shown that stroke induces and enhances 
endogenous neurogenesis in injured brains, indicated by the presence of cells expressing 
markers associated with newborn neurons near the injury sites (Jin et al., 2006). However, 
as mentioned earlier, adult neurogenesis is not sufficient to induce functional and tissue 
recovery after stroke. Hence, stem cells therapies have been proposed as a potential tool 
that would enhance neurogenesis at injury sites and hopefully stimulate functional and 
cellular recovery. Different types of stem cells have been transplanted into animal models 
of ischemic stroke and in general they show positive results on both cellular and functional 
levels. In one of the experiments, transplanted human neural stem cells in a rodent model of 
ischemic stroke have been shown to migrate to the damaged site and differentiate into 
neurons and glial cells replacing the lost neural cells which improved the condition of the 
animals (Chu et al., 2003, Chu et al., 2004). Bone marrow mesenchymal stem cells have 
also been transplanted into animal models of ischemic stroke. Results indicated migration 
and neuronal differentiation of the transplanted cells around the lesion sites inducing 
significant behavioral and functional recovery (Chen et al., 2008, Shen et al., 2007). 
Recently, the UK based biotechnology company “ReNeuron” (Sinden, 2006), announced 
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the start of phase I of the world‟s first clinical trial to treat ischemic stroke using in-vitro 
expanded human neural stem cells derived from 12 week aborted fetuses (Christie, 2009). 
The study aims to treat male patients 60 years old or over suffering from moderate to severe 
disabilities following ischemic stroke. The proposed treatment involves the injection of 
expanded neural stem cell line “ReN001” into the patient‟s brain surgically and under 
general anesthetic. The trial is currently active and recruiting participants (Christie, 2009).  
1.8.5 Umbilical cord blood stem cells for CNS injuries and disorders 
Umbilical cord blood has proven its worth as an effective therapeutic tool for hematological 
disorders and diseases. Its clinical involvement dates back to the early 1970s when it was 
utilized to treat a 16 year old male suffering from lymphoblastic leukemia (Ende and Ende, 
1972). Since then, umbilical cord blood became a regular transplant in hematology at 
clinics and hospitals (Gluckman et al., 1989, Broxmeyer et al., 1990). However, the neural 
differentiation capability of umbilical cord blood stem cells has highlighted the further 
potential of cord blood as a promising therapeutic tool for CNS injuries and disorders. 
Umbilical cord blood stem cells have shown positive results on many animal models of 
CNS injuries and disorders. A few research groups have transplanted umbilical cord blood 
stem cells into rats subjected to middle cerebral artery occlusion (MCAO) in order to 
induce focal ischemia like pathology. Results indicated improvement in the animal‟s 
functional recovery and behavioral deficits associated with the disease after transplantation 
(Chen et al., 2001, Newcomb et al., 2006). Umbilical cord blood stem cells have also 
yielded positive results when transplanted into a rat model of hemorrhagic stroke. The 
stroke was induced in the animals by intra-striatal injections of collagenase to cause 
bleeding in the striatum. Twenty four hours after inducing the injury, the animals received 
cord blood intravenously. Results revealed that transplantation of umbilical cord blood stem 
cells improved the neurologic deficits associated with the disease compared with the 
control groups (Nan et al., 2005).  
Positive results have also been achieved on rat‟s model of traumatic brain injury (TBI) 
transplanted with umbilical cord blood. Intravenously transplanted cord blood stem cells 
were detected in injured brain, where some of the cells were integrated into the vascular 
walls in the boundary walls of the injured area. The transplanted cells tested positive for 
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neuronal specific markers NeuN and MAP2, demonstrating both migratory and neuronal 
capacities. More importantly, the transplanted cells significantly improved motor and 
neurological deficit when compared to the control group 4 weeks after the treatment (Lu et 
al., 2002). Similar positive outcomes were observed when umbilical cord blood was 
transplanted into the injury site of rat‟s model of spinal cord injury. Results from multiple 
studies show that transplanted cord blood cells induce significant functional/motor recovery 
and improved axonal regeneration at the injury site (Kuh et al., 2005, Saporta et al., 2003). 
Umbilical cord blood stem cells have also been involved in studies on animal models of 
neurodegenerative diseases including Parkinson‟s and Alzheimer‟s diseases. In one study, 
the mononuclear (MNC) fraction of umbilical cord blood was transplanted into mouse 
models of PD. Results from this preliminary study revealed that animals from the control 
group which did not receive the treatment died significantly earlier than those treated with 
the cord blood suggesting an ameliorating effect of cord blood on disease progression 
(Ende and Chen, 2002). In another study conducted on a mouse model of AD, 
transplantation of umbilical cord blood into the animals significantly reduced the Amyloid-
β plaques associated with AD in the brain tissues (Nikolic et al., 2008). The ability to 
reduce this pathological hallmark feature of AD represents a very important step toward the 
development of an effective treatment for the disease.  
Umbilical cord blood has already been utilized in a few clinical trials aimed to treat 
neurological diseases. In a clinical trial sponsored by Duke University in the United States, 
autologous umbilical cord blood cells have been utilized to treat newborn infants with 
hypoxic-ischemic encephalopathy, a condition caused by inadequate oxygen supply to 
brain tissues leading to cells damage (Perlman, 2006). The study which was launched in 
January 2008 will carefully monitor and asses the treatment progress during the 12 month 
period following the infusion of cord blood into patients. The study is expected to be 
completed by January 2011 (www.clinicaltrials.gov, trial code: NCT00593242). In another 
clinical trial also sponsored by Duke University, autologous umbilical cord blood is being 
used to treat pediatric patients with spastic cerebral palsy, a condition caused by damage to 
the motor control centers in developing brain leading to movement abnormalities and 
physical disability (www.clinicaltrials.gov, trial code: NCT01072370 and NCT01147653) 
(Harris, 2009). Early studies on animal models of cerebral palsy have indicated that that 
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fusion of cord blood lessens disease progression and significantly alleviates the spastic 
paresis associated with the disease. This therapeutic effect was attributed to the fact that the 
transplanted cells were detected in the brain and were incorporated around the lesion site 
(Meier et al., 2006). The clinical trial which was launched in January 2008 entered phase II 
and is due for completion in July 2013. Official study results are yet to be published but 
several media reports have indicated positive beneficial outcomes following the treatment 
(Kurtzberg, 2009, Harris, 2009). In another recent clinical trial conducted in University of 
Texas Health Science Center, autologous cord blood is utilized to treat pediatric patients 
sustaining moderate/severe  traumatic brain injury (TBI) (www.clinicaltrials.gov, trial code: 
NCT01251003). Clinical trials are still at its early stages but early indications suggest high 
potential and hope toward developing effective therapies for neural disorders and injuries 
using umbilical cord blood.  
1.9 Stem cells: a potential tool for drug testing and toxicology studies 
The process of drug development requires extensive research and testing to insure safety 
and effectiveness of any potential drug. Before any potential drug reaches clinical trials, 
extensive tests are performed mostly on animal models and in-vitro cultures, if available, to 
gather preliminary information about the drug‟s efficacy, toxicity and pharmacokinetics 
(figure 15). These pre-clinical studies are very important to determine whether or not the 
study shall proceed into clinical trials that involve testing on human beings. Pre-clinical 
studies are normally performed on animal models including rodents and mice. These 
studies offer a useful tool to evaluate the safety of the drugs tested. Nevertheless, the 
genomes, transcriptomes, proteomes and metabolomes between humans and animals differ. 
The molecular and physiological differences between humans and animal models might 
account for diverse reactions to a certain drug which might cause unpredicted dangerous 
reactions in humans (Zhao et al., 2009b, Rietjens et al., 2008). In addition, the 
physiological complexity of the animal models might not be helpful when it comes to 
simple toxicity tests and evaluation of drug toxic effects on the cellular level.  
In-vitro cultures of human cells offer a potential tool to overcome the limitations and 
disadvantages of animal models in drug and toxicology testing. Because they are human 
cells, these in-vitro cultures offer a better way to evaluate and predict dangerous reactions 
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to certain drugs when compared to animal models. In addition, the simplicity of such 
cultures, compared with whole animals, offers a more reliable and direct tool to perform 
simple toxicity tests and evaluate the outcomes at the cellular level. Such cultures can be 
established using specific types of human cells such as fibroblast and hepatocytes, 
depending on the nature and target of the drug or toxin tested (Paulsen and Ljungman, 
2005, Petit et al., 2008). Nevertheless, access to certain type of human cells including 
neural cells might be difficult due to limited supply of such cells. 
 
Figure 15. The current process of drug testing and its limitations. The first phase in drug testing is the 
pre-clinical phase (the red dotted box) in which the drug efficacy and safety are evaluated using animal 
models and in-vitro human cell cultures (if available).  This phase is followed by the clinical phase where the 
drugs are tested on human subjects before reaching the shelves for routine clinical use.  
 
Stem cells ability to differentiate into many cell types including neural lineages highlighted 
its potential in drug testing and toxicology studies. The ability to develop and establish 
effective protocols to produce neurons from human stem cells in-vitro offers a possible 
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solution to overcome the problems caused by the limitations of animal models and the 
limited supply of human neural cells needed for drug and toxicology testing targeting 
neural diseases and disorders. These cultures would allow deeper analysis of the drug 
effects on both cellular and molecular levels leading to better evaluation of its safety and 
efficacy before moving into clinical studies on human subjects.  
 
1.10 Summary 
Human umbilical cord blood is probably the largest, but under-utilized source of stem cells 
with the yearly global birth rate of 200 million per year (McGuckin et al., 2006, McGuckin 
et al., 2008). Cord blood non-hematopoietic multipotent stem cells, which demonstrated 
high potential for neural differentiation, are easily accessible, immunologically naive and 
are free from ethical controversies associated with other sources of stem cells. These added 
advantages made umbilical cord blood stem cells a potential candidate for CNS injuries and 
disorders clinical applications which current mode of therapy is inadequate. In addition, 
they might provide an in-vitro model of parenchymal neural cells for toxicology and drugs 
testing research. However, in order to assure potentially effective treatments and 
applications of umbilical cord blood stem cells, more research should be directed toward 
understanding the molecular properties of umbilical cord blood non-hematopoietic and their 
neuronal potential. This requires the development of effective purification and enrichment 
strategies of such cells to allow accurate analysis of the molecular mechanisms regulating 
the process of neuronal differentiation. It is also important to evaluate the neuronal 
functionality of generated cells to assess their therapeutic impact in potential clinical 
applications where the target is to recover brain functions lost a result of certain neural 
disease or condition.  
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1.11 Thesis layout  
The thesis has four main aims: firstly to purify umbilical cord blood non-hematopoietic 
multipotent stem cells; secondly to characterize neuronal differentiation of the purified 
cells; thirdly, to compare between the process of umbilical cord blood purified cells 
undergoing neuronal differentiation in-vitro and the process of human cortical neurogenesis 
and fourthly, to evaluate the neuronal functionality of generated neuron-like cells. Each aim 
is introduced in a chapter in the following order: 
 Chapter 3: Purification of umbilical cord blood non-hematopoietic multipotent 
stem cells. 
 Chapter 4: Defined sequential neuronal differentiation protocol for umbilical cord 
blood non-hematopoietic multipotent stem cells and neural tissue engineering 
application. 
 Chapter 5: In vitro modeling of human cortical neurogenesis using umbilical cord 
blood non-hematopoietic multipotent stem cells. 
 Chapter 6: Functional analysis of umbilical cord blood derived neurons. 
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2. Materials and methods 
 
2.1 Umbilical cord blood collection  
2.1.1 Inclusion criteria 
Ethical approval was sought and obtained from the Local Research Ethics Committee prior 
to any umbilical cord blood collection. Umbilical cord blood was stored in laboratories with 
a Human Tissue Authority license. A negative viral profile and infection status was 
required prior to any tissue collection. Informed consent from parents was obtained prior to 
delivery (refer to appendix.III for samples of collection and consent forms). Umbilical cord 
blood units were collected in the Caesarean sections Delivery Suite of the Maternity Unit in 
the Royal Victoria Infirmary at Newcastle University. All the ethical requirements required 
by hospital, university and National Health Service (NHS) have been fulfilled.  
2.1.2 Collection procedure  
For logistical and reasons of homogeneity of treatment, samples were only collected from 
caesarean section births. Umbilical cord blood collection was performed post partum, after 
the placenta was delivered. Clamping of the umbilical cord was performed by the surgeon 
according to standard protocols at the Royal Victoria Infirmary, Newcastle upon Tyne. The 
delivery procedure was not adjusted or modified for the purposes of this study (figure 16A). 
Three clamps were used for clamping the cord: one close to the cord-placenta joint, the 
second close to the baby and the third in the middle (figure 16B). Using a cone shaped 
collection vessel, the placenta was hung with the umbilical cord hanging downwards 
(figure 16B). Collection bags used for the procedure contained citrate phosphate dextrose 
adenine (CPD-A) as a anticoagulant and each bag had a needle attached [Baxter]. Using the 
needle and starting from the lowest point of the cord above the bottom clamp, the blood 
was drained into the bag using gravitational force (figure 16C,D). Once sample collection 
was complete, the unit was transported to the laboratory and processed the same day.  
Materials and methods 
 
 57 
 
Figure 16 .Umbilical cord blood collection procedure. (A) The placenta is placed on the cone shaped 
collection vessel with the cord on the bottom. (B) The vessel is hung from a stand allowing the clamped 
umbilical cord to hang downwards. (C,D) The blood is drained into the collection bag using a needle to access 
the cord.   
 
2.2 Umbilical cord blood mononuclear cells isolation 
Mononuclear cells (MNC) were separated from whole umbilical cord blood using Ficoll-
Paque™ PREMIUM [GE healthcare] on the same day as cord blood collection. Each 20 ml 
of blood was diluted with an equal volume of 1X phosphate buffered saline solution (PBS) 
[Sigma Aldrich]. The diluted sample was then layered very slowly on 10 ml of Ficoll-
Paque™ PREMIUM (figure 17A). The layered samples were centrifuged at 400 X g for 30 
minutes at room temperature with minimum acceleration and no deceleration. The resulting 
middle white layer containing the MNC was collected carefully using a sterile Pasteur 
pipette and placed in a 50 ml universal tube filled with PBS (Figure 17B). The resulting cell 
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suspension was centrifuged at 630 X g for 7 minutes at room temperature. The supernatant 
was discarded and cells were resuspended in 10 ml of PBS for a wash and the resulting 
suspension was centrifuged at 630 X g for 7 minutes at room temperate. The supernatant 
was again discarded and the cells were resuspended in either culture medium or PBS 
depending on the experimental needs. The cells were quantified using Coulter A
C
 T diff2 
cell counter [Beckton Coulter].  
 
Figure 17. Density gradient separation of umbilical cord blood mononuclear cells using Ficoll. Tube (A) 
shows the diluted cord blood 1:1 with PBS layered over the Ficoll. Tube (B) shows the blood components 
after the centrifugation step. The red blood cells collect in the bottom of the tube, with a layer of Ficoll above. 
The top layer contains the plasma and the mononuclear cells rich white layer lies at the interface between the 
Ficoll and the plasma. 
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2.3 Purification of umbilical cord blood stem cells 
2.3.1 StemSep® Primitive Hematopoietic Progenitor Cell Enrichment Kit (SC kit) 
StemSep® Primitive Hematopoietic Progenitor Cell Enrichment Kit (SC kit) is a 
commercially available kit [Stemcell technologies, catalogue number 14067]. Separation 
medium was prepared using 2% human albumin [Bio Products Laboratory] in PBS. 
Previously isolated MNC were resuspended in this separation medium at a concentration of 
5x10
7 
cells/ml. The StemSep® enrichment cocktail was added to this cell suspension 
(100µl of cocktail per 1 ml of cell suspension) and incubated at +4 ºC for 30 minutes. 
Magnetic colloids were added to the cell suspension (60 µl per 1ml of cells) and incubated 
at +4 ºC for 30 minutes. The resulting mixture was agitated gently every 10 minutes using a 
vortex. The mixture was transferred into a MACS® Cell Separation LS column [Miltenyi 
Biotec] and this placed within a specially designed magnet, MidiMACS ™ Separator 
[Miltenyi Biotec]. Cells were allowed to pass through the column by gravitational force. 
After all the mixture had passed through the column and into the collection tube, the 
column was washed with PBS. The cell suspension that passed through the column was 
centrifuged at 630 X g for 7 minutes at room temperature, the supernatant was discarded 
and the cell pellet was resuspended in culture medium. The cells were then counted and 
cultured.  
2.3.2 Lineage-Negative Separation Kit (Lin-Neg) 
MNCs were resuspended in 1ml of working buffer consisting of 0.2% human serum 
albumin [Bio Products Laboratory] in Hanks‟ balanced salt solution (HBSS) [GIBCO] in 
sterile 15 ml tube at a maximum cell density of 300x10
6
 cells. 500 µL of 2% human 
gamma-globulins [Fluka Chemie GmbH] diluted in PBS was added to the cell suspension 
and incubated for 20 minutes either at 4°C or on ice in order to block non-specific Fc 
receptors. Mouse monoclonal anti-human anti GlyA (CD235a) antibody was added at a 
concentration of 0.22 µg per 1X10
6
 cells and mouse monoclonal anti-human anti CD45 
antibody was added at a concentration of 0.5 µg per 1X10
6
 cells (table 5). The cell 
suspension was incubated for 30 minutes either at 4°C or on ice with gentle agitation on a 
rocker. Excess antibodies were washed using a 0.2% human serum albumin and 10% 
dextran [Baxter Healthcare Ltd] in PBS (wash buffer). The cell suspension was centrifuged 
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at 630 X g for 7 minutes at 4°C with maximum acceleration and medium deceleration. The 
supernatant was discarded and the cell pellet was resuspended in 500 µl of working buffer 
at a final cell density of 1X10
8
 cells. DynaBeads® panmouse IgG [Dynal biotech, 110.42] 
were added to the cell suspension (50 µl of beads per 1X10
7
 cells) and incubated for 30 
minutes either at 4°C or on ice with gentle agitation on a rocker. The resulting cell mixture 
was applied to a Dynal Magnetic Particle Concentrator (MPC-I) [Invitrogen, 120.01] for 2 
minutes. The supernatant was collected into a new sterile tube labelled “GlyA/CD45 
negative cells”. The remaining positive cell fraction was rinsed twice with 4 ml of working 
buffer and the supernatant was added to the “GlyA/CD45 negative cells” tube. The final 
cell suspension in the “GlyA/CD45 negative cells” tube was re-applied to the MPC-I at 
least 3 more times to completely remove all the positive cells. The “GlyA/CD45 negative 
cells” cell suspension was centrifuged at 630 X g for 7 minutes at 4°C with maximum 
acceleration and medium deceleration. The supernatant was removed and the cells 
resuspended in 500 µl of working buffer. Monoclonal anti-human CD33 and monoclonal 
anti-human CD7 antibodies were added to the cell suspension each at a concentration of 1.0 
μg per 1X106 cells and incubated for 30 min either at 4°C or on ice (table 5). 10 ml of 
working buffer was added to the mixture to dilute the unbound antibodies. The resulting 
mixture was centrifuged at 630 X g for 7 minutes at 4°C with maximum acceleration and 
medium deceleration. The supernatant was removed and the cell pellet was resuspended in 
500 µl of working buffer. Beads were applied to the sample as described previously at a 
concentration of 50 µl of beads per 1X10
7
 cells. This mixture was incubated for 30 min 
either at 4°C or on ice with gentle agitation using a rocker. The tube containing the mixture 
was applied to MPC-I for 2 minutes. The supernatant was collected into a new sterile tube 
labelled “Lineage-negative cells”. The positive cell fraction was rinsed twice as previously 
described with 4 ml of working buffer and at each stage the supernatant was added to the 
“Lineage-negative cells” tube. The “Lineage negative cells” tube was re-applied to the 
MPC at least 3 more times to completely remove all the positive cells. The cells were 
counted and resuspended in either PBS or culture medium depending on the experimental 
needs. This lineage negative cell selection method has been previously  described and  
published (McGuckin et al., 2008).  
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Table 5. Table of antibodies used for Lineage-Negative separation 
Antibody Host/isotype 
Concentration per 
1x10
6
 cells  
Catalog number 
Manufacturer 
CD235a Mouse IgG1 0.22 µg 
M0819 
Dako Cytomation 
CD45 Mouse IgG1 0.5 µg 
ABX252 
Autogen Bioclear 
CD33 Mouse IgG1 1.0 μg 
AB163 
Autogen Bioclear 
CD7 Mouse IgG3 1.0 μg 
AB164 
Autogen Bioclear 
 
2.4 Flow cytometry  
Flow cytometry was performed using a Becton Dickinson LSR II machine. When 
processing umbilical cord blood, 100 µl of blood was used for each flow cytometric 
analysis. For purified samples, around 100,000 cells in 100 µl were used for analysis. After 
addition of fluorescent dye conjugated antibodies at the recommended concentrations (table 
6), the tubes were incubated in dark at room temperature for 20 minutes. The whole 
umbilical cord blood samples were lysed and washed in BD FACS Lyse/Wash Assistant 
before being analyzed using BD LSRII in order . 7AAD was used to determine the cells 
viability to determine cells viability after ficoll and SC kit purification (n=4). Data was 
analyzed using BD FACSDiva™ 6.0 and cyflogic softwares. Negative control samples 
were used, where no antibodies were added, to determine the threshold of positive signals 
(refer to figure 66 in appendix III).  
Table 6. Antibodies used for FACS analysis 
Antibody Host/isotype Cat No. Manufacturer volume/100ul 
CD34 (PE/Cy7) Mouse IgG1 348811 BD Pharmingen 5 
CD45 (APC/Cy7) Mouse IgG1 557833 BD Pharmingen 5 
CD133/1 (APC) Mouse IgG1 130-090-826 Miltenyi Biotech 5 
SSEA-4 (PE) Mouse IgG3 FAB1435P R&D Systems 5 
7AAD - 559925 BD Pharmingen 
1:30 
(dilution) 
 
 
Materials and methods 
 
 62 
 
2.5 Culturing and differentiating protocol 
Sterile plastic cover slips (15 mm diameter) [Nunc] were placed into the wells of a 24-wells 
plate [Greiner Bio-One]. Two different materials were tried for coating the cover slips, 
polylysine and collagen IV. Cells plated on polylysine died 48 hours after culturing (data 
not shown) while cells plated on collagen IV coated cover slips survived throughout the 
differentiation protocol. Collagen IV was used as primary coating material in this study. 
The cover slips in the wells were coated with 150 µm of collagen IV [Sigma Aldrich] and 
incubated for 3 hours at 37°C in 5% CO2 to dry the collagen coating. This step has been 
performed to enhance the attachment of cells to the cover slips. Freshly isolated and 
purified cord blood stem cells were then cultured at a concentration of 1x10
6 
cells/ml in 
total of 500 µl of medium (figure 18). The cells were placed in neural early commitment 
medium for 7-10 days (table 7). Half of the medium was changed with fresh medium every 
2-3 days. The cultured cells were then moved into neuronal differentiation medium (table 
8). The medium was changed every other day for a one week period. After one week, the 
cells were moved into neuronal maturation medium (table 9). Half the medium was 
changed with fresh medium on a daily basis and the cells were kept in this medium for 7-10 
days (figure 19). Cells were incubated at 37°C in 5% CO2 and a humidified atmosphere 
throughout the differentiation protocol.  
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Figure 18. Culturing purified umbilical cord blood stem cells. A plastic cover slip is placed in each well of 
a 24-wells plate. The cover slip is coated with Collagen IV by drying before the cells are added to the well.  
 
 
 
Figure 19. A diagram showing the neuronal differentiation protocol along a time line. For convenience, 
undifferentiated cells are termed “Day 0 cells”, cells after early neural commitment are termed “Day 10 
cells”, cells after neuronal differentiation are termed “Day 17 cells” and cells after neuronal maturation are 
termed “Day 24 cells”.      
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Table 7. Early neural commitment medium components and their concentrations 
Neural early commitment media 
Component 
Working 
concentration 
Manufacturer Catalog number 
DMEM/F-12 + GlutaMax™ - Invitrogen 31331-093 
B-27 Serum-Free Supplement (50X) 1:50 Invitrogen 17504-044 
N-2 Supplement (100X) 1:100 Invitrogen 17502-048 
Epidermal growth factor (EGF) 20 ng/ml Immunotools 11343407 
Basic fibroblast growth factor (bFGF) 20 ng/ml Immunotools 11343627 
Heparin 5µg/ml Sigma Aldrich H4784-1G 
Fibronictin 5µg/ml Sigma Aldrich F0895-1MG 
Penicillin-Streptomycin 1:100 Invitrogen 15070-063 
Fungizone 1:100 Invitrogen 15290026 
 
Table 8. Neuronal differentiation medium components and their concentrations 
Neuronal differentiation media 
Component 
Working 
concentr
ation 
Manufacturer Catalog number 
DMEM/F-12 + GlutaMax™ - Invitrogen 31331-093 
B-27 Serum-Free Supplement (50X) 1:50 Invitrogen 17504-044 
N-2 Supplement (100X) 1:100 Invitrogen 17502-048 
 EGF 10 ng/ml Immunotools 11343407 
Brain Derived Neurotrophic Factor (BDNF) 10 ng/ml Immunotools 11343375 
Retinoic acid (RA) 1µM Sigma Aldrich R2625 
Fibronictin 1µg/ml Sigma Aldrich F0895-1MG 
Collagen IV 1µg/ml Sigma Aldrich C5533 
Penicillin-Streptomycin 1:100 Invitrogen 15070-063 
Fungizone 1:100 Invitrogen 15290026 
 
Table 9. Neuronal maturation medium components and their concentrations 
Neuronal Maturation media 
Component 
Working 
concentration 
Manufacturer Catalog number 
DMEM/F-12 + GlutaMax™ - Invitrogen 31331-093 
B-27 Serum-Free Supplement (50X) 1:50 Invitrogen 17504-044 
N-2 Supplement (100X) 1:100 Invitrogen 17502-048 
 EGF 10 ng/ml Immunotools 11343407 
 BDNF 5 ng/ml Immunotools 11343375 
Nerve growth factor (NGF) 10 ng/ml Immunotools 11343354 
Di-buthyryl cyclic AMP 1µM Sigma Aldrich D0627-25MG 
Fibronictin 1µg/ml Sigma Aldrich F0895-1MG 
Collagen IV 1µg/ml Sigma Aldrich C5533 
Penicillin-Streptomycin 1:100 Invitrogen 15070-063 
Fungizone 1:100 Invitrogen 15290026 
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2.6 Three-dimensional (3D) neuronal differentiation 
We used scaffolds supplied by Protista but are not available commercially. The scaffolds 
were supplied as part of collaboration between the company and Newcastle center for cord 
blood represented by Professor Colin McGuckin.  
The Protista scaffolds, which are composed of fibrinogen, dextran and LLA-HEMA, were 
cut into 300 µm slices using a microtome before use. Scaffolds were washed in 70% 
ethanol for 10 minutes for sterilization purposes and then PBS. Washed scaffolds were 
placed in a well of a 24 wells plate. 20µl of neural early commitment medium was added to 
wet the scaffold. Concentrated purified cord blood stem cells (100,000-500,000 cells) were 
placed on the scaffold gently and incubated at 37°C in 5% CO2 for 2-4 hours to allow cell 
attachment to the scaffold‟s matrix. Then 1ml of the medium was added to the well 
containing the scaffold. The differentiation protocol described above was then followed in a 
similar way. After maturation (Day 24), the scaffolds were analyzed using 
immunocytochemistry and confocal imaging (Ali et al., 2009). 
2.7 Cytogenetic analysis 
In order to perform cytogenetic analysis, 0.2 ml of 1:30 KaryoMAX® Colcemid® Solution 
[Invitrogen] was added to the cells at Day10 which were already in a 25 cm
2
 flask (Nunc) 
containing 6 ml of culture medium. This was incubated for 3 hours at room temperature. 
Trypsin-EDTA [Sigma] was warmed in a 37
 o
C incubator. 3ml of the warmed Trypsin-
EDTA was added to the flask after the supernatant was transferred into a labeled centrifuge 
tube. The flask was incubated at 37
 o
C for approximately two minutes. Once the cells de-
attached, the cell suspension was again collected with the previous supernatant and then 
centrifuged at 600 X g for 5 minutes. The resulting cell supernatant was removed from the 
cell pellet leaving 0.2-0.5ml of the supernatant to resuspend the pellet. 1ml of 75mM 
potassium chloride (KCl) solution was then added to the tube and mixed gently before 
placing it in a 37C water bath for 5 minutes. The tube was centrifuged at 600 X g for 5 
minutes. The KCl containing supernatant was then removed without disturbing the pellet. A 
few drops of fixative (Freshly made, 3:1 Methanol: Acetic Acid) were added and the cells 
mixed thoroughly. The tube was then filled up with fixative and then centrifuged at 600 X g 
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for 5 minutes. The supernatant was then removed and the cell pellet stored overnight at -
20C before sending it for analysis at the Northern Genetics Service at the Institute of 
Human Genetics at Newcastle University to prepare the slides and analyze and karyotype 
the samples (samples were analyzed by Dr Simon Zwolinski). A total of 3 different (SC kit) 
purified samples at day 10 were analyzed.  
2.8 Cytospin slides preparation  
In order to perform immunocytochemistry on freshly isolated and purified umbilical cord 
blood cells, cytospin slides were prepared using Shandon-thermo centrifuge at 90 x g for 3 
minutes. The number of cells used for each cytospin was approximately 10,000-30,000 
cells. 
2.9 Immunocytochemistry 
The protocol described below was applied to cells cultured on coated cover slips in 24-
wells plate, cytospins slides and the scaffolds. The medium was removed from the wells 
and the cells then washed with PBS twice for 6 minutes each. PBS was added very slowly 
to the side of the well without any direct contact with the cells. The cells were then fixed 
with Accustain [Sigma Aldrich] and incubated at room temperature for 30 minutes. The 
fixative was removed and the cells were then washed with PBS 3 times for 10 minutes each 
to get rid of any ethanol in the fixative. The cells were permeabilized with 1% Triton®x100 
[Sigma Aldrich] for 15 minutes at room temperature. Non-specific binding sites were 
blocked with 5% foetal calf serum (FCS), 5% goat serum [Zymed] and 0.1% Triton®x100 
[Sigma Aldrich] all in PBS for 1 hour. Cells were washed with PBS twice for 6 minutes 
after this blocking step. The primary antibodies were added to the cells after being 
appropriately diluted in PBS and incubated overnight at +4°C (table 10). Cells were then 
washed with PBS twice for 6 minutes and the secondary antibody was added after being 
appropriately diluted in PBS and left for one hour at room temperature (table 11). Cells 
were washed again with PBS 3 times for 9 minutes at room temperature. Bis-benzimide 
[Sigma Aldrich] was added to the cells at a concentration of 1µg/ml in PBS and left for 10 
minutes to enable visualization of nuclei. The cells were then washed with PBS 3 times for 
9 minutes and the slides and cover-slips mounted using mounting media [Sigma aldrich, 
cat. no. G0918-20ML]. For negative control samples, the primary antibody step was 
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omitted and only secondary antibodies were used (refer to figure 70 in appendix III). Slides 
were stored in the dark at 4°C prior to viewing. Slides and plates were stored in the fridge 
for up to 4 weeks without any exposure to light. The slides were visualized using a 
DMRXA upright confocal microscope (Leica TCS SP2 UV CLSM) operating LCS 2.61 
software [Leica Microsystems]. Slides and plates were stored in the fridge for up to 4 
weeks without any exposure to light. A X40 na 0.85 lens was used to visualise the slides, 6 
optical sections (1.3 µm steps) were taken from each image. Dapi (excitation 360 nm, 
emission 400-540 nm), FITC (excitation 488 nm, emission 500-550 nm) and Texas Red 
(excitation 543 nm, emission 580-650 nm) were imaged sequentially frame by frame to 
avoid crosstalk using two line averages.  The resulting image stacks were viewed and saved 
using Max Projection with threshold and rescale turned off, and finally displayed as tiled or 
overlayed images.  
To obtain the percentages of fluorescing cells, confocal images were obtained at 10x and 
20x magnifications. Firstly, all the DAPI stained nuclei were counted. This refers to the 
total number of cells in each image. The fluorescence positive cells were then counted and 
percentages were generated for each marker at different stages using the formula: number 
of fluorescent cells / total number of cells X 100. The number of samples used to generate 
the statistics per each marker per each time point was 3 different samples (n=3), a 
biological triplicate from each sample.  
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Table 10. The primary antibodies used for immunocytochemistry  (ICC) and immunohistochemistry 
(IHC) and their concentrations 
Antibody Host Isotype Dilution Manufacturer Catalog number 
Pluripotency and proliferation markers 
OCT4 Goat IgG ICC  1:500 Abcam Ab27985 
SOX2 Mouse IgG2a ICC  1:50 R&D systems MAB2018 
NANOG Goat IgG ICC  1:20 R&D systems AF1997 
KI-67 Mouse IgG1 ICC  1:100 Novocastra L111853 
Neural development markers 
NESTIN Mouse IgG1 ICC  1:100 R&D systems MAB1259 
GFAP Rabbit IgG ICC  1:1000 Abcam Ab7779 
NF200 Mouse IgG1 ICC  1:800 Sigma N1042 
GAP43 Rabbit IgG ICC  1:500 Abcam Ab75810 
β-Tubulin III 
(TUJ1) 
Mouse IgG1 ICC  1:500 Abcam Ab7751 
β-Tubulin III 
(TUJ1) 
Rabbit IgG ICC  1:2000 Abcam Ab18207 
PSD95 Rabbit IgG ICC  1:500 Abcam Ab18258 
NEUN Mouse IgG1 ICC  1:100 Chemicon MAB377 
Neurotransmitter transporters 
VGLUT1 Rabbit IgG ICC  1:800 Synaptic systems 135302 
Neurotransmitter receptor 
NMDAR1 Rabbit IgG ICC  1:200 Abcam Ab28669 
Cortical development markers 
PAX6 Mouse IgG1 ICC  1:50 Millipore MAB5554 
PAX6 Rabbit IgG IHC  1:300 Covance PRB-278P 
TBR2 Rabbit IgG1 ICC/IHC 1:500 Abcam Ab23345 
TBR1 Rabbit IgG1 ICC/IHC 1:200 Abcam Ab31940 
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Table 11. Secondary antibodies used for immunocytochemistry (ICC) 
Antibody Type Isotype Dilution Florochrome Manufacturer Catalog number 
Alexa 488 Goat anti-mouse IgG1 1:500 FITC Invitrogen A21121 
Alexa 594 Goat anti-rabbit IgG 1:500 TxRed Invitrogen A11012 
Alexa 488 Rabbit anti-mouse IgG 1:500 FITC Invitrogen A11059 
Alexa 594 Rabbit anti-goat IgG 1:500 TxRed Invitrogen A11080 
Alexa 594 Goat anti-mouse IgG2a 1:500 TxRed Invitrogen A21135 
NorthernLights™ 
NL493 
Donkey Anti-Goat IgG 1:500 FITC R&D systems NL003 
 
2.10 Statistical analysis   
For two groups of data, the student's paired t-test was used to obtain probability (p) values. 
For three or more groups of univariate data, single-factor analysis of variation (ANOVA) 
was used to obtain p values. Results with p values of less than 0.05 were considered 
statistically significant. 
2.11 Polymerase Chain Reaction (PCR) 
2.11.1 Primers  
OCT4, SOX2 and NANOG certified primers sets with confidential sequences were 
purchased from Sabiosciences (table 12). Primers presented in (table 13), except ALB and 
GATA4, were obtained from the PrimerBank website 
(http://pga.mgh.harvard.edu/primerbank) (Spandidos et al., 2008, Wang and Seed, 2003) 
and purchased from Sigma. For primer bank ID refer to (table 19 in appendix III). ALB and 
GATA4 were provided by colleague Dr Saba Habibollah.  
 
Table 12. List of certified primers used for real time PCR obtained from SABiosciences 
Gene Product size GenBank Accession Manufacturer Catalog Number 
POU5F1 138 NM_002701.4 SABiosciences PPH2394E 
SOX2 115 NM_003106.2 SABiosciences PPH02471A 
NANOG 148 NM_024865.2 SABiosciences PPH17032E 
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Table 13. List of primers used for real time PCR and their product sizes 
Gene Primers 
Product 
size 
GenBank 
Accession 
Location  
C-MYC 5‟-TCGGAAGGACTATCCTGCTG-3‟ 
5‟-GTGTGTTCGCCTCTTGACATT-3‟ 
133 NM_002467 1515 1534 
1647 1627 
NEUROG1 5‟-GCTCTCTGACCCCAGTAGC-3‟ 
5‟-GCGTTGTGTGGAGCAAGTC-3‟ 
107 NM_006161 844 862 
950 932 
NEUROG2 5‟-TCCTCCGTGTCCTCCAATTC-3‟ 
5‟-AGGTGAGGTGCATAGCGGT-3‟ 
125 NM_024019 997 1016 
1121 1103 
NEUROD1 5‟- GGATGACGATCAAAAGCCCAA-3‟ 
5‟-CGTCTTAGAATAGCAAGGCACC-3‟ 
178 NM_002500 415 435 
592 571 
NEUROD2 5‟- TGCTACTCCAAGACGCAGAAG-3‟ 
5‟-CACGTAGGACACTAGGTCTGG-3‟ 
120 NM_006160 648 668 
767 747 
PAX6 5‟-ATGTGTGAGTAAAATTCTGGGCA-3‟ 
5‟-GCTTACAACTTCTGGAGTCGCTA-3‟ 
103 NM_000280 686 708 
788 766 
TBR2 5‟- CACCGCCACCAAACTGAGAT-3‟ 
5‟- CGAACACATTGTAGTGGGCAG-3‟ 
109 NM_005442 841 860 
949 929 
TBR1 5‟- GCCTTTCTCCTTCTATCATGCTC-3‟ 
5‟-GTCAGTGGTCGAGATAATGGGA-3‟ 
116 NM_006593 319 341 
434 413 
DLG4 
(PSD95) 
5‟- GGACCAGATCCTGTCGGTCA-3‟ 
5‟- CCTCGAATCGGCTGTACTCTT-3‟ 
137 NM_001365 2398 2417 
2534 2514 
GAPDH 5‟-TGTTGCCATCAATGACCCCTT-3‟ 
5‟-CTCCACGACGTACTCAGCG-3‟ 
202 NM_002046 192 212 
393 375 
ALB 5‟- AAGCTGCCTGCCTGTTGCCA-3‟          
5‟- GCTCAGGCGAGCTACTGCCC-3‟ 
140 NM_000477.5 666 685 
805 786 
GATA4 5‟- GCAGCAGCGAGGAGATGCGT -3‟      
5‟- GGGGAGAGCTTCAGGGCCGA-3‟ 
154 NM_002052.3 1621 1640 
1774 1775 
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2.11.2 Total RNA isolation and preparation 
Total RNA was isolated from cells using Qiagen RNeasy® Plus Mini Kit [Qiagen, 74134] 
following the manufacturer‟s protocol. A DNase digestion step was incorporated for 
optimal purification of total RNA using RNase-Free DNase Set [Qiagen, 79254]. 
2.11.3 cDNA Preparation 
cDNA was produced using a SuperScript ® VILO Kit [Invitrogen, 11754-050] in 20 µl 
total volumes using 1-2.5 µg of total RNA for each reaction and following the 
manufacturer‟s protocol and a MasterCycler® Gradient [Eppendorf]. The cDNA produced 
was quantified using NanoDrop 8000 [Thermo scientific]. Purity of the the cDNA was 
assessed using the 260/280 ratio provided by the NanoDrop. Samples with 260/280 ratio 
between 1.8 and 2.1 were considered optimally pure and used further for real time PCR 
analysis. 
2.11.4 Real time PCR 
All real-time PCR reactions were performed using RT
2 
SYBR® Green/ROX™ qPCR 
Master Mix [Sabiosciences, PA-012-8] and a ABI7900HT machine [applied bio systems]. 
The final volume for each reaction was 10µl, composed of 5µl of the master mix, 1µl each 
of 10µM primers set (forward and reverse), 10-50 ng of cDNA (volume depending upon 
the concentration) and sterile distilled water (dH2). Each reaction mix was transferred to a 
single well of a 384 well plate. The plates were centrifuged at 1000 X g for 1 minute to 
remove any air bubbles which might affect the efficiency of the PCR. 
A two step cycling program was used for all reactions as follow: 95°C for 10 minutes and 
40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. The melting curves were 
checked to confirm the presence of only one amplified product. The relative gene 
expression of each gene analysed was normalized to expression levels of housekeeping 
genes. All results were analyzed using qBase Software (Hellemans et al., 2007). PCR 
reactions of all genes have been optimised using cDNA samples generated from fetal 
cortical tissue (data not shown). In each analysis, the sample of the lowest expression was 
assigned the value of 1 and used as a caliborator.  
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As a control check, PCR reactions using PAX6 and TBR1 primers were performed on 
cDNA samples generated from fetal cortical tissue and adult liver tissue, in addition to day 
0, day 10, day 17 and day 24 cells, in order to determine the tissue specificity of the primers 
(refer to figure 68 in appendix III).  
2.11.5 Agarose gel electrophoresis 
Agarose gels were run to confirm the product size of the amplified genes from the real time 
PCR. 1.5% agarose [Seachem, 1111] gel was prepared in Tris acetate/EDTA (TAE) buffer 
(40 mM Tris-acetate and 1 mM EDTA in distilled water at pH 8.0). The mixture was heated 
in microwave for about two minutes. The mixture was gently mixed until the agrose 
powder completely dissolved in the (TAE) buffer.  SYPRO® Red protein gel stain (5000X 
concentrate in DMSO) was used to visualize the bands of DNA [Invitrogen, S-6653]. The 
gel was poured in the electrophoresis chamber and was allowed to set and then submerged 
in TAE buffer. 10µl of PCR product was mixed with 2µl loading buffer [GelPilot DNA 
Loading Dye, 5x, Qiagen, 239901] and then loaded into gel and electophoresed at 75 volts 
for 80 minutes. The gel was then visualized under a transilluminator [Gene Genius Bio 
Imaging System, Syngene, a division of Synoptics Ltd.]. GelPilot 100 bp plus DNA Ladder 
[Qiagen, 239045] was used to determine the product size for the genes except for C-MYC 
where 50 bp DNA Ladder [Qiagen, 239025] was used (refer to figure 67 in appendix III).   
2.11.6 Pathway PCR arrays 
Profiler™ PCR arrays were purchased from Sabiosciences [PAHS-060E and PAHS-036E] 
(table 14). Each array includes SYBR Green-optimized primer assays designed for neuronal 
specific functional aspct. Each array containes 84 genes involved in neural functioning in 
addition to 5 housekeeping genes. Quality controls were also integrated on each array 
including for genomic DNA contamination, reverse transcription and positive PCR 
controls. The reaction mixes for these controls were performed using an identical cycling 
program to the one described for real time PCR. cDNA samples generated from human 
fetal cortical tissue have been used as a positive control (data not shown).  
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Table 14. Real time PCR arrays 
Array’s name Catalog number Manufacturer 
Human Neuroscience Ion 
Channels and Transporters 
RT² Profiler™  
PAHS-036E 
SABiosciences 
Human Neurotransmitter 
Receptors and Regulators 
RT² Profiler™  
PAHS-060E 
 
2.12 Functional analysis:  calcium imaging 
2.12.1 Dye loading  
Cultures were bulk loaded with Oregon Green 488 Bapta 1 (OGB1)-AM ester, excitation at 
494 nm and emission at 523 nm, using the following protocol.  OGB1-AM [50µg vial, 
Molecular Probes] was mixed with 8µl DMSO [Sigma Aldrich] and 2µl pluronic acid F-
127 solution [10% in DMSO, Molecular Probes], and this solution diluted by adding 90µl 
of culture medium. 12-20µl of this final mixture was then added to the culture well 
containing 3ml of medium.  The final concentrations were OGB1-AM ester, ~12µM; 0.6% 
DMSO, 0.002% Pluronic F-127.  The cultures were incubated for 30-40 minutes at 37
o
C 
and then transferred to medium without OGB1-AM for 20 minutes at 37
o
C prior to 
transferring the cultures to the recording chamber.   
2.12.2 Glutamate application 
In the recording chamber, the cultures were bathed in a continuously flowing stream (1-3ml 
/ minute) of artificial cerebrospinal fluid (ACSF) in 125 mM NaCl, 26 mM NaHCO3, 10 
mM glucose, 3.5 mM KCl, 1.2 mM CaCl2, 1.26 mM NaH2PO4
-
, 1 mM MgSO4,. Glutamate 
at a concentration of 1mM in ACSF was then applied directly using patch pipettes (5-7MΩ 
when filled with K-methylsulphate electrode filling solution) using a picospritzer pressure 
application system (10ms pulses; pressure = 20psi).  The average bolus for a 10ms pressure 
application through these pipettes was approximately 1.6µl. The timing of the pressure 
applications was controlled using the Master 8 pulse stimulator.  The pipette tip was 
positioned approximately 10-50µm from the cells in the open recording chamber. It is 
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unusual to detect any movement artefacts during the glutamate applications unless the 
pipette was broken, indicating that this means of stimulating cells was relatively atraumatic. 
Images for loaded cells with no glutamate induction were obtained to serve as a negative 
control (Trevelyan et al., 2010).  
2.12.3 Cell imaging 
The recording chamber was mounted on an upright Olympus BX51 DSU confocal 
microscope fitted with Scientifica Patchmaster micromanipulators.  Images were collected 
at 10Hz, using a C9100/13 Hamamatsu camera connected to a Dell personal computer 
running Digital Pixel software.     
2.12.4 Data analysis 
Generated images were analyzed using ImageJ software which is a public domain, Java-
based image processing program developed by the National Institutes of Health (NIH). 
Images were taken from multiple regions of each loaded cover slip. Single cells in each 
frame were analyzed individually to generate a final percentage of responsive cells using 
the formula: number of active cells / total number of cells X 100. Changes in intracellular 
calcium concentrations are correlated to the relative changes in fluorescence (F) detected by 
the fast camera before and after induction with glutamate. We used ΔF/F to normalize the 
data to that first data point. This is performed to control for small changes in non-biological 
variables such as the effective dye concentration. The student‟s t test was used to determine 
the significance of any differences between the data.   
2.13 Human foetal brains samples 
Human Foetal brains sections (7-8µm thick) and total RNA samples from human foetal 
brains were obtained from the MRC-Wellcome Trust Human Developmental Biology 
Resource at Newcastle University (HDBR, http://www.hdbr.org). Appropriate maternal 
written consent and approval from the Newcastle and North Tyneside NHS Health 
Authority Joint Research Ethics Committee had been obtained prior to collecting these 
samples. Samples obtained were 12 weeks postconception (PCW) (Bayatti et al., 2008b, 
Bayatti et al., 2008a). 
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2.14 Immunohistochemistry 
 Paraffin sections were dewaxed twice in xylene for 10 minutes and dehydrated twice in 
100% ethanol for two minutes. Sections were treated with 3% hydrogen peroxide [Sigma 
Aldrich] in methanol for 10 minutes and boiled in 10mM citrate buffer. Sections were then 
incubated with primary antibodies (table 10) in 3% horse [Sigma Aldrich, H1138 ]  and 
goat [Zymed] blocking serum in 0.1% Triton X/PBS (PBST) on the slides in a moist 
chamber at 4˚C overnight. After washing three times in 0.1% PBST for 5 minutes each, 
sections were incubated with biotinylated goat anti-rabbit IgG secondary antibody [Vector 
Laboratory, BA-1000] at 1:200 dilution in PBST at 4˚C for two hours. The slides were then 
washed 3 times in 0.1% PBST for 5 minutes each. Sections were incubated with 
streptavidin-horse radish peroxidase [Vector Laboratory] at 1:200 dilution in PBST at 4˚C 
for one hour. After these incubation steps, sections were washed in 0.1% PBST 3 times for 
5 minutes each. Visualization of the immuno-reaction was achieved by adding a substrate 
of the enzyme complex 3, 3'-Diaminobenzidine tetrahydrochloride, also known as DAB 
chromogen, in diluent [Vector Laboratory] at a concentration of 30 µl/ml. This was left for 
colour development for up to 10 minutes before washing in PBS. All sections were then 
dehydrated in a series of ethanol (Two times in 95% ethanol, 10 seconds each and repeat in 
100% ethanol), cleared in xylene and mounted in DPX mountant (Bayatti et al., 2008a, 
Bayatti et al., 2008b).  For negative control, primary antibodies were omitted and only 
secondary antibody was used (refer to figure 71 in appendix III).  
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Chapter 3. Purification of umbilical cord blood non-hematopoietic 
multipotent stem cells 
 
3.1 Introduction 
Umbilical cord blood contains a highly heterogeneous mixture of cells. This mixture 
includes hematopoietic cells including erythrocytes and leukocytes, and in addition a 
population of hematopoietic stem cells (HSCs). It also contains a relatively low 
concentration of non-hematopoietic multipotent stem cells expressing SSEA-4, a surface 
marker expressed by embryonic stem cells (McGuckin et al., 2005, Kucia et al., 2007), and 
the transcription factors OCT4, SOX2 and NANOG normally expressed by pluripotent 
stem cells (McGuckin et al., 2008, Ali et al., 2009, Kucia et al., 2007) (see section 1.5.3). 
The potential use of this non-hematopoietic stem cell population in a range of applications 
underpins the efforts to further characterize and analyze the properties of this unique cell 
population. This required the development of purification strategies that allow the 
enrichment of this population in order to accurately analyze its molecular properties as well 
as the differentiation potential of these cells.  
Many groups have developed different strategies in attempts to purify cord blood non-
hematopoietic stem cells population (table 15). Buzanska et al. (2002) developed an 
immunomagnetic sorting strategy to purify the targeted population. They utilized magnetic 
beads that can specifically recognize CD34, a surface antigen expressed by hematopoietic 
stem cells (HSCs), and depleted the CD34-postive cells (Buzanska et al., 2002). The 
purified CD34-negative cell fraction was reported to express OCT4 and SOX2 (Buzanska 
et al., 2006a, Buzanska et al., 2006b, Habich et al., 2006). Forraz et al. (2004) utilized the 
same immunomagnetic depletion strategy used by Buzanska‟s group but instead of using a 
single antibody, they used a combination of hematopoietic antibodies including CD45, 
CD235a, CD38, CD7, CD33, CD56, CD16, CD3, and CD2 (table 2) in a sequential manner 
to purify the targeted population which were reported to make up around 0.1% of the total 
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mononuclear fraction of the cord blood (Forraz et al., 2004, McGuckin et al., 2004, 
McGuckin et al., 2005). Other groups utilized multi-parameter fluorescence-activated cell 
sorting (FACS) to purify the targeted population. They used a cocktail of antibodies 
including hematopoietic stem cell markers CD133, CD34 and the general hematopoietic 
marker CD45.  The CD45-positive cells were eliminated and at the same time the CD133 
and CD 34 positive cells were enriched using FACS sorting. Those enriched cells expressed 
OCT4 and NANOG in addition to surface embryonic marker SSEA-4. The cells were 
termed very small embryonic-like stem cells (VSEL) due to their small cell size and 
expression of markers (Kucia et al., 2007, Halasa et al., 2008).  
 
Table 15. Reported purification and selection methods of umbilical cord blood non-hematopoietic stem 
cells 
Name of 
isolated cells 
Purification/selection 
method 
Markers 
expressed 
Neuronal 
differentiation 
Reference 
Human 
umbilical cord 
blood-neural 
stem cells 
(HUCB-NSC) 
Continuous depletion of 
CD34 cells (cell line) 
OCT4 
SOX2 
Reported 
Buzanska et al. (2002) 
Buzanska et al. (2006a) 
Buzanska et al. (2006b) 
Habich et al. (2006) 
Lineage-
Negative Stem-
Progenitor Cell 
Population 
Immuno-magnetic 
depletion 
TRA-1-60 
TRA-1-81 
SSEA-4 
SSEA-3 
OCT4 
Reported 
Forraz et al. (2004) 
McGuckin et al. (2004) 
McGuckin et al. (2005) 
 
Very small 
embryonic-like 
stem cells 
(VSEL) 
FACS sorting 
SSEA-4 
OCT4 
NANOG 
Not reported 
Kucia et al. (2007) 
Halasa et al. (2008) 
Progenitor cord 
blood cells 
CD133 positive selection NESTIN Reported Zangiacomi et al. (2008) 
Cord blood 
derived 
embryonic-like 
stem cells 
(CBE) 
Immuno-magnetic 
depletion 
OCT4 
SOX2 
NANOG 
Reported McGuckin et al. (2008) 
Lineage 
negative 
umbilical cord 
blood cells 
Immuno-magnetic 
depletion 
OCT4 
SOX2 
Reported Chua et al. (2009) 
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In the studies outlined in this chapter, we compare two methods for purifying non-
hematopoietic multipotent stem cells from umbilical cord blood. Both methods are based 
on immunomagnetic depletion strategy. The first method is an “in house” purification 
method which has been developed and used previously (McGuckin et al., 2008), and the 
second is a commercially available purification kit. For simplicity, we termed the “in 
house” kit (Lin-Neg) and the second kit (SC kit) (see section 2.3). We utilize FACS to 
analyze the purified fraction from each kit using four surface markers including, CD45, 
CD34, CD133 and SSEA-4. We further characterize the expression of pluripotency 
markers, OCT4, SOX2 and NANOG, in the enriched fractions using 
immunocytochemistry.  
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3.2 Study aims 
 To purify and enrich umbilical cord blood non-hematopoietic multipotent stem 
cells.  
 To characterize umbilical cord blood non-hematopoietic multipotent stem cells by 
analyzing their expression to proteins associated with pluripotency including OCT4, 
SOX2 and NANOG.  
 To compare between the efficiency and practicality of two different protocols in 
purifying and enriching the cord blood non-hematopoietic multipotent stem cells 
and determine the one that will be used for the following experiments.   
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3.3 Results 
3.3.1 Lin-Neg and SC kit purification depleted CD45 positive cells and enriched SSEA-4 
positive cells 
FACS analysis (see section 2.4) on freshly isolated umbilical cord blood revealed that 
95.11±7.25% (n=6) of the cells were positive for CD45 while 24.29±8.79% of the cells 
expressed CD34 (n=6), 0.18±0.16% (n=6) expressed CD133 and 1.29±0.46% (n=6) 
expressed SSEA-4 (figure 20). After isolation of MNCs by depleting red blood cells using 
Ficoll density gradient centrifugation, the cells percentages did not show any significant 
changes compared to their percentages in unprocessed cord blood (figure 20). CD45 
positive cells were 90.13±3.53% (n=6), CD34 positive cells were 24.74±7.06% (n=6), 
CD133 positive cells were 0.2±0.11% (n=6) and SSEA-4 positive cells were 1.39±0.37% 
(n=6).  
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Figure 20. FACS analysis assessing the efficiency of negative depletion strategies through comparison 
with unprocessed umbilical cord blood. Changes in proportions of cells expressing CD45 in blood, Lin Neg 
and SC kit were statistically significant (p<0.005). Changes in proportions of cells expressing CD133 were 
also significant between blood, Lin Neg and SC kit (p<0.05). Changes in proportions of cells expressing 
CD34 were also statistically significant (p<0.05). Changes in proportion of cells expressing SSEA-4 in blood, 
Lin Neg and SC kit were statistically significant (p<0.005). p values were calculated using ANOVA (n=6).  
 
The percentages of cells expressing the analyzed markers after Lin-Neg and SC kit 
purification steps have been compared to their calculated percentages in unprocessed 
umbilical cord blood using ANOVA in order to assess the efficiency of purification step by 
identifying significant differences (figure 20). After Lin-Neg isolation step, percentage of 
CD45 positive cells significantly decreased to 14.34±0.29% (n=6). Percentage of cells 
expressing CD34 also decreased significantly to 10.27±0.35% (n=6). Percentage of CD133 
positive cells increased to 0.63±0.42% (n=6). SSEA-4 positive cells were significantly 
enriched to 6.79±0.29% (n=6). 
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After SC kit isolation step, percentage of CD45 positive cells decreased significantly 
compared to their percentage in freshly isolated cord blood reaching 11.36±4.97% (n=6). 
Percentage of CD34 positive cells increased to 25.97±10.16% (n=6). Percentage of CD133 
positive cells stayed at 0.2±0.13% (n=6) and SSEA-4 positive cells were significantly 
enriched to 10.73±2.23% (n=6) (figure 20). The population of interest which expressed 
SSEA-4 was negative for CD45 (refer to figure 62 in appendix II).   
3.3.2 SC kit versus Lin-Neg : Statistical comparison  
Results obtained by SC kit and Lin-Neg isolations were statistically compared to each other 
in order to determine which kit is more efficient in purifying SSEA-4 positive cells by 
depleting cells expressing hematopoietic mature markers. Student‟s t-test was used to 
determine significant differences between the two kits (figure 21). FACS results showed 
that both methods significantly depleted CD45 positive cells compared to freshly isolated 
cord blood but the difference between the percentages obtained by the two methods was not 
statically significant. For CD34 positive cells, Lin-Neg showed significantly less CD34 
positive cells percentage compared to SC kit (n=6, p<0.05) (figure 21). For CD133, 
differences between the two methods did not show statistical significant. For SSEA-4 
marker, both methods showed statistically significant enrichment compared to freshly 
isolated cord blood but SC kit resulted in higher percentage of SSEA-4 positive cells 
compared to Lin-Neg with statistical significance (n=6 , p<0.05) (figure 21). 
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Figure 21. Statistical analysis between Lin-Neg and SC kit using FACS results to assess statistical 
significant differences between the two methods. Results showed that Lin-Neg had significantly fewer 
CD34 positive cells compared to SC kit (*) which also showed higher statistical significant enrichment rates 
of SSEA-4 positive cells and in comparison to Lin-Neg (**) (p<0.05). For the rest of markers, differences 
were not statistical significant. p values were calculated using Student‟s t-test (n=6). Values for CD133 were 
multiplied in 10 for presentation and scaling purposes.   
3.3.3 Purified cord blood stem cells expressed pluripotency markers 
Both isolation methods (SC kit and Lin-Neg) purified a relatively homogenous population 
of cells in comparison with MNCs after Ficoll centrifugation (figure 22, also refer to figure 
62A in appendix II). The cells were round in shape with a diameter of 6-10µm and high 
nucleus to cytoplasm ratio.  
 
Chapter 3 
 
 84 
 
Figure 22. Purified umbilical cord blood stem cells using Lin-Neg and SC kit showed higher 
homogeneity compared with MNCs after Ficoll. MNC fraction contained a mixture of cells with different 
sizes and morphologies while both negative depletion methods (Lin-Neg and SC kit) yielded a relatively 
homogenous population of round-shaped cells with a diameter between 6-10 µm.  
 
The purified cells co-expressed OCT4 and SOX-2 (figure 23). The two proteins were 
localized in the nuclei of the cells. They also expressed NANOG and KI67 in a similar 
manner (figure 24).  
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Figure 23. Freshly purified umbilical cord blood stem cells expressed OCT4 and SOX-2. Both proteins 
were localized in the nuclei of cells. Cells shown in this image were purified using SC kit. Negative controls 
are shown where only secondary antibodies were used. For additional images, refer to (McGuckin et al., 
2008) attached at the end of this thesis.  
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Figure 24. Freshly purified umbilical cord blood stem cells expressed KI-67 and NANOG. Both proteins 
were localized in the nuclei of cells.  Cells shown in this image were purified using SC kit. Negative controls 
are shown where only secondary antibodies were used 
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3.4 Conclusions 
 Umbilical cord blood contains a distinct population of non-hematopoietic 
multipotent stem cells expressing markers associated with embryonic stem cells.  
 This distinct population of stem cells can be purified and enriched using an   
immuno-magnetic negative depletion strategy. 
 SC kit demonstrated experimental and practical superiority to Lin-Neg kit. 
Therefore, we will utilize SC kit as the purification kit of choice for the rest of the 
research outlined in this thesis.  
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3.5 Discussion  
The studies in this chapter compare two different methods to purify and enrich umbilical 
cord blood non-hematopoietic multipotent stem cells. Both methods utilized a negative 
depletion strategy by which specific antibodies with magnetic properties are used to label 
hematopoietic cells and then deplete them using a magnet to enrich the targeted non-
hematopoietic multipotent stem cell population. The purified cell fraction was then 
characterized using FACS and immunocytochemistry. The purified cells by both methods 
showed significantly elevated expression levels of SSEA-4 when compared with cells prior 
to the purification step, indicating enrichment of the targeted non-hematopoietic stem cells. 
The purified cells also expressed markers normally associated with pluripotent stem cells 
including OCT4, SOX2 and NANOG.  The SC kit showed number of advantages over the 
Lin-Neg kit. Beside its shorter purification time, simplicity and cost, it showed a 
statistically significant higher SSEA-4 positive cell enrichment when compared with Lin-
Neg. Hence, further studies in this thesis utilized the SC kit as the purification kit of choice 
for research.  
3.5.1 Ficoll density gradient centrifugation eliminated umbilical cord blood erythrocytes  
The first step towards isolating and purifying umbilical cord blood non-hematopoietic 
multipotent stem cells involved the use of a Ficoll density gradient centrifugation to 
separate the mononuclear cell (MNCs) fraction, which contains the targeted cells, from the 
erythrocytes (red blood cells). Eliminating erythrocytes before negative depletion step is 
highly recommended to avoid any possible interference of these cells with the depletion 
step (Jaatinen and Laine, 2007). The diluted umbilical cord blood was layered above a 
Ficoll layer, which is composed of highly branched polysaccharides of high molecular 
weight, and then centrifuged (figure 17). This step separated blood cellular contents based 
on their density where denser cells like erythrocytes settle in the bottom of the tube whilst 
the less dense mononuclear cells (MNCs) fraction forms a buffy coat layer between the 
Ficoll layer and the plasma. This layer was then easily isolated and subjected to the 
negative depletion step. The FACS analysis results of unprocessed umbilical cord blood 
samples and samples after Ficoll density gradient centrifugation did not show any 
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significant changes which were expected because this step only eliminated the erythrocytes 
and did not involve any sub-fractioning of the mononuclear fraction (figure 20).  
The mononuclear fraction of umbilical cord blood is a highly heterogeneous mixture of 
cells including various types of mature hematopoietic cells (table 1), hematopoietic stem 
cells and a low concentration of the targeted non-hematopoietic multipotent stem cells (see 
section 1.5.3). Many groups, including ours, have used the mononuclear cells (MNCs) 
fraction of cord blood in neural differentiation protocols without further purification of the 
non-hematopoietic stem cells and showed positive differentiation results (Ali et al., 2009, 
Lee et al., 2007, Neuhoff et al., 2007). However, one problem with such differentiation 
cultures is that the concentration of non-hematopoietic stem cells in the MNCs fraction is 
very low and consequently the concentration of derived neurons in cultures would also be 
low which might limit proper analysis of these cells. In addition the presence of different 
hematopoietic cells in cultures might affect differentiation and influence data analysis. 
Therefore, purification and enrichment of the non-hematopoietic multipotent stem cells 
prior to differentiation would allow accurate analysis of the cells molecular properties as 
well as their differentiation potential.  
3.5.2 Enrichment and purification of umbilical cord blood non-hematopoietic stem cells 
after negative depletion step 
CD45 is a transmembrane protein tyrosine phosphatases that is present on all differentiated 
hematopoietic cells except erythrocytes (Trowbridge and Thomas, 1994, Baldwin and 
Ostergaard, 2001, Arendt and Ostergaard, 1997). This explains the high proportions of cells 
expressing CD45 in both unprocessed cord blood samples and MNCs samples after Ficoll 
density gradient centrifugation (figure 20). The association of CD45 with different types of 
differentiated hematopoietic cell makes it one of the major markers targeted in the negative 
depletion step and both kits used contained an antibody specific for CD45.  
In theory, the depletion of umbilical cord blood hematopoietic cells should leave behind the 
targeted non-hematopoietic stem cell population due to their negativity for the markers used 
in the depletion step resulting in their enrichment. To evaluate this, we used SSEA-4 as 
enrichment indicator in the FACS analysis. SSEA-4 is a surface marker widely used to 
characterize and select embryonic pluripotent stem cells (Thomson et al., 1998, Carpenter 
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et al., 2004, Mitalipova et al., 2003) and is also expressed by umbilical cord blood non-
hematopoietic multipotent stem cells (McGuckin et al., 2005, Kucia et al., 2007). FACS 
analysis of purified cells from Lin-Neg and SC kit showed a significant decrease in the 
proportions of cells expressing the major hematopoietic marker CD45 and statistically 
significant increase in proportions of cells expressing SSEA-4 compared with unprocessed 
cord blood samples (figure 20). This indicates significant purification and enrichment of the 
targeted non-hematopoietic stem cell population.  
3.5.3 SC kit demonstrated number of experimental and practical advantages over Lin-
Neg kit  
One of the major differences between the SC kit and Lin-Neg is that the SC kit which is 
manufactured by Stem cell technologies, is designed to enrich hematopoietic progenitor 
cells while Lin-Neg targets the purification of cord blood non-hematopoietic stem cells 
(McGuckin et al., 2008). This difference was clearly noticed after FACS analysis of CD34, 
a marker of hematopoietic stem cells. Lin-Neg depletion showed a decrease in CD34 
positive cells unlike SC kit which did not show any significant changes in the proportion of 
CD34 positive cells when compared with the unprocessed umbilical cord blood samples 
(figure 20). The antibody content of each kit is different, whilst the SC kit contains a 
cocktail of 12 different antibodies covering only mature and fully differentiated 
hematopoietic stem cells; the Lin-Neg kit utilizes 4 antibodies including CD33 which is a 
marker of a subset of hematopoietic progenitor cells (table 2 and 4). The targeting of Lin-
Neg kit to hematopoietic progenitor cells offers a possible explanation for the significant 
depletion of CD34, a marker of hematopoietic progenitor cells, positive cells unlike the SC 
kit where none of the progenitor cells are being targeted and CD34-postive cells 
proportions did not show any significant changes.  On the other hand, when compared to 
each other, SC kit showed more significant enrichment of SSEA-4 positive cells compared 
to Lin-Neg (figure 21). Since SSEA-4 represent the direct marker associated with the 
targeted non-hematopoietic stem cells, the enrichment rate of these cells by SC kit 
represents a major experimental advantage over the Lin-Neg kit when considering the aim 
of this study.  
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From a practical point of view, the SC kit demonstrated a number of advantages over Lin-
Neg kit. As mentioned earlier, the SC kit consists of a cocktail of 12 antibodies that are 
added all at one step to the MNCs fraction before performing the magnetic depletion of 
tagged cells using a specially designed column and magnet. The duration of the entire 
procedure is less than 90 minutes. On the other hand, the length of the Lin-Neg depletion 
procedure, which involves the use of only 4 antibodies, is around 4 hours because the 
antibodies are added at two separate steps resulting in a prolonged total procedure time 
(refer to section 2.3). Moreover, the cost of Lin-Neg depletion procedure is higher than SC 
kit depletion and this is because the antibodies and magnetic beads used in the procedure 
are purchased separately whereas the SC kit is commercially available and purchased as a 
complete kit.  
The purification kits used in this study utilized negative selection strategies in which the 
antibodies used labeled the hematopoietic cells which were then depleted by the magnet 
leading to enrichment of the wanted non-hematopoietic multipotent stem cell population.  
Nevertheless, this strategy did not remove all the unwanted hematopoietic cells, indicated 
by the FACS analysis of CD45 in purified fractions (figure 21). Using higher concentration 
of CD45 antibodies in the purification kits might help improve the purity of the selected 
fraction. Moreover, utilizing positive selection strategies using FACS might also improve 
the purity of the wanted cells fraction. The mononuclear fraction after Ficoll isolation can 
be labeled with SSEA-4, as a positive marker of the wanted cells population, and CD45, as 
a negative marker. The cells then can be sorted using FACS where (SSEA-4-postive CD45-
negative) fraction is selected. The purity of the selected fraction can be further assessed 
using multiplex qPCR, western blotting and immunocytochemistry.  
3.5.4 Expression of pluripotency markers and the misconception 
The enriched and purified fraction of cells from both kits expressed the main transcription 
factors shown previously to establish, maintain and regulate the pluripotent status of 
embryonic stem cells (Boyer et al., 2005, Boyer et al., 2006). OCT4 and SOX2 were co-
localized in the nuclei of a subset the purified cells (figure 23), and such findings are 
consistent with current understanding of the interaction between these two transcription 
factors which form a heterodimer complex which regulates important gene expression 
(Rodda et al., 2005, Chew et al., 2005, Masui et al., 2007, Okumura-Nakanishi et al., 2005).  
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In addition, purified cells expressed NANOG, another pluripotency marker normally 
expressed by embryonic stem cells. NANOG was localized in the nuclei of a subset of the 
purified cells which also expressed Ki67, a transcription factor mainly expressed in 
proliferative cells (figure 24) (Brown and Gatter, 2002). Our results are consistent with the 
findings of other groups where they isolated similar cells from cord blood expressing 
OCT4, SOX2, NANOG, SSEA-4, TRA-1-60 and TRA1-81 (Kucia et al., 2007, McGuckin 
et al., 2005, McGuckin et al., 2008, Zhao et al., 2006, Zangiacomi et al., 2008, Chua et al., 
2009).  
The confocal images obtained for OCT4/SOX2 staining indicated that the expression of 
OCT4 did not correlate perfectly with DAPI in some cells. OCT4 is a transcription factor 
that is normally expressed in the nuclei of the stem cell. Nevertheless, OCT4 has different 
isoforms with different expression patterns (Cauffman et al., 2006). These isoforms include 
OCT4A and OCT4B which differ only in their N terminals whilst having identical C 
terminals. Whilst OCT4A was expressed mainly in the nuclei of human embryonic stem 
cells, OCT4B was mainly localized in the cytoplasm with no stemness properties 
(Cauffman et al., 2006, Lee et al., 2006). In this study we used an antibody that is not 
specific for certain OCT4 isoform (table 9), the antibody can bind to OCT4A and OCT4B 
as well which offer a possible explanation for the cytoplasmic localization of OCT4 in 
some cells. The quality of images obtained can be improved by using higher magnification 
lenses in order to accurately examine the localization of the transcription factors. The 
specific expression of OCT4A is further examined using qPCR in the next chapter. The 
activity of the SOX2 transcription factor is tightly regulated by post-translation 
modifications such as acetylation which affects its cellular distribution in embryonic stem 
cells (Baltus et al., 2009). This might offer a possible explanation for the weak cytoplasmic 
localization of SOX2 in some cells. It is also possible that the high concentrations of 
primary antibodies used contributed to the cytoplasmic weak staining observed in some 
confocal images for the markers including NANOG and KI67 where negative controls did 
not show any staining.  
Many groups have described these non-hematopoietic stem cells of umbilical cord blood as 
being “embryonic-like” and pluripotent. Such conclusions have been drawn based on 
expression profiles of above-mentioned markers rather than meeting the widely accepted 
criteria used to define pluripotent stem cells (table 14) (McGuckin and Forraz, 2008, Harris 
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and Rogers, 2007, Lu and Ende, 1997, McGuckin et al., 2006, McGuckin et al., 2005, 
Kucia et al., 2007). As mentioned in the introduction, an important and widely accepted test 
of pluripotency is teratoma formation (see section 1.4.2). To date, there has not been a 
single reported case where cord blood stem cells formed teratoma when transplanted into 
SCID mice, therefore associating these cells with terms such as pluripotent and embryonic-
like might not be appropriate. Expression profiles of markers by certain stem cells might 
not be the accurate and ideal way to describe and justify their “potency”; nevertheless, they 
can provide useful indications about the stemness and differentiation status of the cells.  
 In our case, umbilical cord blood non-hematopoietic multipotent stem cells expressed 
OCT4, SOX2, NANOG, Ki67 and SSEA-4. The first three markers provided indications 
about a “stem cell” identity and suggested a possible wide range of differentiation 
capabilities rather than justifying pluripotent property. Expression of Ki67 suggested 
proliferative characteristics of the isolated cells, a property shared by different kinds of 
stem cells in vitro. Expression of SSEA-4 suggested the naïve undifferentiated status of the 
cells and distinguished them from the hematopoietic cell population of umbilical cord 
blood.  
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Chapter 4.  Defined sequential neuronal differentiation protocol for 
umbilical cord blood non-hematopoietic multipotent stem cells and 
neural tissue engineering application 
 
 
 
4.1 Introduction 
Umbilical cord blood stem cells have been shown previously to have a high potential for 
neuronal differentiation (Buzanska et al., 2002, McGuckin et al., 2004, Jurga et al., 2006, 
Zangiacomi et al., 2008, Zangiacomi et al., 2009). This differentiation capability made 
umbilical cord blood stem cells a potential candidate for neuronal clinical applications 
including tissue engineering applications (see section 1.5.4).  However, before regenerative 
medicine and neural tissue engineering applications can be considered in clinics, more 
information is needed about the biological potential of these cells and the possibility that 
they can be used safely in patients.   
One of the most important issues that need to be taken into consideration is the safety of the 
in-vitro cell culturing protocols. It is necessary to design culturing and differentiation 
conditions free of animal products in order to reduce risk of contamination and possible 
infections by animal microbes (Unger et al., 2008). Animal serum is commonly used in 
laboratories as a supplement for the cell culture media. It contains a wide range of 
macromolecules including hormones, growth factors and different low molecular weight 
nutrients (Gstraunthaler, 2003). In stem cells applications, it is important to use well-
defined culturing media in order to accurately study and precisely trigger targeted 
differentiation pathways, and undefined components of serum might interfere and exert 
unwanted effect on cells (Pick et al., 2007). It is important as well to keep the in-vitro 
culturing and differentiation durations as short as possible to reduce the risk of infections 
and chromosomal aberrations common in stem cell populations including embryonic stem 
cells (McGuckin et al., 2008, Corselli et al., 2008, Spits et al., 2008).  
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Moving into regenerative medicine and tissue engineering applications requires the 
development of an efficient 3-dimensional tissue engineering system including bio-
compatible scaffolds that provide the cells with the mechanical support and organization to 
develop functional differentiated tissues. These systems must be accompanied with highly 
efficient and effective isolation and differentiation protocols in order to generate clinically 
functional tissues that could be can be transplanted into patients (McGuckin and Forraz, 
2008). Hence, we incorporated our defined neuronal induction protocol with scaffold-based 
culturing conditions in order to evaluate the potential of using the purified cord blood stem 
cells in future regenerative medicine and neural tissue engineering applications. 
In the studies outlined in this chapter, we present a defined serum-free sequential neuronal 
induction protocol to differentiate purified umbilical cord blood non-hematopoietic 
multipotent stem cells into neuron-like cells over a period of 24 days. The differentiation 
process is further characterized by analyzing the expression patterns and levels of certain 
markers thought to be involved in the process of neurogenesis (table 16). We then 
incorporate this differentiation protocol with a scaffold-based 3-dimensional culturing 
system and analyze the differentiation process.   
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Table 16. Markers used for characterization of neuronal development of umbilical cord blood purified 
stem cells. 
 
Marker Expression pattern References 
Early neural 
commitment 
NESTIN 
An intermediate 
filament associated 
with multi-lineage 
progenitor cells with 
high proliferation 
characteristics. 
Co-expression of 
NESTIN and 
GFAP is 
associated with 
proliferative 
neural stem cells 
in the SVZ of 
cerebral cortex 
and hippocampus. 
Tavazoie et al., 2008, 
Wiese et al., 2004, 
Abrous et al., 2005 
 
GFAP 
An intermediate 
filament expressed in 
astrocytes and a subset 
of neural stem cells in 
CNS. 
Neuronal 
markers 
NF200 
Structural proteins expressed in neurons and 
involved in regulation of neuronal 
cytoskeletal architecture. 
Xiao et al., 2006 
Katsetos et al., 2003 
Mishra et al., 2008 
Β-TUBULIN III 
GAP43 
Later neuronal 
markers 
NEUN 
A DNA-binding 
neuron-specific protein 
associated with 
neuronal mature status 
in CNS. 
Both markers are 
expressed in later 
stages of neuronal 
development. 
Zhao et al., 2008, 
El-Husseini et al., 
2000, Hata and 
Takai, 1999 
PSD95 
Post synaptic density 
protein associated with 
receptors and 
cytoskeletal elements 
at the synapses and 
involved in maturation 
of functional synapses. 
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4.2 Study aims 
 To differentiate previously purified umbilical cord blood non-hematopoietic 
multipotent stem cells into neuron-like cells using defined serum-free sequential 
differentiation protocol in vitro.  
 To characterize and analyze the neuronal commitment of umbilical cord blood non-
hematopoietic multipotent stem cells using real time PCR and 
immunocytochemistry.  
 To incorporate the neuronal differentiation protocol with a scaffold-based 3-
dimensional culturing system to produce 3-dimensional neuronal-like tissue from 
umbilical cord blood non-hematopoietic multipotent stem cells. 
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4.3 Results 
4.3.1 Purified umbilical cord blood stem cells adopted neuronal-like morphology after 
neuronal induction  
Freshly purified umbilical cord blood non-hematopoietic stem cells using SC kit were 
found to make up around 1.2% (S.D=0.7, n=5) of total mononuclear cells after Ficoll 
density gradient step. Cell viability analysis using 7AAD showed that cells after SC kit had 
81.87%±5.72 (n=4) viability while after Ficoll the percentage of viable cells was 
87.10%±4.02 (n=4) (figure 25).  These cells were round in shape with a diameter between 
6-10µm (figure 26). The cells formed aggregates that varied in size. These aggregates 
began to attach firmly to the collagen IV coated cover slips after 24 hours of initial 
culturing (figure 26). By day 10, many cells lost their round morphology and became 
spindle in shape with clear thin projections merging from the cells bodies (figure 27). The 
majority of cells aggregates remained intact and the morphological transformation was 
noticed at the edges of the aggregates and in individual cells (figure 27).  
 
Figure 25. Cell viability after Ficoll isolation and SC kit purification. Cells viability was determined using 
FACS and 7AAD. Results indicated no statistically significant differences in percentages of viable cells 
between cells after Ficoll isolation and after SC kit purification. (Student t test, p>0.05, n=4).  
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Figure 26. Attachment of the freshly purified umbilical cord blood stem cells. Freshly purified stem cells 
(Day 0) formed non-adherent aggregates. Within 24-48 hours of initial culturing (Day 1), these aggregates 
attached firmly to the collagen IV coated cover slips and fine and short processes appeared at the edges of 
these attached aggregates.    
 
Figure 27. Morphological transformation of umbilical cord blood purified stem cells at day 10. After 
early neural commitment phase (Day 10), cells transformed their round spherical morphology into spindle-
shape morphology with clear thin and long projections growing from the cell‟s body (white arrows). The 
morphological transformation was accompanied with noticeable increase in cell size. Note that the change in 
morphology can be seen in individual cells and not within the cells aggregates.      
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After neuronal differentiation (Day 17), cells adapted a clear neuronal-like morphology. 
They started to show polar structures with clear growing main axon-like and dendrite-like 
structures (figure 28).   
 
Figure 28. Differentiated cells acquired a neuronal-like phenotype by day 17. Cells featured polarized 
neuronal-like morphology with thin long axon-like (lower arrow) and short dendrite-like structures (upper 
arrow) developed from cell bodies.     
 
After neuronal maturation (Day 24), the cells acquired a more advanced neuronal-like 
morphology where the axons-like structures became thinner, longer (reaching over 100µm 
in length) and more visible (figure 29). Cells projections showed enhanced branching 
(figure 29C). Physical cell-cell connections formed complex networks and potential 
synaptic junctions between cells (figure 29C). The neuronal maturation process was also 
accompanied with cell death of differentiating cells (figure 29C1, C2). These cells showed 
clear multiple holes in their bodies which indicate dying cells.  
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Figure 29. Cord blood stem cells acquired advanced neuronal-like morphology after the neuronal 
maturation phase (Day 24). Cells showed very thin and long neuronal-like processes (more than 100µm in 
length) (A). Cells featured polarized neuronal-like morphology with axon-like structures (B1) and dendrite-
like structures (B2). Some cell aggregates were still tightly compacted at day 24 (B*).  Physical cell-cell 
connections formed complex neuronal-like networks with possible synapses-like structures between cells (C). 
Dead cells were observed in the cultures after neuronal maturation (Day 24), some of these cells had a 
neuronal-like morphology (C1) while others were round in shape (C2).  
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4.3.2 Down-regulation of pluripotency genes and up-regulation of neuronal genes during 
the 24 days differentiation period 
Quantitative real time PCR (Q-PCR) (see section 2.11.4) showed that OCT4, SOX2, 
NANOG and C-MYC gene expression levels, normalized to GAPDH expression, decreased 
significantly between undifferentiated cells (Day 0) and cells after neuronal maturation 
(Day 24) (p<0. 05, n=3, similar p value for all the genes) (figure 30).  
 
Figure 30. Q-PCR analysis of pluripotency genes (OCT4, SOX2 and NANOG) and (C-MYC) expression 
patterns throughout the 24 days differentiation protocol. OCT4, SOX2 and NANOG were highly expressed 
in undifferentiated cord blood stem cells (Day 0). Their expression levels were down-regulated gradually 
between day 0 and day 24. C-MYC was expressed by undifferentiated stem cells at day 0 and its expression 
level increased reaching its highest point by day 10 before being down-regulated at day 17 and further at day 
24. Genes expression levels were normalized to the expression of GAPDH. The calibrator for the four genes 
is Day 24. Changes in genes expression levels for the four genes throughout the 24 days were statistical 
significant (ANOVA test, p<0.05, n=3 apply for all genes).  
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On the other hand, Q-PCR results showed that PSD95 gene expression level normalized to 
GAPDH was significantly up-regulated between (Day 0) and (Day 24) (p<0. 005, n=3) 
(figure 31). 
 
 
 
Figure 31. Q-PCR analysis of PSD95 expression pattern between day 0 and day 24. PSD95 expression 
level in undifferentiated cord blood stem cells (Day 0) was extremely low before being significantly up-
regulated after early neural commitment (Day 10) and neuronal maturation (Day 24). Gene expression levels 
were normalized to the expression of GAPDH. The calibrator is Day 0. Changes in gene expression levels 
throughout the 24 days were statistical significant (ANOVA test, p<0.005, n=3 apply for all genes).  
 
4.3.3 Immunocytochemistry analysis of neuronal markers throughout the 24-day 
differentiation protocol  
The cord blood stem cells co-expressed NESTIN and GFAP in their cytoplasm (figure 32). 
The percentages of cells expressing NESTIN increased from 10.42±4.31% (n=3) at day 0 to 
reach 73.5±6.18% (n=3) at day 10 and 83.46±7.76% (n=3) at day 17 before decreasing to 
32.12±8.16% (n=3) by day 24 (figure 33). The trend of percentages of cells expressing 
GFAP was similar to NESTIN where only 8.96±3.07% (n=3) expressed GFAP at day 0 
before the percentage increased to 62.57±9.37% (n=3) at day 10 and 68.84±2.53% (n=3) at 
day 17 and then decreased to 30.06±8.79% (n=3) by day 24 (figure 33).  Changes of 
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percentages over the 24 days period were statistically significant (ANOVA, p<0.005 for 
NESTIN and GFAP). 
 
 
 
Figure 32. Umbilical cord blood purified stem cells co-expressed NESTIN and GFAP. Both markers 
were localized in the cells cytoplasm. Lower panel shows overlying of the markers with DAPI 
(Merge).Picture shown is taken from cells at (Day 10).  
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Figure 33. Expression analysis of early neural and neuronal specific markers during the 24-days 
neuronal induction protocol. Percentages of cells expressing NESTIN and GFAP increased between (Day 0) 
and (Day 10) before decreasing after maturation (Day 24) (A). Percentages of cells expressing neuronal-
specific structural proteins NF200, β-TUBULIN III and GAP43 showed major increase after neuronal 
differentiation (Day 17) and stayed high after maturation (Day 24) (B). Percentages of cells expressing 
neuronal specific markers NEUN and PSD95 were extremely low between day 0 and day 10 before showing 
major increase after neuronal differentiation (Day 17). Changes in percentages over the 24 days period were 
statistically significant for all markers. (ANOVA, p<0.005, n=3, for all markers).  
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Percentages of cells expressing NF200, β-TUBULIN III and GAP43 were too low at day 0, 
2.94±1.41% (n=3) for NF200, 0.57±0.4% (n=3) for β-TUBULIN III and 1.82±0.42% (n=3) 
for GAP43 (figure 33). Percentages remained relatively low at day 10, 13.48±3.82% (n=3) 
for NF200, 16.51±6.32% (n=3) for Β-TUBULIN III and 4.11±1.14% (n=3) for GAP43. 
The percentages increased after differentiation at day 17 to 82.91±2.64% (n=3) for NF200, 
74.32±14.72% (n=3) for β-TUBULIN III and 64.64±14.37% (n=3) for GAP43. At day 24, 
percentages stayed at roughly the same levels, 83.94±2.61% (n=3) for NF200, 
62.49±0.88% (n=3) for β-TUBULIN III and 75.39±8.89% (n=3) for GAP43. Changes of 
percentages over the 24 days period were statistically significant (ANOVA, p<0.005 for 
NF200, β-TUBULIN III and GAP43). Differentiated cells expressed the three markers in 
their cytoplasm and noticeably in growing terminals like axons-like structures (figure 34, 
35). 
 
 
Figure 34. Immunocytochemistry analysis of NF200 and β-TUBULIN III. Differentiated (Day 17, data 
not shown) and maturated neuronal-like cells (Day 24) derived from umbilical cord blood stem cells highly 
expressed NF200 and β-TUBULIN III in growing axon-like structures and terminals. Lower panel shows 
overlying of the markers with DAPI (left Merge) and overlying of the markers with DAPI on DIC image of 
the cells (right Merge). Areas with strong co-expression of both markers appear in yellow. Images shown are 
for cells at day 24. 
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Figure 35. Immunocytochemistry analysis of NF200 and GAP43. Differentiated (Day 17, data not shown) 
and maturated neuronal-like cells (Day 24) highly expressed NF-200 and GAP43 in growing axon-like 
structures and terminals. Lower panel shows overlying of the markers with DAPI (left Merge) and overlying 
of the markers with DAPI on DIC image of the cells (right Merge). Areas with strong co-expression of both 
markers appear in yellow. Images shown are for cells at day 24. 
 
Differentiated cells expressed the more advanced neuronal markers NEUN and PSD95. 
NEUN was localized specifically in cell nuclei while PSD95 was expressed in the 
cytoplasm of cells (figure 36). Percentages of cells expressing NEUN increased 
significantly from 0.09±0.1% (n=3) at day 0 and 0.59±0.44% (n=3) at day 10 to 
71.73±6.87% (n=3) at day 17 and 71.31±5.27% (n=3) at day 24. Proportions of cells 
expressing PSD95 followed the same trend. Percentages increased from only 0.82±0.22% 
(n=3) at day 0 and 3.01±1.11% (n=3) at day 10 to 62.92±6.42% (n=3) at day 17 and 
71.18±3.97% (n=3) at day 24 (figure 33). Changes of percentages over the 24 days period 
were statistically significant for both markers (ANOVA, p<0.005). 
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Figure 36. Differentiated and maturated cells expressed neuronal-specific markers NEUN and PSD95. 
NEUN is expressed specifically in cells nuclei and PSD95 is expressed in the cells bodies and terminals. 
Lower panel shows overlying of the markers with DAPI (left Merge) and overlying of the markers with DAPI 
on bright field image of the cells (right Merge). Images shown are for cells at day 24. 
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4.3.4 Cells seeded into scaffolds expressed NF200 after the 24-days neuronal induction 
protocol 
Immunocytochemistry for cells differentiated and maturated in scaffolds showed that the 
scaffold provided the cells with mechanical and organizational support which allowed them 
to differentiate in a 3-D pattern inside the pores of the scaffold. Differentiated cells 
acquired neuronal-like phenotype and highly expressed NF200 (figure 37).  
 
Figure 37. Cord blood stem cells seeded into scaffolds expressed NF200 after neuronal maturation (Day 
24). The cells acquired neuronal-like morphology (white arrows in the merge image) highly expressed 
neuronal marker NF200. The (over exposure) image shows the scaffolds walls that provided mechanical and 
physical supports for the cells (represented with the bright DAPI spheres).  
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4.4 Conclusions 
 Umbilical cord blood non-hematopoietic multipotent stem cells are capable of 
proper neuronal commitment and differentiation in-vitro.  
 Our 24 days defined serum-free induction protocol efficiently differentiated 
umbilical cord blood non-hematopoietic multipotent stem cells into maturing 
neuron-like cells. 
 Umbilical cord blood non-hematopoietic multipotent stem cells are a potential and 
promising candidate for clinical and future neural tissue engineering applications. 
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4.5 Discussion 
In this chapter, the studies show that umbilical cord blood non-hematopoietic multipotent 
stem cells, purified by SC kit, can be differentiated into neuron-like cells in-vitro. A 
defined serum-free differentiation protocol is described, taking into account the 
requirements crucial for possible future clinical application. The neuronal commitment 
process of purified stem cells is characterized by analyzing the expression patterns of 
certain markers at both RNA and protein levels throughout the differentiation protocol. We 
then incorporated our differentiation protocol with 3-dimensional scaffold-based tissue 
engineering systems and showed that neuron-like cells could be produced in these scaffolds 
from seeded purified umbilical cord blood cells.  
4.5.1 Proper cell-cell interaction is essential for cells survival and proper neuronal 
differentiation 
Purified stem cells were cultured initially at a relatively high concentration (see section 2.5) 
because according to previous studies such high concentration of cells is necessary to 
initiate formation of cells aggregates that provide the cells with physical support and are 
important for cells proliferation and survival (Habich et al., 2006, Watt and Hogan, 2000). 
It has also been shown that close cell-to-cell contact is crucial for neuronal differentiation 
of stem cells isolated from umbilical cord blood. Zangiacome et al. (2008) showed that 
when stem cells isolated from cord blood where cultured at low concentration and were 
isolated from each other, they were unable to differentiation into neuron-like cells whereas 
at high concentration, the same cells were capable of neuronal differentiation upon 
induction.  
In neurogenic niche, special molecules called extracellular matrix (ECM) provide the cells 
with structural and functional support that regulate their proliferation and differentiation 
(Raymond et al., 2009). We have coated the cover slips with collagen IV, one of the most 
common ECM molecules in human tissues including nervous tissues and commonly used 
for immobilization of neural stem cell and neuronal cultures in-vitro, to provide the plated 
cells with the physical support they need for proper differentiation (Lin et al., 2004, 
Raymond et al., 2009). It has been shown that collagen IV promotes and enhances neuronal 
differentiation of cortical progenitor cells (Ali et al., 1998). Collagen IV binds to special 
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receptors on cells membrane such as integrins causing changes in protein conformation 
which in-turn initiates signal transduction cascade involving in various cellular functions 
including proliferation and differentiation (Campos et al., 2004). The strategy we applied in 
our cultures aimed to mimic the microenvironment conditions in the neurogenic niches to 
direct the neuronal differentiation of the cultured cord blood purified stem cells.  
4.5.2 Fate commitment: purified stem cells adapting a neural fate  
To evaluate the neural commitment of cord blood purified stem cells, we investigated the 
expression levels patterns of NESTIN and GFAP.  It was thought for a long time that 
Nestin, an intermediate filament, is only associated with neural progenitor cells and 
immaturity in the nervous system (Wiese et al., 2004). However  it has been shown that 
Nestin expressing cells can be differentiated into many cell types such as hepatic cells 
(Kania et al., 2003), pancreatic cells (Denner et al., 2007) and neural cells (Jurga et al., 
2006, Habich et al., 2006). Nestin expression can therefore be viewed as a property of 
multi-lineage progenitor cells with high proliferation characteristics (Wiese et al., 2004). 
Hence, using Nestin on its own as a marker of neural commitment might not be accurate. 
The co-expression of Nestin and GFAP by the same cell is stronger evidence of neural 
committed cells (figure 32) as co-expression of Nestin and GFAP is associated with 
proliferative neural stem cells in the SVZ of cerebral cortex and hippocampus (Abrous et 
al., 2005, Sohur et al., 2006, Zhao et al., 2008, Messam et al., 2002, Messam et al., 2000, 
Suh et al., 2007, Tavazoie et al., 2008). At day 10, a majority of cells co-expressed 
NESTIN and GFAP while only a small fraction expressed neuronal specific markers such 
as NF200 and β-TUBULIN III and none expressed more advanced neuronal markers such 
as NEUN (figure 33). These findings of limited expression of neuronal specific markers 
such as NF200 and β-TUBULIN III and the absence of advanced neuronal markers such as 
NEUN suggest that the cells at day 10 are still in early stages of neural development (figure 
33). The changed from day 0 cultures is also supported by the results obtained from real 
time PCR analysis of OCT4, SOX2 and NANOG which showed significant decrease in 
transcripts level of the three genes at day 10 compared with undifferentiated stem cells 
(Day 0) (figure 30). However, C-MYC expression level at day 10 was almost similar to its 
level at day 0 (figure 30). This suggests that neural committed cells (Day 10) retained their 
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proliferative characteristic despite being commitment to a possible neural fate, which 
resembles a stage of development highly similar to neural stem cells (figure 38).  
The “early neural commitment” medium contained two important growth factors, basic 
fibroblast growth factor (b-FGF) and epidermal growth factor (EGF) (table 7). b-FGF is a 
member of the FGF family of growth factors that play essential roles in development. It has 
been shown that b-FGF stimulates the proliferation and survival of neural stem cells in-
vitro and in-vivo as well (Zhao et al., 2008, Gremo and Presta, 2000). b-FGF acts as a 
mitogen that regulates the proliferation and commitment of neural stem cells and precursors 
without triggering neuronal differentiation (Bartlett et al., 1998, Murray and Dubois-Dalcq, 
1997, Guan et al., 2001). EGF as well has important roles in regulation of neural stem cell 
proliferation and neuronal differentiation (Reynolds et al., 1992, Angenieux et al., 2006, 
Guan et al., 2001). 
The role of b-FGF along with EGF as mitogens and neuro-regulators has been clearly 
observed in the experiments here where the proportion of cells expressing NESTIN and 
GFAP at day 10 increased significantly compared with day 0 and no similar increases were 
seen for neuronal specific markers such as NF200 and β-TUBULIN III indicating possible 
neural commitment but not yet neuronal differentiation (figure 33).  
4.5.3 Neuronal induction: molecular and morphological transformations 
After the neuronal differentiation phase (Day17), the cell morphology had changed to a 
clear neuronal-like morphology featuring growing thin long axon-like and short dendrite-
like structures (figure 28). This change in morphology was also accompanied by a 
molecular transformation in which differentiating cells expressed neuronal specific markers 
in specific patterns. At day 17, cells expressed neuronal-specific structural proteins 
including NF-200, β-TUBULIN III and GAP43, proteins that are likely to be involved in 
the morphological transformation observed (figure 33, 34, 35). NF-200 is an intermediate 
filament found specifically in neurons and is involved in axonal growth and maintenance 
(Xiao et al., 2006). β-TUBULIN III is a microtubule protein specific for neurons and 
neuronal tissues (Katsetos et al., 2003b, Katsetos et al., 2003a). GAP-43 is a polypeptide 
expressed in neurons and is associated with axons growth and is involved in regulation of 
neuronal cytoskeletal architecture (Meiri et al., 1986, Mishra et al., 2008). The expression 
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patterns of these three markers and their concentrate localization in growing neurites 
suggest proper neuronal commitment of the differentiated cells (figure 34 & 35). Although 
the cells at this stage (Day 17) expressed mature neuronal markers such as NEUN and 
PSD95, the proportion of cells co-expressing NESTIN and GFAP was also high (figure 34). 
The expression of markers associated with early stages of neural development (NESTIN 
and GFAP) and markers associated with advanced neuronal stages of development (NEUN 
and PSD95) suggest a developmental transitional stage of the differentiating cells at day 17.  
During this neuronal differentiation phase, two new important factors were introduced to 
the cells after day 10. The first factor was retinoic acid (RA) which is the oxidized form of 
Vitamin A (table 8). RA is known to have an essential role in controlling and patterning 
development in mammalian embryos and in particular the neural plate where it is involved 
in brain formation (Mey and McCaffery, 2004, Maden, 2006). It also has an essential role 
in maintenance and survival of adult neurons (Maden, 2007). RA is believed to be a general 
morphogen that induces and regulates differentiation to all neural lineages including 
astrocytes (Wuarin et al., 1990), oligodendrocytes (Noll and Miller, 1994) and neurons 
(Henion and Weston, 1994, Guan et al., 2001).  
To increase the likelihood of neuronal induction in our cultures, we co-introduced RA 
along with brain-derived neurotrophic factor (BDNF), a member of a closely related family 
of proteins named “neurotrophins” that also includes nerve growth factor (NGF). It has 
been also shown that RA maximizes the cells‟ response to neurotrophins by up-regulating 
the expression of their receptors (Kobayashi et al., 1994, Takahashi et al., 1999). BDNF has 
been shown previously to selectively stimulate neuronal differentiation in neural stem cell, 
embryonic stem cell as well as umbilical cord blood stem cell cultures (Ahmed et al., 1995, 
Li et al., 2005, Habich et al., 2006, Murer et al., 2001). It is also critically involved in the 
regulation of synaptic development and plasticity in the CNS (Poo, 2001, Ji et al., 2005).  
The co-introduction of RA and BDNF successfully directed the neural committed cells 
(Day 10) towards a neuronal fate (Day 17) indicated by the high proportions of cells 
expressing neuronal-specific markers and the morphological changes acquired by the cells 
after neuronal differentiation at day 17 of the differentiation protocol (figure 28 and 33).  
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4.5.4 Neuronal maturation 
After one further week of culture in maturation medium (Day 24), the percentages of cells 
expressing neuronal mature markers NEUN and PSD95 stayed high (figure 33, 36). NEUN 
is a DNA-binding neuron-specific protein that has been routinely associated with neuronal 
mature status in human nervous system (Mullen et al., 1992, Sarnat et al., 1998, Zhao et al., 
2008) while PSD-95 is a post synaptic density protein that is associated with receptors and 
cytoskeletal elements at the synapses and involved in the maturation of functional synapses 
in neurons (El-Husseini et al., 2000, Hata and Takai, 1999). The dominancy of cells 
expressing NEUN and PSD95 (figure 36) , the decreased proportion of cells expressing 
early neural markers NESTIN and GFAP (figure 33), the significant down-regulation of 
pluripotency markers OCT4, SOX2 and NANOG and proliferative marker C-MYC (figure 
30) and the significant up-regulation in PSD95 (figure 31) in addition to the neuronal 
morphological features observed in cultures after day 24 (figure 29), all together offer a 
strong indication of advanced and maturing developmental status of generated neuron-like 
cells at day 24.  
Two new factors have been introduced to differentiating cells at day 17, nerve growth 
factor (NGF) and cyclic AMP (cAMP) (table 8). NGF is a small protein that is involved in 
the maintenance, growth and survival of neurons (O'Keeffe et al., 2008) whilst cAMP is a 
second messenger that is involved in many cellular and biological functions and activities 
by relaying signals through specialized signal transduction cascades.  In neurons, cAMP 
plays a key role in neuronal survival, plasticity and is involved in neuronal morphological 
maturation (Fujioka et al., 2004, Nakagawa et al., 2002). cAMP is also involved in the 
regulation of other important factors crucial for neuronal development and survival. It has 
been found that cAMP regulates the function of BDNF in hippocampal mature neurons 
through modulating the signaling and trafficking of its receptor (TrkB) in dendrites spines 
(Ji et al., 2005, Stewart et al., 2001). The co-introduction of NGF and cAMP at day 17 
successfully enhanced and stimulated the maturation of differentiating cells which is 
suggested by the morphological features and protein expression patterns by day 24 (figure 
29 & 33).   
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At day 24, dead cells were observed in cultures. The morphology of these cells varied, 
some of them showed clear neuronal-like morphology (figure 29C1) while other showed 
large round shape (figure 29C2). Defining the exact factors triggering the cell death 
observed needs further investigations.  
4.5.5 The sequential neuronal induction protocol reflects the dynamic process of 
neurogenesis  
Neuronal differentiation of the purified stem cells from human umbilical cord blood 
observed in our experiment reflected the dynamic process of neurogenesis in vivo which 
involves different stages including commitment, differentiation and maturation. Each stage 
is characterized with specific expression pattern of certain markers (Takahashi et al., 1999, 
Zhao et al., 2008, Duan et al., 2008, Ming and Song, 2005). Our differentiation protocol 
consisted of three phases (figure 38). During each phase the cells were provided with 
specific combination of factors and inducers.  
During the first phase of our differentiation protocol, freshly purified cord blood non-
hematopoietic stem cells were cultured in the presence of b-FGF and EGF (table 7) to 
stimulate neural commitment, suggested by the NESTIN and GFAP co-expression, the first 
step toward neuronal development (figure 37).  
In the next phase, cells were placed in “neuronal differentiation” in which RA and BDNF 
were introduced and b-FGF was removed (table 8) to stimulate neuronal differentiation. 
Earlier studies have shown that the removal of b-FGF from neural stem cells cultures is 
sufficient to induce limited neuronal differentiation, suggesting that b-FGF is more 
involved in the regulation of neural stem cell proliferation and maintenance of their 
undifferentiated status rather than triggering differentiation (Ray et al., 1993, Zheng et al., 
2010). After one week of differentiation (Day 17), significant down-regulation in 
pluripotency genes, in addition to C-MYC, were recorded, cells acquired neuronal-like 
morphology and expressed neuronal markers (including NF200, β-TUBULIN III, GAP43, 
NEUN, and PSD95) which suggest initiation of neuronal differentiation (figure 38).  
 After maturation phase (Day 24) where cAMP and NGF were introduced, proportion of 
cells expressing early neural markers (NESTIN and GFAP) significantly decreased while 
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proportions of cells expressing neuronal specific markers stayed high which suggest a more 
advancing differentiation status of the cells (figure 38). 
 
 
 
Figure 38. Summary of the sequential neuronal induction protocol. The top panel represents the 
experiment time line along with the key factors used in each phase (in green). The expression patterns of 
analyzed genes and proteins are shown in red thorough the experiment. The bottom panel (in blue) describes 
the developmental stage resembled at each time point suggested by the markers expression patterns.   
 
 
4.5.6 Fully defined short-term differentiation protocol, a step closer to clinics 
Animal serum has been commonly used as an essential growth supplement for human cell 
cultures. It has a complex “undefined” content of proteins, growth factors and nutrients that 
promote the growth of human cells in cultures (Gstraunthaler, 2003, Castle and Robertson, 
1999, Martin et al., 2005). Despite being a useful cost-effective media supplement, the use 
of animal serum in human cultures involves some risks factors especially when considering 
potential clinical applications. The contamination with zoonotic agents including animal 
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microbes and viruses is among the most feared risk factors associated with use of animal 
products including serum (Castle and Robertson, 1999, Unger et al., 2008, Wessman and 
Levings, 1999). In addition, the use of animal serum in human stem cell cultures with 
potential use in transplantation applications could induce an unwanted immune response 
upon transplantation. Martin et al. (2005) showed that animal serum contain sialic acids, a 
family of acidic sugars expressed on surfaces of all cell types, that can be absorbed by 
human embryonic stem cells via a defined mechanism (Bardor et al., 2005), and humans 
have circulating antibodies specific for the absorbed sialic acid. So when the cultured 
human embryonic stem cells were exposed to human sera, antibodies in the sera bound to 
the sialic acid on the surface of the human embryonic stem cells which in vivo would lead 
to cell death due to an immune response (Martin et al., 2005). To avoid such risks, the 
media used here for culturing and differentiation were fully defined and free of animal 
serum. The animal serum was substituted with medium supplements B27 and N2 which are 
composed of defined amounts of certain components including amino acids, vitamins, 
hormones and antioxidants that provided our purified cord blood stem cells and derived 
neuron-like cells with nutrients necessarily for survival and growth (Fedoroff and 
Richardson, 2001, Wachs et al., 2003). The use of defined serum-free media allowed better 
control on the culturing environment and facilitated more precise analysis and 
characterization of the differentiation process of purified cord blood stem cells.  
In addition to using defined serum-free culturing conditions, culturing  protocol to be only 
for a relatively short time (24 days), without compromising its effectiveness, to reduce the 
risk of infections and possible chromosomal aberrations as reported by previous study 
where cord blood derived cells showed cytogenetic alterations after culturing and multiple 
passaging (Corselli et al., 2008). As a safety check, a cytogenetic analysis was performed 
on purified stem cells after the “early neural commitment” stage (Day 10) prior to 
differentiation, since chromosomal abnormalities are common in proliferating cells, and 
results showed normal karyotypes (figure 63 in appendix.II). The culturing system 
described in this thesis emphasizes a philosophy of increasing adherence toward clinical 
grade protocols for potential clinical applications by using short and fully defined culturing 
conditions free of animal serum.  
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4.5.7 3-dimensional (3D) differentiation: potential use of cord blood stem cells in neural 
tissue engineering applications  
Standard 2-dimensional (2D) cultures are very important to understand and study the 
differentiation potentials of the stem cells. However when considering tissue engineering 
applications where the target is to produce tissues rather than cells, these standard (2D) 
cultures cannot represent the physical cell-cell interactions and mimic the 3-dimensional 
(3D) spatial organization of the cells within the targeted tissue or organ. Tissue engineering 
applications require proper mimicking of cell-cell interactions and organization in 
functional organs in order to develop potential functional tissues (Mahoney and Anseth, 
2006, Mahoney and Anseth, 2007, Brannvall et al., 2007). In here, we used thin scaffolds 
(300 µm thick) and seeded the purified cord blood stem cells into the scaffolds right after 
purification. After the 24 days neuronal induction protocol, the cells differentiated 
successfully into neuronal-like cells, suggested by the phenotypic features and NF200 
expression (figure 37), and were equally distributed inside the scaffolds indicating that the 
scaffolds provided mechanical support that allow proper cells organization and 3D cells 
growth and differentiation.  
The long term goal of such a study is to be able to produce neuronal tissues suitable for 
transplantation into patients to compensate for brain tissues lost as a result of a neurological 
disease or injury. However, there are several requirements that need to be fulfilled in order 
to ensure potentially successful outcome of such applications. First, it is important to use 
safe and bio-degradable scaffolds to eliminate any possible toxic effect or unwanted 
immune response. Second, the generated tissues must be able to functionally integrate in 
the existing host brain networks. Third, the development of safe and efficient clinical 
procedures for transplanting the generated tissues into patients.   
Here we have taken the first steps towards producing a scaffold-based 3-dimensional 
culture system in which neuronal tissues can develop and thrive. Refer to (Ali et al., 2009) 
attached at the end of this thesis.  
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Chapter 5. Umbilical cord blood non-hematopoietic multipotent stem cells 
model cortical neurogenesis in-vitro 
 
 
5.1 Introduction 
The human adult cerebral cortex is an intricately structured sheet of tissue organized into 
six distinct cortical layers. During development the cortex is formed in an inside-out 
manner in which the earliest born neurons are found in the deepest cortical layers while the 
later born neurons occupy locations within the superficial layers, reviewed in (Shipp, 2007, 
Meyer, 2001). It is composed mainly of two types of neurons: cortical pyramidal neurons 
and cortical interneurons. Pyramidal neurons are excitatory neurons that utilize glutamate 
as a neurotransmitter and they account for 80% of the cortex neuronal content. These 
neurons are derived from progenitor cells in the ventricular zone and migrate radially to the 
cortical plate (Guillemot et al., 2006, Campbell, 2005) . On the other hand, interneurons, 
which account for about 20% of total cortical neurons, are mainly inhibitory and utilize 
GABA as a neurotransmitter. Interneurons are derived from two locations: progenitor cells 
in the proliferative zones of the cortex which migrate radially to occupy different cortical 
layers and from progenitors in the ganglionic eminences that migrate tangentially into the 
cortex (Letinic et al., 2002, Meyer et al., 2000, Jones, 2009).  
During development, the cortex increases its width from less than 1 mm by the 8 post 
conceptual week (PCW) stage to nearly 5 mm by 16 PCW stage (Bayatti et al., 2008a). At 
12 PCW stage the human cortex is divided clearly into distinct layers.  Just above the 
ventricles lies the ventricular zone (VZ) which hosts a population of neural progenitor cells 
that would give rise to the cortical neurons (Noctor et al., 2002). Above the (VZ) lies the 
subventricular zone (SVZ) which can be further divided into inner subventricular zone 
(ISVZ) and outer subventricular zone (OSVZ). The subplate/intermediate zone (SP/IZ) 
resides above the SVZ. It is the layer where the differentiating progenitor cells acquire their 
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neuronal identity (McConnell et al., 1989, Kanold and Luhmann, 2010). The SP/IZ is 
followed by the cortical plate CP and the marginal zone MZ.  
Differentiating progenitor cells at the VZmigrate radially across cortical layers to the CP 
via the aid of radial glial cells (Rakic, 2003, Meyer, 2001). The corticogenesis of pyramidal 
neurons at embryonic stages is a complex but highly ordered process that is tightly 
regulated by specific genes, including PAX6, TBR2 and TBR1 which have attracted 
attention not only for their functional properties but also for their sequential expression 
patterns across the developing cortex (table 17) (Englund et al., 2005, Hevner et al., 2006). 
PAX6 is expressed in the highly proliferative progenitor cells in the cortex where it 
regulates cell cycle and mitotic division and has an essential role in normal neuronal 
development (Gotz et al., 1998, Hevner et al., 2006, Quinn et al., 2010). TBR2 defines 
intermediate progenitor cells (IPC) of the developing cortex where its expression pattern 
suggests its involvement in fate specification and differentiation of glutamatergic neurons 
(Sessa et al., 2008). TBR1 is expressed primarily in postmitotic neurons of the cortex 
(Hevner et al., 2001, Hevner et al., 2006, Hong and Hsueh, 2007). The zonal and sequential 
expression patterns of these genes emphasize their important regulatory role in cortical 
neurogenesis (figure 39) (Hevner et al., 2006, Bayatti et al., 2008b, Englund et al., 2005, 
Bayatti et al., 2008a). Other transcription factors including basic helix-loop-helix (bHLH) 
transcription factors are also highly involved in the regulation of cortical neurogenesis and 
fate decisions at embryonic stages (Mattar et al., 2008, Bayatti et al., 2008b).  
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Table 17. Description of PAX6, TBR2 and TBR1 
Gene Functions Knockout studies 
Associated 
disorders (human) 
Expression in 
CNS 
References 
PAX6 
Transcription 
factor highly 
involved in the 
development 
of CNS, eye 
and pancreas. 
PAX
 
6 knockout 
causes abnormal 
development in 
CNS including 
forebrain axonal 
connections.  
Mutations in the 
gene have been 
found to cause 
aniridia and Peter's 
anomaly.   
Expressed by the 
highly 
proliferative 
progenitor cells in 
cortex. 
(Jones et al., 
2002, Li et al., 
2009, Quinn et 
al., 2010, 
Dansault et al., 
2007) 
TBR2 
Transcription 
factor involved 
in trophoblast 
differentiation, 
gastrulation 
and brain 
development. 
TBR2 knockout is 
lethal due to defects 
in trophoectoderm 
differentiation. 
Conditional 
knockout at early 
embryonic 
development cause 
microcephaly and 
severe behavioral 
deficits.  
Mutations in the 
gene cause 
recessive 
microcephaly, 
polymicrogyria, 
corpus callosum 
agenesis, cognitive 
defects, and severe 
motor delay. 
Expressed by 
intermediate 
progenitor cells 
(IPC) of the 
developing cortex.  
(Sessa et al., 
2010, Baala et al., 
2007, Hodge et 
al., 2008) 
TBR1 
Transcription 
factor involved 
in brain 
development. 
TBR1 knockout 
causes abnormalities 
in cortical 
lamination, axon 
connections, and 
layer-specific 
differentiation. 
Non reported.  
Expressed by 
postmitotic 
neurons in cortex.  
(Hevner et al., 
2001, Englund et 
al., 2005) 
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Figure 39. In situ hybridization localization of PAX6, TBR2 and TBR1 across 12 PCW human 
neocortex. The three markers expressed in a sequence during cortical neurogenesis. PAX6 is mostly 
expressed by progenitor cells reside in the VZ, TBR2 expressed mostly in intermediate progenitor cells (IPC) 
residing mainly in ISVZ and TBR1 expressed mostly by post-mitotic neurons located at the CP (Bar = 
200µm). Figure adapted from (Bayatti et al., 2008b).  
 
The cortex, and in particular the motor cortex and/or corticospinal tract is a common site of 
damage and injury that might lead to severe neurological disorders, to which current modes 
of therapy are inadequate (Johnston and Hoon, 2006). Stem cells have been proposed as a 
potential therapeutic tool that offers a new level of therapeutic intervention which 
theoretically would open the doors for neural replacement strategies to compensate for the 
neurons lost as a consequence of the neurological condition. Such strategies rely on the 
ability of stem cells to produce neurons, with similar developmental and functional 
properties as the one targeted for replacement, which when integrated successfully in the 
lesion sites would stimulate functional and physiological recovery. Thus, it is important 
first to identify the molecules and mechanisms that determine and regulate the 
differentiation of endogenous cortical neurons and determine whether the same 
mechanisms can induce stem cells to produce neurons with similar characteristics to the 
ones targeted for therapy.  
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In this study, we show that the process of differentiating umbilical cord blood non-
hematopoietic multipotent stem cells can provide an in vitro model of human cortical 
neurogenesis of glutamatergic neurons. We compare the expression patterns of markers 
previously found to be expressed sequentially across the 12 PCW human neocortex that are 
crucially involved in human cortical neurogenesis of neurons, and their expression patterns 
in cord blood purified stem cells throughout the differentiation protocol described 
previously (refer to section 2.5). We further investigate the expression of certain markers 
associated with glutamatergic neurotransmission, the dominating neurotransmission system 
in cortex, in cord blood derived neuron-like cells.  
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5.2 Study aims 
 To assess the ability of umbilical cord blood non-hematopoietic multipotent stem 
cells to model cortical neurogenesis in vitro by analyzing the expression patterns of 
markers associated with cortical neurogenesis at mRNA and protein levels 
throughout the neuronal differentiation protocol.  
 To investigate the expression of certain markers associated with glutamatergic 
neurotransmission in cord blood derived neuron-like cells. 
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5.3 Results 
5.3.1 PAX6, TBR2 and TBR1 are expressed in a sequence across the 12 PCW human 
neocortex 
In sections of 12 PCW fetal human neocortex, PAX6-immunoreactive cells were localized 
mainly in the VZ and to a lesser extent in the SVZ including ISVZ and OSVZ. No PAX6 
immunoreactive cells were detected in either SP or CP (figure 40). TBR2-immunoreactive 
cells were largely confined to the ISVZ, with some positive cells in the OSVZ and also in 
the VZ but away from the ventricular surface. Similar to PAX6 positive cells, no TBR2 
positive cells were detected in either the SP or the CP (figure 40). TBR1-immunoreactive 
cells were mainly localized in the CP and few reactive cells were detected in the SP. No 
TBR1 positive cells were detected in the VZ and the SVZ (figure 40). All three proteins 
showed nuclear localization.  
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Figure 40. Immunohistochemistry analysis of PAX6, TBR2 and TBR1 at protein level in 12 PCW 
human neocortex. PAX6 positive cells were localized primarily in the ventricular zone (VZ) and in the sub-
ventricular zone (SVZ) at lower extent. No PAX6 positive cells were detected in the sub-plate (SP) and the 
cortical plate (CP).  TBR2 positive cells were mainly localized in the inner sub-ventricular zone (ISVZ) and 
some were localized in the outer sub-ventricular zone (OSVZ) and the ventricular zone (VZ) away from the 
ventricular surface.  No TBR2 positive cells were detected in the sub-plate (SP) and the cortical plate 
(CP).TBR1 positive cells were confined in the cortical plate (CP) and some were localized in the sub-plate 
(SP). No TBR1 positive cells were detected in the ventricular zone (VZ) and the sub-ventricular zone (SVZ). 
All three markers showed nuclear localization. (Bar = 200µm). 
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5.3.2 PAX6, TBR2 and TBR1 expression patterns define sequential neurogenesis in cord 
blood differentiating stem cells 
Q-PCR  analysis of umbilical cord blood stem cells throughout the 24-days induction 
protocol showed that the normalized expression level of PAX6 increased from day 0 to day 
17 and decreased after maturation at day 24 (figure 41); these changes in expression pattern 
throughout the 24 days were statistically significant (ANOVA, p<0.005, n=3). TBR2 
expression normalized to GAPDH decreased between day 10 and day 17 and stayed low at 
day 24 (ANOVA, p<0.005, n=3) (figure 41). Normalized expression of TBR1 increased 
gradually and significantly between day 0 and day 24 (ANOVA, p<0.005, n=3) (figure 41).  
Detection of PAX6, TBR2 and TBR1 immunoreactivity in cord blood stem cell cultures 
showed that the protein expression patterns strongly correlate with the corresponding 
mRNA expression patterns. 48 ± 7.6% of PAX6 positive cells were present at day 0 and 45 
± 5.6% on day 10 before decreasing to 15 ± 4.4% by day 24. These changes were 
statistically significant (ANOVA, p<0.005, n=4) (figure 42, 43). TBR2 positive cells 
increased from 5.2 ± 4.4% at day 0 to 17.7 ± 3.7% at day 10 and decreased by day 24d to 
3.4 ± 1.6%, again these changes were statistically significant (ANOVA, p<0.05, n=3) 
(figure 43, 44). TBR1 positive cells increased from 3.3 ± 1% at day 0 to17.8 ± 5.3% at day 
10 and 66 ± 6.2% at day 24 (figure 42, 43). These changes were statistically significant 
(ANOVA, p<0.005, n=3). Primers for PAX6 and TBR1 have been checked for neural 
specificity by testing on cDNA isolated from human adult liver, human fetal cortex and 
cord blood cells. PCR results on liver samples were negative for both markers while fetal 
cortex and cord blood samples showed positive results (refer to figure 68 in appendix III).  
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Figure 41. Q-PCR analysis of PAX6, TBR2 and TBR1 expression pattern in umbilical cord purified 
stem cells through the 24-days neuronal induction protocol. PAX6 expression level increased gradually 
between day 0 and day 17 before decreasing to its lowest level by day 24. TBR2 expression level was high at 
day 0 and day 10 before decreasing after neuronal differentiation (Day 17) and maturation (Day 24). TBR1 
expression level increased gradually during the differentiation protocol reaching its highest level by day 24. 
Gene expressions levels were normalized to GAPDH expression level. For PAX6 and TBR2 the calibrator is 
Day 24, for TBR1 the calibrator is Day 0. Changes in expression levels of the three genes over the 24 days 
period are statistically significant (ANOVA, p<0.005, n=3, for the three genes). 
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Figure 42. Expression analysis of PAX6, TBR2 and TBR1 during the 24-days neuronal induction 
protocol. Percentage of cells expressing PAX6 was at its highest at day 0 and day 10 before decreasing 
significantly by day 24. Proportion of cells expressing TBR2 increased between day 0 and day 10 before 
decreasing after neuronal maturation (Day 24). Percentage of cells expressing TBR1 increased gradually 
throughout the 24-days induction protocol reaching its highest point at day 24. Changes in percentages of 
positive cells over the 24 days period are statistically significant (ANOVA, p<0.005 for PAX6 and TBR1, 
p<0.05 for TBR2,   n=3). 
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Figure 43. Localization of PAX6, TBR2 and TBR1 in cells throughout the differentiation protocol using 
immunocytochemistry. At day 0, cord blood stem cells strongly expressed PAX6 showing nuclear 
localization while TBR1 expression was weak compared to PAX6. At day 10, nuclear co-expression of PAX6 
and TBR2 can be detected. At day 24, TBR1 was highly expressed in the cell‟s cytoplasm while PAX6 
expression was greatly reduced compared with its expression at day 0. 
 
5.3.3 Cord blood differentiated stem cells expressed glutamate receptor and transporters 
After neuronal maturation (Day 24), cells expressed immunoreactivity for NMDAR1 in 
their cytoplasm (figure 44) and VGLUT1 (vesicular glutamate transporter 1) which 
appeared as punctuated staining on the surface of cells suggestive of nerve terminals (figure 
46). No expressions of NMDAR1 and VGLUT1 in freshly purified cord blood stem cells 
(Day 0) were detected (refer to figure 64 and figure 65 in appendix II). 
Quantitative PCR analysis showed a significant increase in glutamate transporter gene 
SLC1A1 expression levels between day 0 and day 24 (figure 46) (p<0.05, n=3).  
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Figure 44. Generated neuron-like cells from umbilical cord blood stem cells expressed NMDAR1 in 
their cytoplasm at day24. No expression of NMDAR1 was detected in purified cord blood stem cells (Day 
0), refer to (figure 64) in appendix II.  
 
 
 
Figure 45. Cord blood generated neuron-like cells expressed vesicular glutamate transporter 1 
(VGLUT1) at day24. VGLUT1 appeared as punctuated staining concentrated in the cell‟s terminals (white 
arrows)   suggestive of nerve terminals. Cells co-expressed VGLUT1 with neuron-specific tubulin β-
TUBULIN III.  No expression of VGLUT1 was detected in purified cord blood stem cells (Day 0), refer to 
(figure 65) in appendixII. 
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Figure 46. Q-PCR analysis of glutamate transporter SLC1A1expression pattern between (Day 0) and 
(Day 24). Expression of SLC1A1 was extremely low in undifferentiated cord blood stem cells (Day 0) but 
increased significantly after neuronal maturation (Day 24).  Calibrator is Day 0.Gene expression level was 
normalized to housekeeping genes HPRT1, RPL13A and GAPDH. Student‟s t-test (p<0.05, n=3). 
 
5.3.4 Expression patterns of basic helix-loop-helix (bHLH) genes throughout the 24-days 
induction protocol 
Q-PCR analysis showed that NEUROD normalized expression level was very weak at day 
0 and slightly increased at day 10 and day 17 before reaching its highest expression level at 
day 24 (ANOVA, p<0.005, n=3) (figure 47). NEUROD2 normalized expression level was 
very weak at day 0 and increased significantly at day 17 and day 24 (ANOVA, p<0.005, 
n=3) (figure 47). NGN1 and NGN2 expression patterns were relatively similar. Their 
normalized expression levels increased over the “neural early commitment” phase reaching 
their highest levels at day 10 before their expression levels decreased gradually after 
neuronal differentiation (Day 17) and neuronal maturation (Day 24) (ANOVA, p<0.005, 
n=3, for both genes) (figure 47).  
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Figure 47. Q-PCR analysis of basic helix-loop-helix (bHLH) genes expression patterns in cord blood 
stem cells throughout the 24-day neuronal induction protocol. NEUROD expression level was weak at day 
0, slightly increased at day 10 and day 17 and had increased substantially by Day 24. NEUROD2 expression 
level was weak between day 0 and day 10 before significantly increasing by Day 17 and staying high at Day 
24. NGN1 and NGN2 had relatively similar expression patterns, their highest expression levels were recorded 
at day10 before being down regulated at Day 17 Day 24. Expression levels of the five genes were normalized 
to GAPDH expression level. Calibrator for NEUROD and NEUROD2 and NGN2 is Day0, for NGN1 is Day 
24.Changes in expression levels of the five genes throughout the 24-days induction protocol were statistically 
significant (ANOVA, p<0.005, n=3, for the four genes).  
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5.4 Conclusions 
 PAX6, TBR2 and TBR1 show sequential expression at early stages across the 
developing human neocortex.  
 Umbilical cord blood non-hematopoietic multipotent stem cells undergoing our 
previously described neuronal induction protocol also show a similar sequential 
expression pattern of PAX6, TBR2 and TBR1 and produced neuron-like cells 
expressing markers associated with glutamatergic neurotransmission. 
 Umbilical cord blood purified stem cells could provide an in-vitro model of human 
neurogenesis of glutamatergic neurons.  
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5.5 Discussion 
In this chapter we have demonstrated that the induction of neuronal differentiation in 
human umbilical cord blood non-hematopoietic multipotent stem cells results in the 
recapitulation of gene expression patterns seen in the development of cortical neurons. The 
expression patterns of PAX6, TBR2 and TBR1 at both the transcriptional and translational 
levels in purified stem cells undergoing the previously described sequential neuronal 
induction protocol in vitro, resembled patterns of expression seen across the human 
developing neocortex from the proliferative zones to the cortical plate that characterize 
glutamatergic neurogenesis. Proper neuronal differentiation has also been suggested by 
expression patterns of basic helix-loop-helix transcription factors that are known for their 
regulatory role in neurogenesis. At the end of the neuronal induction protocol, the 
generated neuron-like cells properly expressed specific glutamatergic markers, including 
glutamate transporters and receptors, which provide evidence supporting their 
glutamatergic identity. Thus we have developed a possible in vitro model for human 
cortical neurogenesis.  
5.5.1 PAX6, TBR2 and TBR1 sequential expression across the human neocortex defines 
the corticogenesis of glutamatergic neurons  
Corticogenesis of glutamatergic neurons is a highly dynamic process in which proliferating 
progenitor cells at the (VZ) differentiate and migrate radially across cortical layers to reside 
in the (CP) with early born neurons occupying deeper layers (Rakic, 2003, Meyer, 2001, 
Angevine and Sidman, 1961). The fate commitment of progenitor cells and the 
differentiation process is regulated by genetic programs that involve certain transcription 
factors. It has been shown by several groups that PAX6, TBR2 and TBR1 are crucially 
involved in the regulation and fate commitment of glutamatergic cortical neurons (Bayatti 
et al., 2008a, Bayatti et al., 2008b, Hevner et al., 2006, Hevner, 2007). In the studies here 
we show, using immunohistochemical analysis on human neocortex, that PAX6, TBR2 and 
TBR1 are expressed in a sequence across the neocortical layers where PAX6 was mainly 
localized in VZ and SVZ that host a large subset of progenitor cells identified as radial glia 
(Hansen et al., 2010). TBR2 was localized mostly in the ISVZ and to a lesser degree in 
OSVZ, representing an additional pool of precursor cells termed intermediate progenitor 
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cells (IPC) which are derived from radial glia cells with neuronal-specified fate (Hevner et 
al., 2006).  TBR1 was localized mainly in the CP where it specifies post-mitotic mature 
glutamatergic neurons (Hevner, 2007) (figure 39 and 40). The sequence of PAX6 → TBR2 
→ TBR1 observed across the neocortex reflects the process corticogenesis of glutamatergic 
neurons (figure 48). The exact function of each transcription factor in corticogenesis is not 
fully understood however their involvement can be predicted based on their expression 
patterns. The association of each transcription factor with certain cortical layers suggests 
their stage of involvement during corticogenesis. The expression pattern of PAX6 suggests 
that it is involved in early fate specification events where TBR2 is involved in neuronal 
subtype differentiation and migration and TBR1 is involved in neuronal maturation. The 
sequential expression of PAX6, TBR2 and TBR1 defines the corticogenesis of 
glutamatergic neurons in human fetal neocortex and plays a major role in specifying their 
fate and identity.  
5.5.2 Neuronal differentiation of umbilical cord blood purified stem cells recapitulated 
key events observed in the human fetal neocortex that regulate the development of 
glutamatergic neurons 
In order to evaluate the efficiency of our in-vitro system in modeling human cortico-
neurogenesis, we investigated the expression patterns of PAX6, TBR2 and TBR1 in 
differentiating purified cord blood stem cells throughout the 24 days induction protocol and 
compared them to expression patterns observed in the developing neocortex at both the 
transcriptional and translational levels.  
Quantative-PCR and immunocytochemistry analysis showed that PAX6 and TBR2 were 
more associated with early rather than late stages of differentiation unlike TBR1 which 
gradually and significantly increased during the 24 days neuronal induction protocol 
reaching its highest levels after neuronal maturation (Day 24) (figure 41 and 42). PAX6 
was expressed by almost half of the freshly purified cells (Day 0). This transcription factor 
is expressed in the highly proliferative progenitor cells of cortex where it is involved in the 
regulation of cell cycle and mitotic division and plays a key role in neuronal development 
and differentiation (Gotz et al., 1998, Hevner et al., 2006, Quinn et al., 2010). So this 
population of cells at day 0 which highly expressed PAX6 but not TBR1 resembles the 
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population of progenitor cells (radial glia) located in the VZ of the neocrtex. After early 
neural induction (Day 10) the cells continued to express PAX6 in addition to TBR2 which 
was co-localized in the cells nuclei with PAX6 indicating advancing differentiation and 
commitment (figure 43). The protein co-expression pattern of PAX6 and TBR2 in cells at 
day 10 highly resembles the intermediate progenitor cells (IPC) observed in the OSVZ of 
neocortex where we observed clear overlapping of zonal expression patterns of the two 
markers at both transcriptional and transitional levels (figure 48).  
As a transcription factor, TBR1 is expected to be expressed in nuclei of the cells and this 
was the case in the cells located in the CP of the neocortex. However, TBR1 was mainly 
localized in the cytoplasm of cells at day 24 (figure 44). Hong et al. (2007) have shown 
using DAB staining and confocal imaging that TBR1 at embryonic stages is mainly 
expressed in cellular nuclei before a significant amount of the protein is translocated to the 
cytoplasm in adult brain where it is thought to be involved in regulation of synaptic 
activity, indicating that the sub-cellular distribution of TBR1 in the brain is 
developmentally regulated. After neuronal maturation (Day 24) majority of cells expressed 
TBR1 and proportions of cells expressing PAX6 and TBR2 decreased compared with their 
proportions at day 10 (figure 48). Similar expression patterns were observed for the 
transcriptional levels of the three markers. These results, in addition to the morphological 
transformation, suggest that cells at day 24 resemble the post-mitotic neurons of the CP of 
the neocortex where the cells expressed TBR1 but were negative for PAX6 and TBR2.  
The key events regulating glutamatergic neurogenesis within the neocortex were 
recapitulated in the developed in-vitro system where the sequential expression patterns of 
PAX6, TBR2 and TBR1 at both transcriptional and translational levels were resembled 
throughout the 24 days sequential induction protocol of cord blood purified stem cells.   
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Figure 48. Summary of PAX6, TBR2, TBR1 expression patterns in 12 PCW human neocortex and in-
vitro neuronal induction protocol of cord blood purified stem cells. The diagram represents markers 
expression patterns alongside a zonal axis in human neocortex and a time-line axis in cord blood 
differentiating cells establishing a “zonal/time-point” relationship between the neocortex based corticogenesis 
and cord blood stem cells based neuronal differentiation system. 
 
5.5.3 Umbilical cord blood derived neurons and the glutamatergic identity   
In order to assess whether our differentiated cord blood purified stem cells express 
glutamatergic specific markers normally expressed by cortical glutamatergic neurons, we 
analyzed the expression of common glutamate receptor NMDAR1 which is involved in 
synaptic transmission, synaptic plasticity and is essential for neuronal survival in the central 
nervous system (Martel et al., 2009, Platel et al., 2010, Mattson, 2007). Additionally, we 
examined expression of the vesicular glutamate transporter 1 (VGLUT1) which is 
predominantly expressed by glutamatergic neurons in human cerebral cortex and is partly 
responsible for uptake of glutamate from the synaptic space during synaptic transmission 
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and SLC1A1 which encodes a high affinity glutamate transporter (neurotransmitter 
transporters will be further discussed in chapter 6) (Arnth-Jensen et al., 2002, Nie and 
Weng, 2009, Fremeau et al., 2004). Immunocytochemistry results indicated a robust 
induction of expression of both markers by day 24 (figure 45, 46), and Q-PCR results 
showed significant up-regulation in SLC1A1 transcript level at day 24 in comparison with 
day 0 (figure 46). Therefore at this time point (Day 24) the cells have undergone a 
differentiation process that has resulted in the sequential expression of genes known to be 
important in specifying glutamatergic identity, as well as expressing receptors and 
transporters for the neurotransmitter which confirm their neuronal glutamatergic identity. 
5.5.4 Basic helix-loop-helix (b-HLH) transcription factors are involved in cortical fate 
specification  
Basic helix-loop-helix (b-HLH) is a structural protein motif that consists of two α-helices 
connected by a loop which characterizes a large family of transcription factors named b-
HLH class of transcription factors (Guillemot, 1999). Members of this structurally and 
functionally diverse family of transcription factors are involved in various developmental 
processes including neurogenesis, myogenesis and haematopoiesis (Morgenstern and 
Atchley, 1999, Porcher et al., 1999). A subgroup of b-HLH transcription factors termed 
pro-neural b-HLH transcription factors have been shown to play major roles in neocortex 
where they regulate neurogenesis and neuronal fate specification (Schuurmans et al., 2004). 
As mentioned earlier the human neocortex is composed of two types of cortical neurons: 
glutamatergic neurons and GABAergic neurons (Letinic et al., 2002, Au and Fishell, 2008, 
Guillemot et al., 2006, Campbell, 2005). The mechanisms regulating fate specification of 
cortical progenitor cells to either glutamatergic or GABAergic is tightly regulated by 
members of b-HLH family of transcription factors including MASH1, NGN1 and NGN2. It 
has been shown that MASH1 promotes progenitor cells in the VZ and SVZ to adapt a 
GABAergic fate where NGN1 and NGN2 promote glutamatergic fate (Campbell, 2005, 
Schuurmans et al., 2004, Mattar et al., 2008). Such effects have been demonstrated by a 
number of studies. In one study, it has been shown that repression of mash1 in cortex is 
sufficient to prevent formation of GABAergic interneurons (Roybon et al., 2010). In 
another study, it was shown that knocking out ngn1 and ngn2 resulted in severe disruption 
of glutamatergic neurogenesis in the animal cortex (Schuurmans et al., 2004). So it is clear 
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that early specification of cortical identity is regulated by genetic programs involving 
MASH1, NGN1 and NGN2 which act as regulators for downstream genes.  
In our study, we analyzed the transcript expression levels of four important b-HLH 
transcription factors throughout the 24 days induction protocol. Factor analyzed included 
NGN1 and NGN2 which are crucially involved in early stages of glutamatergic fate 
specification in the cortex, and NEUROD and NEUROD2 which are involved in late stages 
of cortical development of glutamatergic neurons(Schuurmans et al., 2004) (figure 47). Q-
PCR results showed that NGN1 and NGN2 were up-regulated after early neural 
commitment stage (Day 10) before being down-regulated at following stages. The 
transitional expression of the two genes at early stage (day 10) recapitulated their early 
involvement in fate specification in human cortex where they regulate a cascade of 
downstream genes that are involved in the development and specification of cortical 
glutamatergic neurons (Letinic et al., 2002, Guillemot et al., 2006). We further analyzed the 
transcript expression patterns of NEUROD and NEUROD2 in cord blood differentiating 
cells. Q-PCR results showed that NEUROD was significantly up-regulated after neuronal 
maturation (Day 24) where NEUROD2 was up-regulated after neuronal differentiation (Day 
17) and stayed high after maturation (Day 24). The expression patterns of both genes agree 
with their reported involvement in cortical neurogenesis where they have been shown to be 
involved in late stages of neuronal development regulating neuronal maturation and 
stimulating survival (Gao et al., 2009, Mattar et al., 2008). Bayatti et al. (2008b) have 
analyzed the expression pattern of NEUROD across a 12 PCW human neocortex, similar to 
the one used in our experiment, using ISH and showed that NEUROD expression was more 
restricted to the CP in a similar manner to TBR1 which suggests its involvement at late 
stage of corticogenesis (figure 49). Our Q-PCR results on cord blood differentiating stem 
cells indicated that NEUROD and TBR1 had similar expression patterns where their highest 
peaks recorded after neuronal maturation (day 24) which resemble their expression patterns 
observed across the neocortex. These results offer another strong indication that our in-vitro 
differentiation system properly recapitulated key corticogenesis events involved in 
regulation of fate specification and differentiation of glutamatergic cortical neurons.   
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Figure 49. Laminar localisation of NEUROD in 12 PCW human neocortex. NEUROD expression is 
concentrated in the CP. Image adapted from Bayatti et al (2008b). Scale bar: 200µm 
 
5.5.5 Advantages of using human cord blood stem cells for cortical differentiation 
Two recent independent studies showed that mouse embryonic stem cells can be induced to 
recapitulate key cortical neurogenesis events in vitro producing specific cortical neuronal 
subtypes expressing certain cortical layers markers, such as Otx1 and Tbr1, following 
defined induction protocols. Both studies showed that the neurons produced were mostly 
excitatory and glutamatergic using electrophysiology and calcium imaging (Eiraku et al., 
2008, Gaspard et al., 2008).  Although both groups obtained similar results, the culturing 
systems utilized by each group were different. Gaspard et al. (2008) used a standard 
adherent monolayer approach similar to the one we utilized in our experiment. One of the 
advantages of this approach is the simplicity of the procedure; however it doesn‟t represent 
the layered physical organization of cells observed in the cortex.  Eiraku et al. (2008) used 
embryoid body formation assay which is very complex when compared with the standard 
monolayer approach. However, the formation of three-dimensional structures in-vitro 
which highly resembled the spatial organization of cells observed in mouse cortex allowed 
a more precise analysis of stages of cortical development in a three-dimensional context. 
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This may provide insights on the effects of cellular spatial organization and interaction on 
fate specification and cortical development. 
Both groups have used mouse embryonic stem cells to establish in-vitro models of 
corticogeneis. Such models are important in studying and investigating major mechanisms 
involved in regulation of mammalian corticogenesis in general due to the high degree of 
conservation across mammalian species. However there are some disadvantages to these 
approaches when wanting to target human development and disease. Although cortical 
neurogenesis in humans and mice share a lot of similarities, there are some major 
differences in structure and function that are underpinned by differences in cortical 
development (Bystron et al., 2008, Clowry et al., 2010).  Examples in human include the 
presence of a larger and differentiated SVZ containing a larger pool of progenitors as 
compared to rodents, and differences in laminar expression patterns of genes involved in 
neurogenesis and laying down the early cortical map (Kornack, 2000, Hansen et al., 2010, 
Jones, 2009).  Therefore using human stem cells to establish such models should more 
accurately mirror the developmental mechanisms regulating cortical neurogenesis in the 
human brain. Our in vitro system has recapitulated events occurring during cortical 
development which are important in the differentiation of a type of neuron commonly 
damaged in cerebral palsy as well as by stroke in adults. Such in vitro system should allow 
us to better understand and target potential brain repair strategies and provide in vitro 
models of neural diseases for toxicology and drug testing research.   
In conclusion, umbilical cord blood non-hematopoietic multipotent stem cells undergoing 
our previously described neuronal induction protocol sequentially expressed genes crucially 
involved in human cortical neurogenesis of glutamatergic neurons, and expressed markers 
associated with glutamatergic neurotransmission. Such a stem cell-based system may aid 
the development of stem cell based therapeutic interventions for CNS injuries and 
disorders. Having an in-vitro model of human corticogenesis would also contribute towards 
a better understanding of the developmental mechanisms regulating neurogenesis in the 
cortex. In addition, they can provide cortical tissues with possible uses in toxicology and 
drugs testing research.  
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Chapter 6. Functional analysis of umbilical cord blood derived neurons 
 
6.1 Introduction 
One of the main targets of any stem cell differentiation protocol is the ability to generate 
cells with the same functional properties as the targeted cell type or tissue. This is very 
important when considering potential clinical applications where generated cells and tissues 
are used to replace diseased tissues. In the studies outlined in this chapter the neuronal 
functional properties of umbilical cord blood derived neuronal-like cells are evaluated. 
Using real time PCR arrays (refer to sections 2.11.6), we analyze the expression of ion 
channels genes involved in action potential generation and transmission (refer to section 
1.7.3.1). We also analyze the gene expression of genes involved in modulating the 
biological processes of neurotransmitter biosynthesis, uptake, transport and signaling 
through neurotransmitter receptors (refer to section 1.7.3.1). In addition, we analyze the 
calcium influx activity in cord blood derived neuronal-like cells, a feature of neurons (refer 
to section 2.12).  
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6.2 Study aims 
 To assess the functionality of cord blood derived neuron-like cells by analyzing the 
expression levels of genes coding ion channels involved in the generation and 
transmission of neuronal action potential.  
 To analyze the subtypes of neuron-like cells produced from umbilical cord blood 
non-hematopoietic multipotent stem cells by analyzing the expression of genes 
involved in the biological processes of neurotransmitter biosynthesis, uptake, 
transport and signaling through neurotransmitter receptors. 
 To evaluate the functionality of generated neuron-like cells by monitoring calcium 
influxes in cord blood derived neurons using calcium imaging system.  
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6.3 Results 
6.3.1 Q-PCR analysis of ion channels 
Q-PCR analysis of umbilical cord blood stem cells between day 0 and day 24 showed 
significant fold increase in ion channel genes expression levels (figure 50).  Cells at day 24 
also showed significant increase in expression levels of sodium channels genes including 
amiloride-sensitive channels ACCN2 and ACCN3 (p<0.005, n=3, for both genes), and 
voltage-gated channels SCN1B and SCN8A (p<0.005, n=3, for both genes).  
Q-PCR also showed significant increase in expression levels of potassium channels genes 
at day 24 compared to day 0. Genes included inward rectifier channels KCNJ1 and KCNJ5 
(p<0.005, n=3, for both genes), delayed rectifier channels KCNA5 and KCNS1 (p<0.005, 
n=3, for both genes), voltage-gated channels KCNC4, KCND1, KCNH1 and KCNQ3 
(p<0.005, n=3, for all four genes) and calcium-activated potassium channel KCNMB1 
(p<0.005, n=3).  
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Figure 50. Q-PCR analysis of ion channels expression patterns between undifferentiated cord blood 
stem cells (Day 0) and cells after neuronal maturation (Day 24). Results showed significant increase in 
genes expression levels after neuronal maturation (Day 24) compared to undifferentiated stem cells (Day 0). 
Calibrator is Day 0 for all genes. All genes expression levels have been normalized to housekeeping genes 
HPRT1, RPL13A and GAPDH. Changes in expression levels for all shown genes between day 0 and day 24 
are statistically significant, student‟s t-test (p<0.005, n=3).  
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6.3.2 Q-PCR analysis of neurotransmitter regulatory enzymes  
Q-PCR results showed significant increase in expression level of neurotransmitter 
biosynthesis enzyme GAD1 between days 0 and day24 (p<0.005, n=3) (figure 51). On the 
other hand, there were no detectable increases in expression levels of CHAT and TPH1 
between day 0 and day 24. For neurotransmitter catabolic enzymes, ABAT, ACHE and 
COMT, significant increase in expression levels were detected between undifferentiated 
stem cell stage (Day 0) and cells after neuronal maturation (Day 24) (p<0.005, n=3, for the 
three genes) (figure 51).  
 
Figure 51. Q-PCR analysis of neurotransmitters regulatory enzymes genes between day 0 and day 24.  
For neurotransmitters biosynthesis enzymes, only GAD1 showed significant increase in gene expression level 
on day 24 compared to day 0. CHAT and TPH1 showed no detectable increases in gene expression levels after 
maturation. For neurotransmitter catabolic enzymes, ABAT, ACHE and COMT, all showed significant increase 
in gene expression levels after maturation (Day 24). Calibrator is Day 0 for all genes. All genes expression 
levels were normalized to housekeeping genes HPRT1, RPL13A and GAPDH. Changes in expression levels of 
shown genes, except CHAT and TPH1, between day 0 and day 24 were statistically significant, student‟s t-test 
(p<0.005, n=3).  
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6.3.3 Q-PCR analysis of neurotransmitter transporters 
Q-PCR analysis on neurotransmitter transporters showed significant increase in expression 
levels of glutamate transporters SLC1A1 (p<0.05, n=3) and SLC1A2 (p<0.005, n=3) 
between day 0 and day 24. Similar significant increases were also found in GABA 
transporter SLC6A12 (p<0.05, n=3) and serotonin transporter SLC6A4 (p<0.005, n=3). On 
the other hand, there were no detectable increases in expression levels of dopamine 
transporter SLC6A3 and glycine transporter SLC6A (figure 52). 
 
Figure 52. Q-PCR analysis of neurotransmitters transporters genes between day 0 and day 24.  All 
transporters genes presented above showed significant increases in gene expression levels by day 24 
compared to day 0 except for dopamine transporter SLC6A3 and glycine transporter SLC6A9. Calibrator is 
Day 0 for all genes except SLC6A3 Day 24.  All genes expression levels have been normalized to 
housekeeping genes HPRT1, RPL13A and GAPDH. Changes in expression levels of shown genes, except 
SLC6A3and SLC6A9, are statistically significant, student‟s t-test SLCA1A and SLC6A12 (p<0.05, n=3) and 
rest of genes (p<0.005, n=3).  
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6.3.4 Q-PCR analysis of neurotransmitter receptors 
Q-PCR analysis showed significant increase in gene expression levels between day 0 and 
day 24 for glutamate receptors GRIA1 and GRIN1 (p<0.005, n=3, for both genes), GABA 
receptors GABRA3 and GABRR2 (p<0.005, n=3, for both genes), acetylcholine receptors 
CHRNA2, CHRNA5, CHRNB2, CHRNG (p<0.005, n=3, for the four genes), dopamine 
receptors DRD1(p<0.05, n=3) and DRD2 (p<0.005, n=3) and glycine receptors GLRA1 and 
GLAR2  (p<0.005, n=3, for both genes) (figure 53). 
 
Chapter 6 
 
 151 
 
Figure 53. Q-PCR analysis of neurotransmitters receptors genes between day 0 and day 24. All the  
neurotransmitter receptor genes investigated showed significant increase in expression level after neuronal 
maturation (Day 24) compared to undifferentiated cord blood stem cells (Day 0). Calibrator is Day 0 for all 
genes. All gene expression levels have been normalized to housekeeping genes HPRT1, RPL13A and 
GAPDH. Changes in expression levels of shown genes are statistically significant, student‟s t-test, DRD1 
(p<0.05, n=3) and rest of genes (p<0.005, n=3).  
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6.3.5 Q-PCR analysis of neuropeptides receptors 
Q-PCR analysis showed significant increase in gene expression levels of neuropeptide 
receptors MCHR1, SORCS1 and SORCS2 between day 0 and day 24 (p<0.005, n=3, for 
the three genes), neuropeptide Y receptors PPYR1 (p<0.05, n=3) and NPY1R (p<0.005, 
n=3) and galanin receptors GALR2 (p<0.05, n=3) and GALR3 (p<0.005, n=3) (figure 54).  
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Figure 54. Q-PCR analysis of neuropeptide receptors genes between day 0 and day 24. All presented 
genes showed significant increase in gene expression levels after neuronal maturation (Day 24) compared to 
day 0. Calibrator is Day 0 for all genes. All genes expression levels were normalized to housekeeping genes 
HPRT1, RPL13A and GAPDH. Changes in expression levels of shown genes are statistically significant, 
student‟s t-test, PPYR1and GALR2 (p<0.05, n=3) and rest of genes (p<0.005, n=3).  
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6.3.6 Calcium Influx imaging  
Calcium imaging of neuronal induced cord blood stem cells at (Day 24) showed positive 
readings for fast calcium influxes inside the cells. Some cells demonstrated spontaneous 
fast calcium influxes without induction (figure 55).  
Other cells generated fast calcium influxes only upon induction with glutamate. These 
influxes were recorded right after glutamate was applied to the cells via patch pipettes from 
a 10-50µm distance from the cells of interest. These influxes were not recorded when 
glutamate was not applied to these cells (figure 56, 57). In both spontaneous and glutamate-
induced calcium influxes, the duration of a single influx (represented by the sharp peaks on 
graphs) was similar (about a second).  
 
Figure 55. Spontaneous calcium influxes in cells after neuronal maturation (Day 24). Calcium influxes 
are represented by the peaks of ΔF/F florescence level graph. Top right picture represents the analyzed cell.  
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Figure 56. Glutamate-induced calcium influx in cord blood differentiated stem cells (Day 24). 1mM 
glutamate was applied twice, at frame 40 and frame 60 (black arrows). Cells responded to glutamate with 
calcium influxes represented by ΔF/F florescence level (black graph). Without glutamate, no calcium influxes 
were detected (red graph). The cell analyzed for this example shown on the top right corner.  
 
Figure 57. Three dimensional representations of the analyzed cell’s surface upon induction with 
glutamate. The fluorescence intensity (purple to red) correlates with the intensity of the calcium influx.  
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The proportion of cells showing detectable calcium influx increased from only 4.88 ± 
2.19% at day 0 to 40.42±7.92% (spontaneous) and 27.7±8.74% (induced) at day 24 
(p<0.05, n=3, for both) (figure 58). 
 
 
Figure 58.  Proportion of cells generating spontaneous and induced Calcium influxes increased 
significantly after neuronal maturation (Day 24) compared to undifferentiated cord blood stem cells 
(Day 0). Results are statistical significant  (student‟s t-test p<0.05, n=3). 
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6.4 Conclusion  
 Umbilical cord blood non-hematopoietic multipotent stem cells yielded functional 
neuron-like cells after the 24 days in-vitro neuronal induction protocol as shown by 
the calcium influx studies. 
 Expression of markers associated with the function of certain subtypes of neurons 
including glutamatergic, GABAergic and serotonergic neurons suggests neuronal 
subtype specification.  
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6.5 Discussion 
In this chapter the neuronal functional properties of the umbilical cord blood derived 
neuron-like cells are evaluated. Expression patterns of genes involved in action potential 
generation and propagation are examined by comparing gene expression levels between 
undifferentiated stem cells (Day 0) and cells after neuronal maturation (Day 24) using Q-
PCR. Similarly, the expression of genes involved in modulating the biological processes of 
neurotransmitter biosynthesis, uptake, transport and signaling through neurotransmitter 
receptors are also examined. We further evaluate the functionality of cord blood derived 
neuron-like cells using a direct approach that monitored and recorded spontaneous and 
induced calcium influxes in cells after neuronal maturation (Day 24). Gene expression 
patterns and calcium imaging suggest that the generated neuron-like cells have proper 
neuronal functional properties which further confirm their neuronal-like identity.  
6.5.1 Generated neuron-like cells expressed genes involved in action potential generation 
and propagation 
Ion channels are involved in a wide range of central nervous system functions including the 
generation and propagation of action potential in neurons. We compared the expression 
levels of gene transcripts using Q-PCR between cells after neuronal maturation (Day 24) 
and undifferentiated cells (Day 0) and found significant up-regulation in many genes 
coding ion channels after the neuronal induction protocol (figure 50). Up-regulated genes 
included Amiloride-sensitive cation channel 2 and 3 (ACCN2 and ACCN3). These two 
channels are members of an H
+
-gated subgroup of the degenerin/epithelial Na
+
 channel 
(DEG/ENaC) family of cation channels highly expressed in neurons. ACCN2 is expressed 
dominantly in brain neurons where it regulates and mediates glutamate-independent Ca
2+ 
entry into neurons upon acidosis (Askwith et al., 2004, Zha et al., 2009). ACCN3 is more 
associated with PNS neurons where it is involved in initiating responses to mechanical and 
painful stimuli (Wemmie et al., 2006, Hruska-Hageman et al., 2004). ACCNs are an 
important component of neuronal physiological regulatory system where their “functional 
sensitivity” to pH changes is thought to be involved in regulation of many neuronal 
functions.  
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Action potential is generated and propagated across neurons by rapid opening and closing 
of specialized sodium and potassium ion channels (refer to section 1.7.3.1). Q-PCR results 
showed significant up-regulation in gene transcripts coding various ion channels crucially 
involved in the generation and propagation of action potential. Among the up-regulated 
channels were sodium voltage-gated ion channels SCNB1 and SCN8A which are subunits of 
trans-membrane channels specific for sodium and sensitive to voltage changes across the 
membrane. These channels are crucially involved in the depolarization phase of action 
potential where they open in response to increases in the membrane potential which allow 
Na
+
 to enter the cell resulting in further increase in the membrane potential (Barnett and 
Larkman, 2007). Up-regulated genes also included potassium voltage-gated channels 
represented by KCNC4, KCND1, KCNH1 and KCNQ3 which are involved in the 
repolarization phase of the action potential where the increased membrane potential triggers 
their opening resulting in rapid movement of K
+
 outside the neuron resulting in 
repolarization phase which would bring the membrane potential back to negative value 
(Yellen, 2002, Barnett and Larkman, 2007). Other more specialized potassium channels 
have also been significantly up-regulated after neuronal maturation (Day 24). These 
channels included inward rectifier channels represented by KCNJ1 and KCNJ5.   These 
channels differ from typical potassium channels in that they allow K
+
 positive current to 
move inside the cells rather than outside the cell and play a key role in establishing the 
resting potential in neurons (Tao et al., 2009). Also significant up-regulation was recorded 
for potassium large conductance calcium-activated channel (KCNMB1). This channel can 
be activated by voltage changes as well as increases in concentration of intracellular 
calcium ion (Ca
2+
) and plays a major role in regulation of neuronal excitability by 
modifying action potential duration, frequency and synaptic efficacy (Miller, 2000, Yuan et 
al., 2010, MacDonald et al., 2006). 
The expression of ion channels involved in regulation of neuronal functions including the 
generation and propagation of action potential suggests that the cord blood derived neuron-
like cells have reached a maturing neuronal-like functional status after neuronal maturation 
(Day 24). These results can be further analyzed and confirmed using patch clamping. This 
laboratory technique allows direct selective recording of currents that flow through ion 
channels during action potential transmission (Purves, 2004, Sun et al., 2005). Such 
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analysis offers a more direct approach to confirm the neuronal functional properties of the 
generated cells.  
6.5.2 Generated neuron-like cells expressed genes involved in neurotransmitter 
biosynthesis and regulation 
Neurotransmitters are chemicals released by neurons at the synapses to allow the 
transmission of action potential signal from one neuron to the other. Neurotransmitters are 
synthesized in neurons through chemical reactions which are catalyzed by certain enzymes. 
The expression of a particular enzyme by certain neuron can be used as marker to classify 
neurons based on the neurotransmitter they manufacture. The production of 
neurotransmitters is a fundamental component of the neuronal functional properties, hence 
we investigated the expression of certain genes coding enzymes involved in biosynthesis 
and regulation of neurotransmitters in our cord blood derived neuron-like cells (Day 24) 
(figure 51). We have selected the enzymes involved in biosynthesis of most common 
neurotransmitters in the central nervous system (refer to section 1.7.3.1) and found that 
GAD1, unlike CHAT and TPH1, was significantly up-regulated in cells after neuronal 
maturation (Day 24) compared with undifferentiated cells (Day 0). GAD1 is the gene 
encoding glutamic acid decarboxylase which catalyzes the production of gamma-
aminobutyric acid (GABA) from L-glutamic acid in GABAergic neurons (Dirkx et al., 
1995). On the other hand, results did not show any significant up-regulation in levels of 
CHAT, which encodes choline acetyltransferase that catalyzes the production of 
acetylcholine from Acetyl-CoA and choline in cholinergic neurons (Blusztajn et al., 1987) 
and TPH1, which encodes tryptophan hydroxylase 1 which is the rate-limiting enzyme in 
the biosynthesis of serotonin from tryptophan in serotonergic neurons (Andreou et al., 
2010). However, expression of TPH1 is not restricted to neurons; it is also expressed by 
mononuclear leukocytes of peripheral and umbilical cord blood (Rahman, 1988). Our Q-
PCR analysis compares the expression levels between undifferentiated purified stem cells 
(Day 0) and cells after neuronal maturation (Day 24). Any up-regulation at day 24 is 
measured relatively to the initial expression level of the gene at day 0. The negative 
depletion step does not eliminate all the leukocytes, suggested by the FACS analysis of 
CD45 expression after purification (figure 20), and it is possible that the purified fraction 
contained a portion of hematopoietic cells expressing TPH1. Such cells might have 
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interfered with the Q-PCR analysis of the neuronal induction between day 0 and day 24. In 
order to further investigate whether TPH1 is expressed by cord blood derived neuron-like 
cells or not, immunocytochemistry analysis of the enzyme and another neuronal general 
marker such NF200 or β-TUBULIN III would offer a very good opportunity to examine 
neuronal specific expression of TPH1. Such results suggest that our derived neuron-like 
cells contained a possible subgroup of GABAergic neuron-like cells but not cholinergic 
neurons. Whether or not cord blood derived neuron-like cells contained a subgroup of 
serotonergic neurons need to be further analyzed.  
Up-regulated genes also included genes coding neurotransmitter catabolic enzymes 
including ABAT, ACHE and COMT. ABAT encode 4-aminobutyrate aminotransferase 
which is the enzyme responsible for catabolism of GABA, the most abundant inhibitory 
neurotransmitter in the CNS, into succinic semialdehyde at the synapses and therefore 
terminating the synaptic transmission of GABA (Larsson and Schousboe, 1990).  ACHE 
encodes acetylcholinesterase which is the enzyme that degrades acetylcholine into choline 
and acetate group and thereby terminates its synaptic transmission (Descarries et al., 2004, 
Anglister et al., 2008).  COMT is the gene that encodes Catechol-O-methyltransferase, the 
enzyme that degrades catecholamines including dopamine (Mannisto and Kaakkola, 1999). 
These catabolic enzymes perform a very important regulatory role in CNS by regulating 
synaptic transmission mediated by neurotransmitters.  
The expression of genes involved in neurotransmitter biosynthesis and regulation not only 
reflects on the maturing neuronal-like status of our cells but also suggests proper neuronal-
like functional regulatory properties acquired by the cells after neuronal maturation (Day 
24).  
6.5.3 Generated neuron-like cells expressed various neurotransmitter transporters 
Another important component of the neuronal functional system is neurotransmitter 
transporters that are specialized proteins located on cellular membranes of the neurons and 
primarily involved in transporting neurotransmitters across membranes intra-cellularly. 
They carry out a crucial regulatory role that precisely controls the intensity and duration of 
synaptic transmission. When neurotransmitters are released at the synapses, they activate 
their receptors on the post-synaptic neurons and initiate synaptic transmission response. 
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This process is terminated when neurotransmitters are eliminated from the synaptic cleft by 
active transport of neurotransmitters by the neurotransmitter transporters (Masson et al., 
1999). After neuronal maturation (Day 24), multiple genes encoding neurotransmitter 
transporters were significantly up-regulated (figure 52). These genes included neuron-
specific glutamate transporter SLC1A1 which encodes excitatory amino acid transporter 3 
(EAAT3), the major neuronal glutamate transporter in the CNS (Foster and Kemp, 2006), 
and SLC1A2 which encodes excitatory amino acid transporter 2 (EAAT2) that is expressed 
mostly by CNS glia cells (Chen and Swanson, 2003, Schmitt et al., 2002). Both transporters 
are Na
+
 dependent, where the driving force of transport is provided by the trans-membrane 
gradient of Na
+
 and also K
+
 (Meldrum, 2000). Those high affinity glutamate transporters 
clear the excitatory neurotransmitter from the synaptic cleft in CNS. This process is very 
crucial to regulate glutamate-mediated synaptic transmission and to prevent neuronal 
damage and death as a result of excessive activation of glutamate receptors (Meldrum, 
2000, Mattson, 2008).  
Up-regulated genes also included multiple genes that encode transporters which belong to 
solute carrier family 6 (SLC6). These transporters function through a Na
+
 and Cl
-
 
dependent manner. Up-regulated genes included SLC6A12 which encodes a high affinity 
GABA transporter. This transporter protein is located in the membrane of the pre-synaptic 
terminals and is involved in the regulation of GABA synaptic transmission through 
mediating fast GABA removal from synaptic cleft into the cell to avoid excessive 
activation of GABA receptors (Borden et al., 1995). Up-regulated genes also included 
SLC6A4, which encodes a serotonin transporter that regulates serotonin-mediated synaptic 
transmission and function in a similar manner to SLC6A12 where it reuptakes serotonin 
from the synaptic cleft and transports it into pre-synaptic terminals to be recycled and 
reutilized (Masson et al., 1999). It is logical that this transporter is expressed by neurons 
capable of producing serotonin (expressing TPH1). Based on such results, it is possible that 
our cord blood derived neuron-like cells contained a subgroup of serotonergic neurons. 
Nevertheless, the previously suggested immunocytochemistry analysis of TPH1 and 
another neuronal marker such as β-TUBULIN III or NF200 would provide a better way to 
confirm the identity of the such cells.  
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6.5.4 Generated neuron-like cells expressed various neurotransmitter receptors 
Neurotransmitter receptors are an important component of the neuronal functional system. 
These membrane receptor proteins are involved in neuron-neuron chemical communication 
through synapses that facilitate neuronal signal transmission. They are expressed at the 
synapse of post- and pre-synaptic neurons.  When neurotransmitters are released in the 
synaptic cleft from specialized vesicles on pre-synaptic neuron in response to appropriate 
stimuli, they interact and bind to their specific receptors initiating proper response in the 
post-synaptic neurons. After neuronal maturation (Day 24), cord blood derived neuron-like 
cells showed significant up-regulation in genes encoding different neurotransmitter 
receptors (figure 53). The up-regulated genes included GRIA1 and GRIN1 which encode 
glutamate receptors AMDAR1 and NMDAR1 respectively in addition to genes encoding 
GABA, acetylcholine, dopamine, galanin and glycine receptors. In CNS a single neuron 
can receive inputs from multiple sources utilizing different types of neurotransmitters and 
therefore it can express different neurotransmitter receptors (Clendening and Hume, 1990) 
which explains the diverse types of receptors expressed by our cells. In the same context, 
one neuron can express receptors for a particular neurotransmitter, which it does not 
produce; this explains the expression of the acetylcholine receptors by our cells while no 
significant CHAT expression was detected.   
In addition to neurotransmitters, neurons also utilize small peptides for communication 
called “neuropeptides”. Similarly to neurotransmitters, neuropeptides are expressed and 
released by neurons mediating synaptic transmission either in a direct or indirect manner 
(Li and Kim, 2008). In addition, neuropepetide plays a key role in the regulation of certain 
physiological functions including food intake, memory and learning (Wilding, 2002, Feany, 
1996). Among the receptors expressed by cells at Day 24, Neuropeptide Y (NPY) receptors 
PPYR1, which is expressed predominantly in peripheral organs, and NPY1R which is 
expressed predominantly in CNS (Naveilhan et al., 1998). NPY is a peptide composed of 
36 amino acids express widely in the brain. Beside its role in regulating food intake and 
energy balance (Gerald et al., 1996), NYP has also demonstrated neuroproliferative and 
neuroprotective properties (Xapelli et al., 2006, Thiriet et al., 2011). Neuroproliferative 
properties were demonstrated when genetic knockout of NYP receptors in mice decreased 
the number of proliferative neuroblasts in the SVZ (Stanic et al., 2008) while 
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intracerebroventricular injection of NPY enhanced the proliferation of neuroblasts in mice 
SVZ (Decressac et al., 2009). The neuroprotective properties were demonstrated in studies 
performed on organotypic slice cultures of rat hippocampus (Silva et al., 2003). In this 
study, selective activation of NYP receptors using agonists protected the neural cells from 
neuronal degeneration as a result of AMPA mediated excitotoxicity (Silva et al., 2003).  
Our results showed significant up-regulation in transcripts of genes encoding neuropeptide 
receptors in cord blood derived neuron-like cells (Day 24) compared with undifferentiated 
cells (Day 0) (figure 54). The expression of neurotransmitter and neuropepetide receptors 
highlights the neuronal functional potential of generated neuron-like cells.  
 
6.5.5 Functional properties of generated neuron-like cells confirmed by spontaneous and 
induced calcium influxes    
In addition to the indirect approaches in analyzing neuronal functional properties of our 
cord blood derived neuron-like cells through mRNA expression and protein localization 
assays, we utilized a direct method to evaluate the functionality of generated neuron-like 
cells by monitoring the calcium ions (Ca
2+
) influxes in the cells. Calcium ions play a major 
role in neuronal development and functionality. Neuronal calcium influx triggered by either 
neurotransmitters or electric signals is involved in regulation of many biological and 
functional processes in neurons including neuronal differentiation, neurites outgrowth, 
synaptic plasticity, action potential and neuronal survival (Elmslie, 2003, Mattson, 2008, 
Ryglewski et al., 2007).  
We investigated the calcium activity in generated neuron-like cells after neuronal 
maturation (day 24) by bulk loading the cells with a dye that is sensitive to Ca
2+
 which 
allowed monitoring spontaneous and induced influxes of Ca
2+
, a characteristic of functional 
neurons (refer to section 2.12). The calcium imaging procedure have been used previously 
to evaluate the functional properties of endogenous CNS neurons (Murayama et al., 2005, 
Johannssen and Helmchen, 2010) and neurons derived from stem cells (Zangiacomi et al., 
2008, Eiraku et al., 2008). 
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We used glutamate ,the most abundance neurotransmitter in mammalian brain (Erecinska 
and Silver, 1990), to induce Ca
2+
  influxes and we recorded precise waves of Ca
2+
 influxes 
in response to glutamate. When glutamate was withdrawn, no Ca
2+
 influxes were recorded 
from the same cells which suggest that the recorded influxes were induced by glutamate 
(figure 56). Such process is thought to be involved in the stimulation of the neuronal 
depolarization phase of action potential. Our cells expressed two glutamate receptors 
AMPAR and NMDAR which are ligand-gated ion channels. When the receptors are 
activated by glutamate, the ion channels open and allow various ions into the cell such as 
Ca
2+
. These receptors play a key role in mediating excitatory responses and controlling 
synaptic plasticity at the majority of CNS synapses (Mayer, 2005, Li and Tsien, 2009). Our 
results suggest that our derived neuron-like cells, which express glutamate receptors 
AMPAR and NMDAR, acquired an active functional status demonstrated by their precise 
responses to glutamate with Ca
2+
 influxes.  
Calcium influxes can also be stimulated in neurons using KCI which activates calcium 
influxes through calcium voltage dependent channels (Zangiacomi et al., 2008). 
Additionally AMPA has also been used to stimulate calcium influxes in neurons (De Melo 
Reis et al., 2011). Using channel blockers such as tetrodotoxin (TTX), AMPA and NMDA 
antagonists would provide stronger evidence and indication of the channels mediating the 
observed Calcium influxes. In this study, we have not used such blockers due to insufficient 
time available on the equipment. 
In addition to glutamate-induced Ca
2+
 influxes, we also recorded spontaneous influxes 
without using glutamate (figure 55). Such glutamate-independent influxes can occur 
through different channels, other than AMPAR and NMDAR, including the neuronal 
specific amiloride-sensitive cation channel 2 (ACCN2) which regulates and mediates 
glutamate-independent Ca
2+ 
entry into neurons upon acidosis (Askwith et al., 2004, Zha et 
al., 2009). It is also possible that these influxes are mediated by calcium voltage-dependent 
ion channels (Jarvis and Zamponi, 2007).  
Collectively, the proportion of cells showing detectable calcium influxes showed 
significant increase after neuronal maturation (Day 24) compared with undifferentiated 
purified stem cells (Day 0) (figure 58). This result suggests that the calcium-influx 
Chapter 6 
 
 166 
characteristic was acquired in response to the neuronal induction protocol that stimulated 
neuronal-like molecular and morphological transformation, highlighting active neuronal-
like functional status of the generated neuron-like cells.  
 
6.5.6 Putting the pieces together: the neuronal functional system 
The transmission of neuronal action potential in the human body is a very dynamic process 
that involves different components that contribute either directly to the process of signal 
transmission or by performing regulatory roles that regulate the over all process. These 
components collectively form the neuronal functional system which labels and defines the 
neuronal identity. Any therapeutic potential for stem cell-based therapies to treat 
neurological disorders relies on the ability of such cells to produce neurons capable of 
performing and carrying on neuronal functional duties similar to those of nervous system 
endogenous neurons.  
Signal transmission in neurons occurs through two different mechanisms; chemically from 
one neuron to the other across synapses, and electrically along axons of neurons (figure 14). 
For chemical signaling, neurons produce and utilize neurotransmitters to transmit signals 
across synapses. In studies outlined in this chapter, it is shown that cord blood derived 
neuron-like cells expressed transcripts encoding enzymes involved in neurotransmitter 
production. When neurotransmitters are released across synapses, they bind to special 
neurotransmitter receptors which get activated and initiate proper response.   This chemical 
signaling is regulated through catabolic enzymes which degrade the excess 
neurotransmitters and terminate the signaling and also by neurotransmitter transporters 
which reuptake neurotransmitters from the synaptic cleft and transport it into the neurons 
for recycling and reutilization. Depending on the neurotransmitter type 
(excitatory/inhibitory), activated receptors initiate proper response. In the case of excitatory 
effect, the activated receptor will stimulate an electric signal of action potential across the 
neuron as a result of rapid movement of ions across the neuron membrane through 
specialized ion channels. This entire process of chemical/electric signal transmission 
defines the functional identity of neurons. Cord blood derived neuron-like cells expressed 
genes encoding element involved in each stage of the signal transmission process. They 
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also directly demonstrated proper functionality by generating spontaneous and glutamate-
induced calcium influxes, similar to nervous system endogenous neurons.  
The concept of stem cell based therapies for CNS injuries and disorders is base on the 
ability to compensate and replace the dead or diseased neural tissues with new ones 
generated from stem cells. It is crucial that the stem cells used can produce functional 
neurons that are able of compensating for the dead/diseased tissues physically and 
functionally. Our results indicate that umbilical cord blood non-hematopoietic multipotent 
stem cells are capable of producing neuron-like cells with neuronal-like functional 
properties. Such results further highlight the potential of umbilical cord blood stem cells as 
a therapeutic tool for CNS injuries and disorders which current mode of therapy is 
inadequate. 
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Chapter 7. Concluding discussion 
 
The work in this thesis has shown that the sequential neuronal induction protocol used here 
induces umbilical cord blood non-hematopoietic multipotent stem cells to adopt a neuronal-
like fate. At the end of the differentiation protocol (Day 24), the cells adopted a neuronal-
like morphology and expressed neuronal specific markers. We further showed that the 
process of neuronal differentiation of purified cells highly resembled the development of 
glutamatergic neurons in human neocortex. Indirect and direct functional analysis 
suggested that the generated cells have proper neuronal-like functional status. Such results 
highlight the potential of umbilical cord blood stem cells as a therapeutic tool for CNS 
injuries and disorders and also as a research tool for toxicology and drugs testing studies.  
 
7.1 In-vitro model of cortical neurogenesis: GABAergic neurogenesis would complete 
the model  
We have shown that the sequential induction of umbilical cord blood purified stem cells 
recapitulated key events taking place in human neocortex regulating cortical neurogenesis 
of glutamatergic neurons. We further showed that generated neurons expressed components 
involved in glutamatergic neurotransmission including glutamate receptor subunits and 
neuronal specific glutamate transporters (refer to chapter 5). In addition, the generated cells 
responded to glutamate induction with influxes of calcium demonstrating proper functional 
status (figure 56). As mentioned earlier the human cortex mainly hosts two kinds of 
neurons: glutamatergic neurons which accounting for 80% of the cortex neuronal content 
and GABAergic neurons which account for the remaining 20% (Letinic et al., 2002, Meyer 
et al., 2000, Guillemot et al., 2006, Jones, 2009). The excitatory and inhibitory systems, 
represented by both types of cortical neurons, function in a collaborative and coordinated 
manner regulating neuronal firing patterns, network activity and synaptic plasticity which 
contribute to the diverse and complex  CNS functions (Foster and Kemp, 2006). We 
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showed that sequential induction of cord blood purified stem cells provided a good in-vitro 
model for the cortical excitatory system (chapter 5). However, including the GABAergic 
cortical neurogenesis as well would provide a more accurate and complete model of human 
cortical neurogenesis. Q-PCR results after neuronal maturation (Day 24) indicated that the 
cells expressed markers involved in GABA-mediated transmission and are routinely used to 
characterize GABAergic neurons. These markers included GAD1 and high affinity GABA 
transporter (figure 51 and figure 52). These results suggest a possible existence of 
GABAergic neuron-like cells in cultures after neuronal maturation (Day 24). The 
possibility of studying and analyzing the commitment and differentiation processes of these 
cells in-vitro and comparing them with their differentiation pathways in human cortex 
would provide a more complete in-vitro representation of human corticogenesis. Such a 
stem cell-based system could lead to a better understanding of the developmental 
mechanisms regulating human corticogenesis. Such improved understanding may aid the 
development of therapeutic interventions for injuries and disorders affecting the human 
cortex in particular and CNS in general. 
7.2 Umbilical cord blood non-hematopoietic stem cells: potential therapeutic tool for 
CNS injuries and disorders 
As mentioned earlier, cell therapy has been proposed as a potential therapeutic tool for 
many CNS injuries and disorders (refer to section 1.9). The principle of the approach is 
based on the idea of restoring the function of the brain, lost and impaired due damage or 
disease, by replacing the diseased or dead neurons with new healthy generated neurons 
thorough transplantation. The effectiveness of this approach relies on several important 
factors (figure 60):  
 The ability of stem cell used to generated functional neurons with similar 
characteristics and properties to the one targeted for replacement. 
 The ability of the transplanted cells to survive and functionally integrate into the 
brain neuronal network. 
 The development of efficient and safe transplantation procedures to deliver the cells 
to the targeted regions.  
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Figure 59. Umbilical cord blood and the pathway for CNS clinical applications. Effective clinical 
applications require an abundant and ethical supply of stem cells that are genetically stable (do not form 
teratoma). These stem cells must be accompanied with effective and safe in-vitro neuronal differentiation 
protocols (dotted red box highlights our protocol and results). Such protocols require efficient transplantation 
procedures to deliver the cells to the targeted regions. Extensive research must be conducted on animal 
models of CNS injuries and disorders to assess and evaluate the therapeutic impacts of such potential 
therapies before moving to clinical applications.   
 
The studies outlined in this PhD thesis demonstrate that umbilical cord blood non-
hematopoietic stem cells can produce neuron-like cells similar to CNS endogenous cortical 
neurons using a defined, short and safe differentiation in-vitro protocol (chapter 4, 5 and 6). 
Such results highlight the potential use of such cells as a therapeutic tool for many CNS 
injuries and disorders. Studies on rat‟s model of traumatic brain injury (TBI) have shown 
that intravenously transplanted cord blood stem cells were able to migrate to the brain and 
differentiated into neurons inducing motor and neurological improvements (Lu et al., 
2002). Such results demonstrate that umbilical cord blood stem cells have both migratory 
and neuronal capacities which are important factors for any potential therapeutic 
application. Nevertheless, more extensive efforts should be aimed toward analyzing and 
Concluding discussion 
 
 171 
studying the cellular and functional integration of the transplanted cells into the brain 
networks which is crucial for long-term recovery and functional restoration.  The 
possibility of producing functional glutamatergic neuron-like cells with similar 
characteristic to human endogenous cortical glutamatergic neurons, and possibly 
GABAergic neuron-like cells as well, from umbilical cord blood non-hematopoietic stem 
cells highlights it potential use for cell replacement therapies aimed to treat CNS injuries 
including stroke and TBI where the affected regions are likely to host glutamatergic and 
GABAergic neurons, the primary neurotransmission systems in the brain (Foster and 
Kemp, 2006).  
One of the important issues that need to be taken into consideration when considering cell 
replacement therapies for CNS injuries and disorders is the cell dosage needed to replace 
the dead/diseased cells. We found that the umbilical cord blood non-hematopoietic stem 
cells make an average of 1.29±0.46% of total nucleated cells in umbilical cord blood 
sample. The average total nucleated cells per cord blood unit was estimated as 890x10
6
 
cells (Reed et al., 2003). This means an average of 11.6 million non hematopoietic stem 
cells per cord blood unit.   This low number of stem cells per cord blood unit represents a 
limitation when considering cell replacement therapies for neurodegenerative diseases such 
as AZ and PD which affect large portions of the brain. However this obstacle can be 
tackled with the possibility of combining multiple cord blood units in order to increase the 
final transplanted cell dose resulting in improved engraftment and survival of the 
transplanted cells (Brunstein and Wagner, 2006, Stanevsky et al., 2009, Ringden et al., 
2008, Slatter et al., 2006).  In addition, the development of safe and effective in-vitro 
strategies to expand umbilical cord blood non-hematopoietic stem cells before 
differentiation and transplantation may also contribute to the development of efficient 
therapies.  
Another element that is crucial for any potential involvement in clinical applications is the 
safety of the proposed cell therapies. It is very important to ensure that the cells which will 
be used for transplantations are safe and do not pose any cancerous risk after 
transplantations into patients. Umbilical cord blood stem cells do not pose any risk of 
cancerous transformation unlike other types of stem cells such as fetal stem cells.  In a 
recent clinical trial, a boy with ataxia telangiectasia (AT), a rare inherited 
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neurodegenerative disease, developed multifocal brain tumor after 4 years of treatment by 
human fetal neural stem cells injections. Cells from the tumor were non-host stem cells 
suggesting they were derived from the transplanted cells which was confirmed by 
microsatellite and HLA analysis (Amariglio et al., 2009).  To date, there has not been a 
single reported case where cord blood stem cells formed teratoma when transplanted into 
SCID mice or humans.  Many recent studies showed that human umbilical cord blood stem 
cells have positive impact on animal models of various neural injuries and diseases. In 
addition, umbilical cord blood stem cells have already reached the clinics in number of 
clinical trials aimed to treat neurological disorders including hypoxic-ischemic 
encephalopathy and cerebral palsy and showed promising results (refer to section 1.9.5). 
Such results further highlight the potential role of umbilical cord blood stem cells as a 
therapeutic tool aimed towards the development of safe treatments for CNS injuries and 
disorders for which current modes of therapy are ineffective.  
7.3 Umbilical cord blood derived neuron-like cells: potential role in drug testing and 
toxicology studies 
We have shown that umbilical cord blood non-hematopoietic multipotent stem cells can 
produce neuron-like cells similar to the CNS endogenous glutamatergic cortical neurons. 
Such in-vitro model offers a potential tool that can be used to test drugs and compounds 
targeting neural diseases and disorders, it can also be used for toxicology studies. Many 
drugs have been designed to target components of glutamate and GABA systems (such as 
neurotransmitter receptors and transporters) in attempts to develop treatments for a wide 
range of CNS disorders (Foster and Kemp, 2006). A number of drugs have already reached 
the markets including Namenda™ which is a drug that functions as NMDA antagonist 
helping in treating symptoms of Alzheimer‟s disease (AD) (Ferris, 2003). Others are still in 
clinical trials including SGS742, which is a drug that antagonizes GABA receptors as a 
potential treatment for AD symptoms (Froestl et al., 2004). More drugs are still in research 
and pre-clinical phases. The neuron-like cells we generated from umbilical cord blood 
purified cells expressed many molecular components targeted by potential drugs for a 
number of CNS diseases and disorders, such feature suggests possible involvement of such 
cells in studies aimed toward the development of drugs for various CNS disorders. 
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Our in-vitro model of cortical neurogenesis using umbilical cord blood non-hematopoietic 
multipotent stem cells would offer an additional tool allowing more extensive drug testing 
leading to a better understanding of the drug‟s molecular effects on the neurons before 
moving into clinical trials. This in-vitro model should not be regarded as a replacement for 
animal models in pre-clinical phases of drug development and testing, but it should be 
viewed as an extra tool which would allow more extensive molecular analysis and testing 
on human nervous tissues and cells resulting in more reliable information ahead of clinical 
trials.  
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7.4 Conclusion 
Umbilical cord blood can be viewed as a promising source of stem cells for research and 
clinical applications. It is ethically sound, abundant supply, immunological immaturity and 
high plasticity made it superior to other sources of stem cells. Umbilical cord blood non-
hematopoietic stem cells showed high potential for neuronal differentiation. We showed 
that these cells can produce neuron-like cells in-vitro with similar developmental and 
functional properties to endogenous cortical neurons. Pre-clinical trials using umbilical 
cord blood on animal models of neural injuries and disorders showed promising results. 
Clinical trials are still at its early stages but results obtained so far demonstrated high 
potential and hope toward developing effective therapies for various CNS injuries and 
disorders. 
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8. Future work 
Investigating the molecular determinants of neuronal fate: glutamatergic versus 
GABAergic 
Our Q-PCR results indicated significant up regulations in genes encoding markers normally 
associated with GABAergic neurotransmission. These genes included GAD1 and GABA 
high affinity transporter (SLC6A12) (figure 51 and figure 52). These results suggest a 
possible existence of GABAergic neuron-like cells in addition to the glutamatergic neuron-
like cells in cultures after neuronal maturation (Day 24). The co-existence of both types of 
neurons in the same culture which was exposed to the same culturing conditions over the 
24 days duration suggests that the neuronal fate specification (glutamatergic versus 
GABAergic) was determined by molecular mechanisms independent from culturing 
conditions.  
Previous studies have shown that the cortical fate specification (glutamatergic versus 
GABAergic) in the developing cortex is determined by certain molecules which decide the 
neuronal fate specification in the cortical progenitor‟s cells. Key molecules in this process 
are bHLH transcription factors neurogenin2 (NGN2) and MASH1 (Guillemot, 1999, 
Guillemot et al., 2006). According to the model of genetic programs controlling neuronal 
specification, NGN2 is thought to be involved in specifying the neuronal glutamatergic fate 
and MASH1 is involved in specifying the neuronal GABAergic fate (refer to section 5.5.4). 
These two transcription factors are involved in two cortical-specific differentiation 
programs involving a set of other specific factors that regulate the neuronal specification 
process (Schuurmans et al., 2004).  We analyzed the glutamatergic fate commitment of our 
cells and showed that the in-vitro differentiation system offered a model for human 
glutamatergic neurogenesis. Similarly, GABAergic fate commitment can also be analyzed 
in cord blood cultures undergoing the same differentiation protocol. First, GABAergic 
neurons need to be further characterized using immunocytochemistry to localize 
GABAergic specific proteins (such as GAD1 and GABA transporters) to confirm their 
identity. Then we will analyze the expression patterns of markers including MASH1, DLX1 
and DLX2 which define the GABAergic commitment process in the human cortex 
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(Guillemot et al., 2006, Cobos et al., 2007). It is also important to investigate the expression 
patterns of NGN2 and MASH1 using immunocytochemical co-staining in order to define 
the different progenitor populations and decide at which stage those mechanisms are 
involved. 
Deeper analysis of those mechanisms and other molecular systems regulating 
developmental and functional processes in the cortex using neocortical tissues can be 
difficult due to the histological and cellular complexity of the neocortex (Gaspard et al., 
2009). In vitro modeling of human corticogenesis would allow deeper analysis of molecular 
mechanisms regulating the specifications of neuronal subtypes in the cortex. Understanding 
these mechanisms will also aid the establishment of in-vitro culturing conditions specifying 
a certain neuronal fate which can be useful in the development of potential cell therapies 
targeting neural diseases or conditions that affect certain neuronal subtype.  
Neuronal functional testing: patch clamping 
We aim to confirm our Q-PCR results of ion channels involved in the generation and 
propagation of neuronal action potential using patch clamping, a laboratory technique that 
allows the direct selective recording of currents that flow through ion channels during 
action potential transmission (Purves, 2004, Sun et al., 2005). Such analysis offers a more 
direct approach to confirm the neuronal functional properties of the generated cells.  
Investigating and characterizing the glial cellular content in cultures after neuronal 
maturation (Day 24)  
Glial cells are an important component of the nervous system (refer to table 1 in 
appendix.I). These non-neuronal cells provide support for the neurons physically and 
functionally. For example, astrocytes are critically involved in formation of neuronal 
synapses and signal modulating in the nervous system. Our Q-PCR results indicated 
significant up-regulation in SLC1A2 transcript which encodes which encodes excitatory 
amino acid transporter 2 (EAAT2) that is expressed mainly by CNS astrocytes (figure 52) 
(Chen and Swanson, 2003, Schmitt et al., 2002). This indicates possible existence of 
astocytic-like cells in the cultures. However, this result need to be further analyzed using 
immunocytochemistry using astrocytic specific markers such as S100β and EAAT2. 
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Additionally, we can also check for the existence of oligodendrocytes using specific 
markers such as myelin-oligodendrocyte glycoprotein (MOG) and Myelin Basic Protein 
(MBP). The ability of umbilical cord blood non-hematopoietic stem cells to generate glial 
cells in addition to neurons is important to insure proper neuronal functionality. Such 
feature can be very important when considering cell replacement therapies of CNS injuries 
and disorders such as stroke and TBI, where damaged cells include glial cells in addition to 
neurons.    
Transplantation of neural tissues derived from umbilical cord blood non-
hematopoietic cells into animal models of CNS injuries and disorders  
Umbilical cord blood has already been utilized in a number of clinical applications aimed to 
treat hypoxic-ischemic encephalopathy and spastic cerebral palsy. In both trials, pediatric 
patients were transplanted with umbilical cord blood intravenously (refer to section 1.9.5). 
For other CNS injuries and disorders which affect certain regions of the brain, it might be 
more useful to transplant in-vitro pre-differentiated neural tissue directory into the lesion in 
order to stimulate faster recovery. It is really important to investigate the cellular physical 
and functional integration of the transplanted cells into the pre-existing brain networks. 
Successful integration and survival of the transplanted cells is necessary to stimulate 
functional recovery. As we showed, umbilical cord blood non-hematopoietic stem cells can 
be differentiated into neurons within scaffolds. Such differentiation system offers a useful 
and efficient way to transplant the differentiated neurons into the lesion sites with precision.  
Using animal models of CNS diseases and injuries for such studies is really important to 
evaluate the effectiveness of such procedures before moving into clinical trials.  
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9. Appendices 
9.1 Appendix. I  
Additional information  
Table 18. cellular components of the nervous system 
Cell type Description 
Astrocytes 
Astrocytes are star-shaped glial cells residing in the brain and spinal cord. It has long 
been thought that glial cells including astrocytes have only a passive supporting role 
for neurons in the nervous system. However, following studies have shown that 
astrocytes are critically involved in the formation of synapses and neuronal signal 
modulation  in the nervous system in addition to their physical and nutritive 
supportive role for neurons (Allen and Barres, 2009, Temburni and Jacob, 2001, 
Gross, 2006).  Astrocyte processes form close associations with neurons at synaptic 
junctions. Like neurons, they express several neurotransmitter receptors including 
glutamate receptors. When neurons release glutamate at the synaptic junction in 
response to stimuli such as the action potential, astrocytic glutamate receptors get 
activated and Ca
2+
 influx triggers the release of glutamate from these astrocytes 
enhancing the synaptic transmission (Temburni and Jacob, 2001, Parpura and 
Haydon, 2000). In addition, astrocytes also remove and degrade excess 
neurotransmitters from the extracellular space which ensures precise and discrete 
synaptic transmission between neurons (Rothstein et al., 1996, Maciejewski and 
Rothman, 2008, Gross, 2006).  
Oligodendrocytes 
and Schwann cells 
These cells are mainly involved in insulation of neurons axons with a lipid-rich 
membrane called “myelin”. This sheathing is crucial for rapid action potential 
conduction and propagation along neuron axons (Barkovich, 2000, Barnett and 
Larkman, 2007). In addition, the myelin sheath is important for proper formation of 
the axonal cytoskeleton (Brady et al., 1999) and it also provides the axons with a 
physical protective layer against potential injuries (Rodriguez, 2003). Myelination of 
neuron axons in the CNS is associated with oligodendrocytes whereas in the PNS it is 
associated with Schwann cells (Allen and Barres, 2009). The loss or damage of the 
myelin sheath around the neuron axons results in “demyelination” and this is 
associated with a number of neurological diseases such as multiple sclerosis, which 
emphasizes the essential role oligodendrocytes and Schwann cells have in nervous 
system (Mowry et al., 2009, Waxman, 1998).  
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Microglial cells 
Microglial cells are the local immune cells of the nervous system. They are, perhaps, 
the only neural cells that are not derived from neural stem cells. Microglia are derived 
from monocytes which are in turn derived from hematopoietic stem cells in the bone 
marrow (Chan et al., 2007, Rock et al., 2004). They share morphological and 
functional similarities with the macrophages of hematopoietic system (Gehrmann et 
al., 1995, Rock et al., 2004). They form the first and main immune defensive line in 
the brain and spinal cord (Streit et al., 2004, Aloisi, 2001). They fight bacterial and 
viral infections in neural tissues via phagocytosis, and they also work as 
“housekeepers” removing dead cells and debris from neural tissues (Rock et al., 
2004). Microglia become activated in several neurodegenerative diseases such as 
Alzheimer disease, but whether its activation is helpful or harmful in these cases is 
still a debatable issue (Rock et al., 2004, Allen and Barres, 2009).   
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9.2 Appendix. I I 
 
Additional results 
 
 
Figure 60. Positive cells fraction after Lin-Neg purification. The white arrow indicates the beads attached 
to cells after depletion. Scale bar 50 µm. (refer to section 2.3.2) 
 
 
Figure 2. Positive cells fraction after SC kit purification. The white arrow indicates the beads attached to 
cells after depletion. Scale bar 50 µm. (refer to section 2.3.1) 
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Figure 62. FACS analysis on SSEA-4 positive cells (yellow) showed that this subset of cells is negative 
for CD45. SSEA-4 positive cells were gated and then analyzed. Forward scattered (FSC-A) analysis showed 
that SSEA-4 positive cells are relatively small homogenous population of cells (A). The same population was 
negative for major hematopoietic marker CD45 (B) which is also demonstrated by histograms (C and D) 
where (C) indicates positivity for SSEA-4 and (D) negativity for CD45. Cells in this figure were purified 
using SC kit.  
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Figure 63. Cytogenetic analysis of cells after early neural commitment stage (Day 10). The results 
showed normal karyotype (n=3). (refer to section 2.7) 
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Figure 64. Freshly purified umbilical cord blood stem cells (Day 0) did not express NMDAR1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 184 
 
Figure 65. Freshly purified umbilical cord blood stem cells (Day 0) did not express VGLUT1.  
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9.3 Appendix. III 
Addiotnal experimental data and controls 
 
 
Figure 66. Negative control for FACS analysis. Unstained cells (without antibodies) have been used as 
negative control (red graph). In stained samples, signals located within the red graph are considered negative 
whilst signals detected outside the red histogram are considered positive (blue graph). This procedure has 
been performed for each marker used for FACS analysis. Example shown is for CD45.  
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Figure 67. PCR product size confirmation. The product size is shown in yellow and the DNA ladder size in 
red. Refer to section (2.11.1) 
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Table 19. Primer Bank ID of primers obtained from primerbank website. 
<http://pga.mgh.harvard.edu/primerbank/> 
Gene 
Primer Bank 
ID 
C-MYC 12962935a2 
NEUROG1 5453770a1 
NEUROG2 31077092a3 
NEUROD1 4505377a2 
NEUROD2 21314638a1 
PAX6 4505615a1 
TBR2 22538470a2 
TBR1 5730081a1 
DLG4 
(PSD95) 
4557529a1 
GAPDH 7669492a2 
 
 
 
Figure 68. Primers tissue specificity check. PAX6 and TBR1 primers were tested on cDNA samples 
generated from umbilical cord blood purified cells samples  from day 0 (D0), day 10 (D10), day 17 (D17) and 
day 24 (D24) “for TBR1, cDNA from mononuclear cell fraction was also used (MNC)”. As a negative control, 
we used cDNA generated from adult liver tissue obtained from primer-design and results were negative for 
both genes. As a positive control, we used cDNA generated from fetal cortical tissue and results were positive 
for both genes. The obtained results from cord blood derived cells are consistent with TBR1 and PAX6 
expressions in brain.  
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Figure 69. Q-PCR analysis of liver markers ALB and GATA4. Results show that ALB and GATA4 are 
highly expressed in adult liver and extremely low in embryonic cortex and day 24 cells. This analysis has 
been performed as a negative control for the targeted neuronal fate.  
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Figure 70. Negative control for immunocytochemistry. Only secondary antibodies were used along with 
DAPI. Refer to section 2.9. 
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Figure 71. Negative control for immunohistochemistry. Only the secondary antibody was used. Refer to 
section 2.14. 
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9.4 Appendix.IV 
Umbilical cord blood collection forms 
 Participant Information Sheet 
 Consent form 
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Participant Information Sheet 
Evaluation of Cord Blood and Related Tissue Stem Cells 
for processing, preservation and tissue engineering. 
You are being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully. Talk to others about the study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. Please 
take time to decide whether or not you wish to take part. 
PART 
1 
What is the purpose of the study? 
The purpose of the study is to learn more about the best ways to collect, process, 
and store cord blood and related tissue for transplantation and research. 
This study will evaluate and develop products for the optimal processing of cord blood samples 
in order to improve the ways cord blood is separated into different blood cell groups and then 
stored in a freezer. 
We will further investigate the potential of cord blood and related tissue stem cells for ‘tissue 
engineering’ whereby stem cells are grown in our laboratory and instructed by chemicals 
and materials to produce defined tissue structures such as blood or liver. 
Basic information about Cord Blood and related tissues: 
 Umbilical cord blood is the blood present in the umbilical cord which connects the baby 
to the placenta. 
 Several research studies, including at the University of Newcastle, have shown that cord 
blood contains stem cells - the origin of all tissues and organs in the body – that can be 
turned into specific tissues in a laboratory offering high prospect for the advancement 
of medicine. 
 Other related tissues including the cord, placenta and membranes also provide a 
source of stem cells 
 Cord blood has been used clinically for over 20 years for the treatment of certain 
blood disorders (including leukaemia, lymphoma, and sickle cell disease) and 
immune deficiencies. 
 
 
Newcastle Centre for Cord Blood 
Institute of Human Genetics 
International Centre for Life 
Central Parkway 
NE1 3BZ, United Kingdom 
Phone : 0191 241 8817 
e-mail: cord.blood@newcastle.ac.uk 
International Centre for Life North East England Stem Cell Institute 
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By donating your umbilical cord blood and related tissues to our research programme you 
will contribute the development of technologies and scientific discovery to better understand 
how umbilical cord blood and related tissue stem cells can help repair the human body. 
Why have I been chosen? 
You have been chosen because you are in the second or third trimester of your pregnancy. 
You may therefore wish to participate in this study by donating your cord blood and related 
tissues at the time of birth. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. Cord blood and related tissue donation 
for this research is entirely voluntary. If you decide to take part, you will be given this 
information sheet to keep and be asked to sign a consent form. You will be free to withdraw 
at any time and without giving a reason. A decision to withdraw at any time, or a decision not 
to take part, will not affect the standard of care you will receive or the delivery of your baby. 
What will happen to me if I take part? 
> If you decide to take part in this study, you will be asked: 
-to read this patient information sheet carefully and ask us any question you might 
have with regard to this study. 
-to sign a consent form for cord blood and related tissue donation. 
> Cord blood collection will occur after birth with no harm to your baby or yourself. 
The umbilical cord will be clamped when it is of no further use to your 
baby. Any samples will be taken after delivery of the placenta and cord and in a 
separate room by a member of staff. Blood will be drawn from the umbilical cord and 
placental vein. Samples of related tissues (such as cord, placenta and 
membranes) may sometimes be taken at this time.  
> Donated cord blood and related tissue will be anonymised before it is used for the 
research study at the University of Newcastle. Laboratory researchers will not have 
access to your 
name, clinical records or any confidential information about your baby or yourself. 
> As part of your routine clinical care you would have been or will be tested for sexually 
transmitted diseases. You may donate cord blood and related tissue only if you have 
been tested for sexually transmitted diseases. If any evidence of infection is found, you 
will receive advice and support from the NHS carers. Please ask a member of staff for 
more information and advice if you have any question on this matter. 
> There is no cost to you for participating in this study. You will not receive payment for your 
participation in this study. 
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What do I have to do? 
If you decide to take part in this research study by donating your cord blood and related tissue 
please: 
 Read this Participant Information Form carefully. 
 Complete and sign the consent form and return to: 
Dr Majlinda Lako/Dr Lyle Armstrong, Newcastle Centre for Cord Blood, Institute of Human 
Genetics, International Centre for Life, Central Parkway, Newcastle Upon Tyne, NE1 3BZ 
Phone: 0191 241 8817 
Or to the Research Nurse during your next clinic visit.. 
What is the device / procedure that is being tested? 
> In our laboratory at the University of Newcastle, we will investigate different products 
and methods to collect, to process and to store cord blood and related tissue for research 
and clinical applications. 
> We will further develop techniques and methods to grow and transform cord blood and 
related tissue stem cells into different tissues including blood, brain and liver tissue. 
What are the alternatives? 
> The placenta, umbilical cord, and cord blood will be discarded as per hospital policy. 
> You may also choose to arrange prior to your admission to the hospital, with a private 
company who will charge a fee to process and store your baby’s cord blood. Please 
note that this is not currently facilitated by the NHS. 
What are the side effects of any treatment received when taking part? 
> No known side effects or discomforts are anticipated when taking part in this study. 
> Cord blood and related tissues will be collected after birth with no harm to you or the baby. 
Your care and the delivery of your baby will not be altered if you decide to take part, or 
not, in this research study. 
What are the other possible disadvantages and risks of taking part? 
> You and your family will not be able to retrieve or access the cord blood, related 
tissue or derived-cells for personal or clinical use at a later stage. 
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What are the possible benefits of taking part? 
> There are no direct benefits to you or your baby other than that the knowledge gained 
from this study may assist researchers in the discovery of improved methods for the 
collection, processing, and storage of cord blood and related tissue for transplant and 
research. 
> The study may also lead to new ways of using umbilical cord blood and related tissue 
stem cells to detect or treat a wide variety of diseases in the future. 
What happens when the research study stops? 
> Donated cord blood and related tissue not used will be discarded at the end of the study. 
> The information from this study will be collated with a view to understanding Cord Blood 
and related tissue better. 
 
What if there is a problem? 
> Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
Part 2. 
Will my taking part in the study be kept confidential? 
> Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. However, if you wish to discuss your participation in 
the study with others you are free to do so. 
Contact Details: 
For further information please contact, Dr Majlinda Lako or Dr Lyle Armstrong 
Newcastle Centre for Cord Blood, Institute for Human Genetics, International Centre for Life, 
Central Parkway, Newcastle Upon Tyne, Ne1 3BZ 
Phone: 0191 241 8817 E-mail: cord.blood@newcastle.ac.uk 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any decision. 
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What if relevant new information becomes available? 
If new information about this study becomes available prior to your consent or donation, 
you will be approached by a member of staff with an up-to-date participant information sheet. 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study we will not collect your cord blood or any other related 
tissues. You may then withdraw from the study until your sample has been anonymised. We 
will then dispose of your identifiable sample as per hospital policy. You will not have to give any 
reason for withdrawing from the study and it will in no manner affect your care or the delivery of 
your baby. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with Dr Majlinda 
Lako or Dr Lyle Armstrong.  
If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital. 
NHS Indemnity does not offer no-fault compensation i.e. for non-negligent harm, and NHS 
bodies are unable to agree in advance to pay compensation for non-negligent harm. They are 
able to consider an ex-gratia payment in the case of a claim where the injury probably resulted 
from any test or procedure you received directly as part of this study. Any payment would be 
without legal commitment. (Please ask if you wish more information on this). 
 
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements. If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation 
against the Newcastle Hospitals NHS Trust. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
Will my taking part in this study be kept confidential? 
Cord blood and related tissue will be anonymised before being used by laboratory research 
staff that will not have access to your name, your baby’s name or your medical records. 
Anonymised data regarding your delivery date, number of weeks in your pregnancy, the sex 
of your child, your age at delivery may be stored and used for statistical comparison only. 
Any information about you which leaves the hospital/surgery will have your name and address 
removed so that you cannot be recognised from it. 
Authorised University researchers, sponsors and regulatory authorities may have access to 
these data as granted by the Chief Investigator, Dr. Lako. Data will be stored for a maximum 
of 10 years on a university PC and secured server. 
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However, any information which is collected about you or your baby during the course of the 
research will be kept strictly confidential and be anonymised so that you and your baby 
cannot be recognised from it. 
Handling, processing, storage and destruction of your data are compliant with the Data Protection 
Act 1998. 
What will happen to any samples I give? 
Cord blood will be drawn from the umbilical cord vein after your baby is born with no harm to 
you or your baby. Samples of placenta, cord or membranes may also be taken. Remaining 
tissues will be disposed of as per usual hospital policy. Your sample will be anonymised by a 
trained member of staff. Your cord blood and related tissue sample will then be dispatched to 
the Newcastle Centre for Cord Blood research staff. 
Your donated cord blood and related tissue samples will be considered as a ‘Gift’ to the 
University of Newcastle in accordance with the Medical Research Council proposition. 
Donated Cord Blood and related tissue will be used to evaluate techniques and commercial 
products to collect, process, and store cord blood for transplantation and research. 
Cord blood and related tissue cells may also be tested for ‘tissue engineering’ (that is exposing 
cord blood cells to a range of chemicals and materials to direct the way they grow) 
applications and product development growing cells into specific tissue types for instance 
blood, liver or neural tissues. 
 
 
Will any genetic tests be done? 
Anonymised donated cord blood and related tissue cells may be tested for gene expression 
levels as required by the study, in order to monitor cells response to different growth 
conditions. 
What will happen to the results of the research study? 
The results and cells derived from the study may be used for academic scientific 
publications, commercial product development or validation, clinical application 
development and / or regulatory authorities’ evaluation. 
Results and progress of the study will be communicated through peer-reviewed scientific 
journals, international and regional conferences and also be disseminated to the general 
public with local seminars, media and the research group website (www.ncl.ac.uk/cordblood 
 
 
 198 
or www.iscbrm.org ). Because your cord blood and related tissue sample will be anonymised, 
you will not be identified in any report, publication or communication. 
Who is organising and funding the research? 
Our current research is organised by the University of Newcastle and funded by the University 
of Newcastle, OneNorth East, BioE Inc, StemCyte Inc and the Fondation Jerome Lejeune. 
This list may change during the study. 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by the Newcastle 
and North Tyneside Local Research Ethics Committee. 
You will be given a copy of the information sheet and a signed consent form for you to 
keep. 
We thank you for considering taking part or taking time to read this sheet
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Consent Form 
Patient Identification Number for this trial: 
Title of Project: Evaluation of Cord Blood and Related Tissue Stem Cells for 
processing, preservation and tissue engineering. 
Name of Researcher: 
1. I confirm that I have read and understand the information sheet dated 
16/01/2009 (version 9) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving reason, without my medical care or 
legal rights being affected. 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by responsible individuals from the 
University of Newcastle, from regulatory authorities or from the NHS trust, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
4. I agree to take part in this study. 
 
_________________________ __________   
Name of Participant   Date   Signature 
_________________________ __________   
Name of Person taking consent Date   Signature 
_________________________ __________   
Researcher    Date   Signature 
 
When completed and signed please retain one copy (1 for participant) and return 
the other copy (1 for researcher file) to: Dr. Majlinda Lako/Dr Lyle Armstrong 
Newcastle Cord Blood Centre, Institute of Human Genetics, International Centre 
for Life, Central Parkway, NE1 3BZ, Newcastle Upon Tyne 
Phone: 0191 241 8817 Email: cord.blood@newcastle.ac.uk 
Or return the signed consent form to the Research Nurse at your next clinic visit. 
 
 
 
 
 
Newcastle Centre for Cord Blood 
Institute of Human Genetics 
International Centre for Life 
Central Parkway 
NE1 3BZ, United Kingdom 
Phone : 0191 241 8817 
e-mail: cord.blood@newcastle.ac.uk 
International Centre for Life North East England Stem Cell Institute 
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